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Abstract 
Digital pathology is a technology with the potential to transform the way in which 
histopathological diagnoses are made and cancer diagnostic services are delivered. Despite 
this, clinical deployment of digital slides has lagged behind research and educational uses. 
This thesis describes some of the key barriers to widespread clinical adoption, which largely 
relate to a lack of guidance and information for pathologists regarding validation, training 
and patient safety. The evidence base for patient safety was analysed in a novel way to 
provide the basis for a validation and training protocol which was trialled in real world clinical 
settings, and guidance documents were developed and disseminated to the clinical 
pathology community to help with the transition from glass slide to digital slide reporting.  
 
In Chapter 1, background information and an overview of the published literature regarding 
clinical use of digital pathology is provided. In the second chapter, the results of a national 
survey on access to and usage of digital pathology hardware, in addition to attitudes to digital 
pathology, is presented.  
 
One significant barrier preventing digital pathology adoption has been a lack of widespread 
acceptance of digital slides as a safe alternative to conventional glass slides. Historically, 
validation literature investigating the safety of digital pathology as an alternative to 
conventional light microscopy has focussed on concordance metrics of glass and digital 
diagnoses, when arguably, it is appreciation of discordant cases that provides the clinical 
pathologist with the best opportunity to evaluate the scope of safe digital practice in their 
specialty.  Chapter 3 describes a novel study to analyse diagnostic accuracy of whole slide 
imaging and identify key training and educational targets for novice digital pathologists. 
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Chapter 4 presents the validation and training protocol developed by the author for Leeds 
Teaching Hospitals NHS Trust, which was subsequently adopted by the Royal College of 
Pathologists as an example of best practise in digital pathology implementation.1 Chapter 5 
describes the deployment of this protocol to train and validate the primary digital diagnosis 
of cohorts of breast and neuro- pathologists. Chapter 6 introduces modifications of the 
protocol for use for more niche reporting scenarios: frozen section diagnosis and 
immunohistochemistry assessment. Chapter 7 responds to concerns in the pathology 
community regarding accreditation of digital services, and the use of WSI for primary 
assessment of screening programme specimens.   
 
The body of work presented in this thesis has generated multiple peer reviewed publications 
which have influenced national and international digital pathology guidance. In this time 
period, enormous progress has been made in converting digital pathology from a niche 
technology for the early adopter to a mainstream topic at clinical digital pathology 
conferences, and the number of deployments and planned deployments in the National 
Health Service and beyond has risen dramatically. The use of digital slides in routine clinical 
practice represents a major departure from conventional light microscopy working practices, 
and the author hopes this work will help the pathology community maintain diagnostic 
quality in a time of change.  
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Chapter 1. Clinical Digital Pathology – Background, Barriers and Benefits 
 
This chapter summarises work by the author from the following publications: 
Williams BJ, Bottoms D, Treanor D 
Future-proofing pathology: the case for clinical adoption of digital pathology 
Journal of Clinical Pathology 2017;70:1010-1018. 
 
Williams BJ, Bottoms D, Clark D, Treanor D. 
Future-proofing pathology part 2: building a business case for digital pathology 
Journal of Clinical Pathology 2019;72:198-205. 
 
Digital pathology (DP) is a technology by which conventional glass microscopy slides 
are scanned using a high quality microscope lens to capture a digital whole slide 
image (WSI). These digital images are stored, transmitted and shared, and can be 
viewed and annotated by a pathologist on a computer screen using specialised slide 
viewing software.  The transferability and flexibility of digital slides has led to 
widespread use of DP for education and research purposes in the healthcare sector 
and higher education. 2-4 More recently, healthcare providers have expressed 
increasing levels of interest in complete or partial digitisation of digital pathology in 
diagnostic settings.  
In the clinic, early adoption of WSI systems has largely focussed on secondary 
diagnosis (e.g. for second opinions and frozen diagnosis), with only a few centres 
utilising DP for large scale, routine primary diagnosis, including sites in Sweden, the 
Netherlands and Canada. 5-7 WSI systems have been European Conformity (CE) 
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marked for primary diagnostic use in Europe for many years, and during the course 
of this work the Food and Drug Administration (FDA) has announced approval for 
marketing of two WSI devices for primary diagnosis in the United States.8, 9 These 
regulatory milestones have accelerated interest in digital deployment for primary 
diagnosis.  
In this chapter, the fundamentals of WSI technology and its deployment are 
described, in addition to a detailed list of proposed clinical uses for digital pathology. 
The strategic context of digital pathology adoption is discussed, and the key benefits 
of and barriers to clinical DP implementation are reviewed. 
 
1.1 Digital pathology: the technology 
Whole slide imaging systems are commercially available from a range of different 
vendors, but all systems share common imaging workflows that allow digitisation, 
storage and transfer of high resolution digital images of glass slides. The work 
contained with this thesis almost exclusively utilises scanning hardware from Leica 
Biosystems, (predominantly Leica AT2, Leica Biosystems, Vista, CA, US) and the 
imaging workflow for this system will be described. 
 
1.1.1 Pre- imaging, focussing and image acquisition 
Firstly, glass slides are manually loaded into the scanner in slide racks, either singly, 
or in batches of up to 400 slides per scanner. Low resolution cameras inside the 
scanner acquire low power “snapshots” of the slide and slide label. The low power 
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image of the slide is analysed by an inbuilt algorithm to detect tissue on the slide. 
Image focus points are applied to the detected tissue in a mesh-like network. A single 
high resolution image of each focus point is acquired, and an algorithm detects the 
optimal plane of focus in the z axis for each focus point. This process generates a map 
of the optimal focus planes for that slide. This map is then used to acquire the WSI 
using microscope objective lenses of 20x or 40x magnification, resulting in effective 
resolutions of 0.2 to 0.5 microns per pixel. Slides are illuminated by a light source 
beneath the scanning stage, and the microscope lens is moved across the static slide 
to capture serial images of the slide. In the Leica system, these images are acquired 
in stripes in the y plane.  
 
1.1.2 Image processing, storage and viewing 
The image is then processed so that image stripes are stitched together, and the 
image can be sharpened. The resulting image files are compressed to produce more 
practical file sizes for transfer and storage. Images are stored on a file server, and 
image management database software is used to access the images. The images can 
be viewed on the computer screen using software which allows the pathologist to 
pan through tissue, zoom in and out, make digital measurements, and add 
annotations. An example of this software, the Leeds Virtual Microscope 10, can be 
seen in figure 1. 
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Figure 1. Leeds Virtual Microscope – an example of digital slide viewing software10. The 
entire slide tray can be viewed on the bottom right, with a thumbnail of the selected slide 
above. The magnified view of the selected slide is navigated on the left. 
 
1.2 Clinical uses of digital pathology 
The transferability and flexibility of the digital slide format lends itself to a number of 
different use cases, supporting different areas of the pathology workload and 
workstream, all of which represent varying degrees of clinical “risk”.  These use cases 
are identified and clarified in this section. 
 
1.2.1 Primary diagnosis of pathological specimens 
This is the replacement of conventional light microscopic examination of glass slides 
with examination of whole slide images on screen by a pathologist to make a 
diagnosis as part of their standard diagnostic workflow. A diagnostic department may 
decide to use digital pathology for the primary diagnosis of the entirety of its 
workload, or may select individual histopathology subspecialties (eg, breast 
pathology) or an individual histopathologist’s workload to digitise. Kalmar and 
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Linkӧping Hospitals in Sweden were early adopters of digital pathology, with slide 
scanning fully integrated into laboratory workflow, and primary diagnosis made on 
digital slides by a proportion of their pathologists.7 Primary histological assessment 
of diagnostic and therapeutic specimens can provide definitive diagnosis, grading and 
staging information, and direct medical and surgical management of a patient, and 
thus primary diagnosis represents the highest risk “use case” for DP. 
 
1.2.2. Assessment of immunohistochemistry (IHC) 
This is the replacement of conventional light microscopic examination of glass slides 
with examination of whole slide images by pathologists to assess 
immunohistochemical stains. Such immunohistochemistry slides are often 
secondary/ancillary tests, which do not form part of the initial laboratory or 
diagnostic workflow for a case. Reconciling these secondary studies with the original 
histology can be time-consuming, and the immunohistochemistry slides may be 
reported by the initial pathologist that requested them, or by a second pathologist. 
These tests can help refine diagnosis, suggest the origin of a metastatic tumour, or 
direct therapeutic management.  
 
1.2.3 Multi-disciplinary team meetings (MDTM) /tumour board 
This is the selection, collection, review and presentation of whole slide images or 
annotated regions of interest of cases for discussion at multidisciplinary 
meetings/tumour boards with clinicians, radiologists and other healthcare 
professionals to review diagnosis and prognosis and direct patient management. 
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1.2.4 Frozen section diagnosis 
This is the use of whole slide images to provide rapid, intraoperative 
histopathological opinion. The pathologist may be on site, or may be working 
remotely, particularly if the service is required out of hours. This use case for digital 
pathology has been successfully implemented in Canada for over 10 years, with 
neuropathology frozen sections reported remotely on digital slides since 2006.5, 11  
 
1.2.5 Requesting second opinions 
This is the use of a digital pathology system to request a second opinion on a 
previously examined case. Second opinions may be required: 
a) within a department for difficult cases (mandatory for reporting of certain 
entities, eg, dysplasia in patients with Barrett's oesophagus undergoing 
surveillance12) 
b) within a regional network for referral and review of MDT/tumour board cases 
c) from regional/national/international experts for rare/complicated cases 
d) as part of quality assurance protocol within a department to audit and detect 
diagnostic errors. 
 
1.2.6 Receiving second opinions/review cases 
This is the use of a digital pathology system to render a second opinion on a 
previously examined case, for example, a case submitted for MDT/tumour board 
discussion, or referral of a difficult skin case from a general pathologist to a 
dermatopathologist. 
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1.2.7 Remote working 
This is the use of a digital pathology system to enable diagnostic pathologists to view 
slides and make diagnoses from off-site locations, which may include other 
networked hospitals, academic institutions or home. Gävle hospital, Sweden, were 
able to solve a local recruitment problem by employing a pathologist to work 
remotely from home, receiving their workload in the form of digital slides.13 As well 
as providing more flexible modes of employment, remote working may be required 
on a temporary basis in times of exceptional service need, when employees are 
unable to work in the department (e.g. during viral pandemics, or extreme weather 
conditions). 
 
1.2.8 Insourcing/outsourcing diagnostic work 
This is the use of a digital pathology workflow to allocate units of work across and 
beyond regional/national networks, or between public and private institutions to 
generate income, eliminate backlogs or make best use of available diagnosticians. On 
an international scale, digital pathology may help to broaden access to quality 
diagnostics, while offering income generating opportunities, a strategy already being 
explored at a number of centres, including the University of Pittsburgh Medical 
Center.14 Similarly, time-sensitive diagnostic slides could be outsourced to trusted 
partners in alternative time zones to enable rapid diagnostic turnaround out of 
hours, without resorting to costly and inconvenient pathologist on-call rotas. 
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1.3 Deployment strategies 
Deployment strategies are likely to vary according to the strategic context, and local 
constraints of the institution, but a number of common scenarios for adoption can 
be described.  
 
1.3.1 Solving specific, local logistical problems 
A department may find it temporarily lacks sufficient diagnosticians in a particular 
field, either due to staff losses or increasing workload, for example, gynaecological 
pathology. Introduction of a single scanner to scan all or part of the gynaepathology 
workload might aid the department by (a) encouraging return or retention of peri-
retirement diagnosticians, who will be able to work flexibly and remotely, (b) 
potentially attracting new workforce applicants that are interested in working 
digitally and (c) enabling rapid outsourcing of work to regional partners. 
 
1.3.2 Digitizing specific, discrete parts of the department’s service 
Departments may elect to digitise particular parts of their service in insolation to 
solve a particular local issue - for example, remote reporting of frozen section/urgent 
out of hours specimens. The ability to report these specimens remotely makes on call 
duties less onerous for the diagnostician, and could improve turnaround times of out 
of hours reporting, as consultants will not be required to travel to the hospital to 
make their diagnosis. This is an application of digital imaging already utilised in the 
field of radiology. The technology would also help in situations where the local 
specialist is not available to make a diagnosis (eg, due to illness, annual leave), and 
the slides can be transmitted to a regional partner. 
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1.3.3 Full digitisation of diagnostic services 
Following successful procurement of a digital pathology solution, deployment 
timescales and resource allocation will depend on the scope of the investment and 
number of Information Technology (IT) systems that need interfacing. 
The installation of scanners and pathologist workstations is relatively simple, 
provided sufficient space and basic infrastructure (eg. uninterruptable power supply, 
network points) are in situ. However, interface development, testing and “go- lives” 
are likely to prove time consuming and error prone, therefore planning and testing 
should be prioritised as early as possible in the project. 93 The major area of disruption 
is likely to concern the interconnectivity of systems in a multi-site deployment, which 
will require liaison and concerted action from network managers and information 
governance leads to ensure appropriate and secure information storage and 
exchange.   
Implementation of digital pathology will have significant implications for workflow 
and resource utilisation, and it is crucial that working processes are examined. In NHS 
pathology settings, LEAN/six-sigma analysis are the methods most commonly used in 
the early stages of implementation. Deployment of the technology will be disruptive 
and pathologists’ opinions of migration to digital reporting are likely to vary 
significantly, from those that are keen to adopt, to those that are resistant. Training 
and individual validation for digital pathology reporting is an important part of safe 
digital adoption, and should be carefully planned to ensure timescales and targets 
for digital reporting are appropriate. Full clinical adoption in a busy teaching hospital 
is likely to be a phased process over 2-3 years, at the end of which time there would 
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still be requirement for some, minimal light microscopy use for a limited number of 
situations where digital microscopes cannot be used (e.g. to examine polarisable 
material).  
Digitisation of the diagnostic activities of a histopathology department may occur in 
a phased manner, allowing stepwise introduction of a number of use cases, and 
gradual accrual of experience with the technology. This would result in stepwise 
accumulation of the benefits of digitisation over a number of years. For an example 
of a phased deployment and the accumulation of benefits, see figure 2. Smaller, 
simpler changes in workflow with immediate efficiency savings, for example, second 
opinion cases, MDT digitisation could be prioritised early in the digitisation, with 
more complex, large-scale changes in practice such as use of digital diagnosis for 
standard primary diagnosis deferred until the laboratory, and diagnosticians have 
gained experience in the laboratory workflow, and the digital diagnostic process. 
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Figure 2. Example of a phased deployment with gradual accrual of benefits. 
Institutions can proceed stepwise from initial niche uses to complete digitisation. 
 
1.3.4 Regional transformation projects 
Digitisation may form part of larger, regional sustainability plan, with scanners and 
diagnostic workstations installed at a number of sites to form a regional network for 
collaboration, transmission of cases to MDT or for second opinion, redistribution of 
workload in response to fluctuations in demand and capacity. In this way, digitisation 
could underpin the structure of laboratory mergers and centralisation of laboratory 
services. 
 
Initial
• Second opinion and frozen section
• Potential benefits:
• Faster access to second opinion - faster turnaround
• Less risk of slide loss/damage in transit
• Ability to provide remote frozen section opinion
• Pathologists gain skills in digital diagnosis
Midterm
• MDT meetings and Immunohistochemistry
• Potential benefits:
• Efficiency improvements
• Turnaround times immuno assessment improved
• Pathologists gain skills in digital case review
Longterm
• Primary diagnosis and Regional networking
• Potential benefits:
• Patient safety - paperless system
• Demand / capacity matching within institution and across 
network
• Workforce flexibility, improved recruitment and retention
• Improved diagnostic efficiency
• Improved collaboration
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1.4 The Strategic Context 
Diagnostic pathology services in the United Kingdom, and worldwide, are facing 
unprecedented challenges as they strive to provide quality, timely diagnoses against 
a background of increasing services pressure. In this section, the strategic context of 
digital pathology adoption is discussed. 
 
1.4.1 Increasing Volume and Complexity of the Workload 
Clinical pathology departments face the universal challenge of increasing workload, 
in terms of both case volume and case complexity. In the UK, year on year, the 
volume of cellular pathology requests received by laboratories has increased by an 
average of 4.5%.15The drive to identify pre-cancerous conditions and early stage 
cancers adds to the complexity of histopathological assessment, when morphological 
clues can be subtler and more time consuming to interpret.   
In addition to an increase in specimen requests, the pathologist is required to take 
more tissue slides and create more slides for each cancer diagnostic and therapeutic 
specimen. These extra slides are required to satisfy the  requirements of increasingly 
detailed minimum data sets for cancer reporting published by the Royal College of 
Pathologists (RCPath) and the College of American Pathologists (CAP).15 In parallel 
with this, the arsenal of adjunctive immunohistochemical and molecular tests that 
can refine diagnosis, prognosis and therapeutic decision making expands year on 
year, again requiring more input from the pathologist. 
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1.4.2 Specimen Turnaround Times and Targets 
The National Health Service (NHS) already imposes challenging turnaround targets 
for the investigation of possible cancer, with the 2015 report of the Independent 
Cancer Taskforce proposing even higher standards, proposing that in 2020, 50% of 
patients referred for cancer testing by their general practitioner (GP) should have 
their definitive diagnosis within 2 weeks, and 95% within 4 weeks. 16 
 
1.4.3 Workforce crisis 
Against this background of escalating diagnostic workload, pathology is in the midst 
of an emergent workforce crisis. In the USA, it is predicted that the number of 
practicing pathologists will have declined from 5.7 to 3.7 per 100 000 people between 
2010 and 2030.17 In the next 5–10 years, there will be a similar shortage of consultant 
pathologists in the UK across all subspecialties. Data from the Royal College of 
Pathologists show that 32% of cellular pathologists are over the age of 55 (615 
people), and are expected to retire in the next 5 years.15 Meanwhile, from August 
2015 to June 2016, only 52 trainees in histopathology were recommended to the 
General Medical Council for completion of training. Waiting times are starting to 
increase as a result of increasing mismatch between staffing 
capacity and demand. 
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1.4.4 The need to increase capacity 
In the USA, it is predicted that pathologist workforce demand will have increased by 
16% by 2030,17 while numbers of pathologists per capita decline. In their November 
2016 publication, ‘Testing times to come? An evaluation of capacity in pathology’,15 
Cancer Research UK highlights the need to ensure pathology services maximise 
efficiency, with networking and consolidation of pathology services prioritised. In 
light of increasing costs for staff overtime and outsourcing, optimisation of the 
pathology workforce is vital. Improved retention of near-retirement consultants, and 
increased efforts to drive recruitment in medical schools have been proposed, but 
these measures are not sufficient to solve the problem. The report recommends that 
departments and trusts should invest in infrastructure to support digital pathology, 
and that on-screen examination of histological slides should be used to enable more 
efficient networked services. This sentiment is echoed in the Nuffield Trust’s 
publication ‘The Future of Pathology’ which states that ‘without change it will be 
difficult to maintain an adequately skilled workforce in many areas of the country’.18 
The Life Science Industrial Strategy suggests that systematic digitisation of pathology 
images could be readily established providing substantial efficiencies in the 
pathology service within the NHS, allowing the system to become increasingly virtual 
and reducing the need for every hospital to have the full on-site set of pathologists. 
Whilst the strategy serves as a recommendation to government rather than formal 
policy, NHS England appears to support the recommendations.19 
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1.4.5 The drive towards networks and service mergers 
In the UK, the two Carter reviews of pathology, of 2006 and 2008 both recommended 
the formation of networked pathology services, with centralisation of laboratory 
resources, and the development of ‘hub and spoke’ local networks. 20, 21 More 
recently, the report by Lord Carter into operational productivity in the NHS suggested 
further consolidation and collaboration between services, stating that ‘Our further 
analysis has confirmed that consolidated pathology organisations are the most 
efficient in the NHS’.22 Digital pathology offers an enabling platform for centralised 
slide production, with dispersal of diagnostic pathologists across or between regions. 
Digital imaging has the potential to assist trusts in the flexible use of clinical 
pathologist expertise in relation to laboratory locations, pathologist offices and MDT 
inputs. In their paper, ‘Can Digital Pathology Result In Cost Savings? A Financial 
Projection for Digital Pathology Implementation at a Large Integrated Health care 
Organization’, Ho et al describe how a digital pathology system would enable 
enterprise wide reporting of specimens, while allowing laboratory services to 
consolidate from 20 dispersed hospitals to two centralised sites.23 
 
1.4.6 The drive towards digitisation of healthcare 
As part of the Five-Year Forward View, the Independent Cancer Taskforce Strategy’s 
paper, ‘Achieving world class outcomes; a strategy for England 2015–20’ highlights a 
drive towards achieving earlier diagnosis, the need to invest to deliver a modern, 
high-quality cancer service and the importance of training staff to realise advances 
in technology.16, 24 The National Information Board’s Framework for Action 
‘Personalised Health and Care 2020’, similarly emphasises the importance of 
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improving access to healthcare records, implementing personalised medicine, 
supporting innovation and getting best use from technology. Digital pathology can 
take medicine a step further towards the information governance target of a 
‘paperless’ healthcare system.25 The National Advisory Group on Health Information 
Technology’s paper ‘Making IT work—harnessing the power of health information 
technology to improve care in England’ (August 2016) states the Five Year Forward 
View aims will not be met without prioritising digitisation of services, and that 
digitisation is likely to reap safety and quality improvements, concluding that 'the 
one thing the NHS cannot afford to do is to remain a largely non-digital system, it is 
time to get on with IT'.26 
 
1.5 The benefits of digital pathology adoption 
The principal perceived benefits of adoption of digital pathology can be broadly 
divided into four domains: improving patient safety, improving diagnostic workflow, 
improving workforce factors and improving service quality, with improvement in any 
one domain likely to contribute to improvement in all other domains, and benefits 
felt at multiple levels from patient to region.  (see figures 3 and 4)  
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Figure 3. The benefits of digital pathology, reproduced from Williams BJ, et al. J Clin Pathol 
201727. Benefits can be divided into those that improve the diagnostic workflow, service 
quality, workforce issues and patient safety. 
 
1.5.1 Improving patient safety 
1.5.1.1 Reduced risk of patient/slide misidentification errors 
The use of an integrated digital pathology system, with paperless transmission of 
digital slides directly to the pathologist significantly reduces the possibility of a 
misidentification or transposition error (eg, mixing up slides from two patients). 
These are potentially the most serious errors that can originate in the diagnostic 
laboratory, with an incidence estimated at 1%.28 Digitisation of prescription 
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practices, with the introduction of e-prescribing lead to a significant reduction in the 
relative risk of medication error of 13%–99%.29  A fully digital end to end pathology 
workflow would remove the majority of manual patient identification checks which 
are prone to human error.  
 
1.5.1.2 Reduced risk of tissue/slide loss or damage 
Potential loss and damage of valuable patient tissue on glass slides is a risk faced by 
laboratories on a daily basis as they transport glass from the laboratory to the 
diagnostician, from the feeder hospital to the regional cancer centre for review, or 
from the general pathologist to the recognised expert. Digital slides provide a 
portable, instantaneously transmissible diagnostic image which does not fade or 
degrade, and is not subject to the transport risks faced by glass slides. 
 
1.5.1.3 Enhanced safety features of digital reporting 
Digital pathology slide viewing software can incorporate a number of additional 
safety checks to aid the pathologist, including computerised reminders if slides, or 
tissue regions have not been reviewed by the pathologist before case sign-out. 27 
 
1.5.2 Improving the diagnostic workflow 
 
1.5.2.1 Workload allocation 
A digital pathology system offers the flexibility and agility for streamlined ‘pushing’ 
and ‘pulling’ of cases to and by pathologists to respond to fluctuations in workload 
or case mix in a department. Digital slide management software can allow the 
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entirety of a pathology workforce access to outstanding or backlogged work, 
enabling pathologists with extra capacity to ‘pull’ pool cases. 
 
Conversely, a digital pathology system also allows for expedited ‘pushing’ of cases 
from a pool, or between pathologists, to ensure cases are promptly transferred to 
the most appropriate diagnostician within a network, or across a region. Enabling 
flexible workload distribution, both within an institution and across a network allow 
for closer capacity-demand matching and a more lean approach to achieving the 
requisite diagnostic output for a population. 
 
1.5.2.2 Rapid case tracking, archival and retrieval 
In the conventional laboratory with glass slide diagnostics, trays of slides and request 
forms are delivered to and transferred between a variety of locations within the 
laboratory and the diagnostic department. There are ample opportunities for slides 
to get mislaid, and urgent sourcing of a glass slide can be time consuming for clerical 
and diagnostic staff. A digital system ensures that a crucial or time-sensitive case can 
be accessed instantly, by any registered user, should the need arise. Review of 
previous specimens can be vital in cases such as the assessment of progressive 
disease or evaluation of a new tumour in a patient with cancer, and is likely to 
improve the quality of the pathologists’ assessment of a live case. The storage of 
digital slides allows for instant retrieval and review of cases, a process which is time 
consuming and inefficient using conventional glass slide archives. 
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1.5.2.3 Increased diagnostic efficiency 
One time and motion study identified potential for a 13% time saving in pathologist 
diagnostic efficiency with digital slide reporting, with efficiency gains in the 
organisation of, querying, matching and searching of cases. 30In addition, a limited 
number of diagnostic centres and individual diagnosticians have reported increased 
diagnostic efficiency using digital microscopes versus conventional light 
microscopes.31 These improvements relate to a number of specific areas, including 
rapid availability of images, faster on-screen measurements and annotations of slides 
and ability to multitask while using a computer screen for diagnosis, instead of 
switching between the microscope and the PC. In addition, pathologists do not have 
to physically load and unload microscope slides, compare glass slide labels with paper 
request forms or refocus their microscopes for tissue of different thicknesses. 
While the existing literature shows promise, more work is needed in terms of large-
scale clinical deployments before there is sufficient evidence to support improved 
diagnostic efficiency. 
 
1.5.2.4 Reduced case transfer times between the laboratory and the diagnostic 
pathologist 
Current glass slide dependent processes rely on delivery or collection of assembled 
cases of glass slides from the laboratory, an inefficient process requiring time and 
manpower, which risks loss or damage of slides. With a digital pathology system, 
slides are instantaneously accessible to diagnosticians without the need for physical 
case assembly and delivery. 
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1.5.2.5 Faster diagnosis of urgent cases 
Prioritisation of urgent cases can be difficult to manage using conventional glass slide 
processes, and is often reliant on manual tagging or labelling of specimens as urgent. 
This can be difficult to do when slides are in transit, in pools or on pathologists’ desks. 
Recategorisation or escalation of case urgency is difficult and time consuming. Digital 
pathology allows easy flagging and escalation of priority of cases, and enables the 
laboratory administrator to ‘push’ the most urgent cases to the top of pathologist’s 
worklists, without the need for explicit communication. 
 
1.5.2.6 Faster access to external second opinion 
Substantial numbers of slides are transferred between hospitals, either as 
submissions for MDT discussion at regional cancer centres, or for second opinion of 
difficult or rare entities from recognised specialists. Faster second opinion referral 
times of these cancer specimens are likely to lead to increased use of second 
opinions, and improved quality of cancer diagnosis and care. The Royal College of 
Pathologists recommends that all pathologists should actively participate in referral 
practice as this is in the best interests of patients, good continuing professional 
development and good practice, and that financial considerations should not be a 
deterrent to referral.32 
 
1.5.2.7 Faster access to molecular/ancillary testing 
Digital pathology provides a platform for parallel specimen workflows between 
histopathology and molecular medicine. When the pathological assessment of a case 
is liberated from stained tissue on glass, the glass and tissue can be expedited to 
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molecular medicine where appropriate, converting a sequential histopathology—
molecular workflow to a more efficient parallel process. Digital pathology allows 
rapid tumour annotation and cellularity assessment for downstream 
microdissection. 
 
1.5.3 Improving workforce factors 
As discussed previously, pathology departments are facing unprecedented workforce 
challenges, which digital pathology could improve in a number of ways. 
 
1.5.3.1 Platform for flexible working 
Digital pathology offers the potential for more flexible patterns of work for 
pathologists, freeing the diagnostician from geographical and temporal restraints on 
where and when they can work. In this respect, it can help to optimise the working 
hours of the workforce, helping those working less than full time to maximise the 
hours they can offer and providing an incentive for those considering retirement to 
continue to offer their services on more flexible terms. 
 
1.5.3.2 Platform for remote working 
The ability of digital pathology to support working from remote locations has the 
potential to optimise the existing workforce by allowing the pathologist to make 
efficient use of their time, regardless of the location at which they are based, for 
example, allowing them to review their MDT cases from University locations, 
allowing regional ‘spokes’ to take on extra work from ‘hub’ institutions when there 
are backlogs, etc. This mode of working can also help cover temporary staffing issues, 
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for example, allowing local colleagues to cover specialist reporting during periods of 
illness/annual leave. 
 
1.5.3.3 Improved teaching, training and mentoring 
Improved access to, and sharing of instructive and unusual cases is likely to prove of 
great benefit to undergraduate and postgraduate education, histopathology training 
and continuing professional development. Access to quality teaching cases can vary 
within and between departments. Digitisation and subsequent anonymisation of 
pathology images for a local teaching/training archive would provide an excellent 
resource for a department. In addition, the ability to view digital cases 
simultaneously allows a trainer and any number of trainees to share cases in real 
time, so the trainee and trainer can receive instantaneous feedback on a case. 
 
1.5.3.5 Recruitment and retention 
The inherent flexibility of a digital pathology diagnostic system should help to future-
proof histopathology, allowing the workforce to offer their skills in a variety of ways. 
As well as aiding retention of staff peri-retirement, the perceived ‘revolution’ from 
light microscopy to digital microscopy could help to rebrand histopathology as a 
modern, innovative and exciting field for junior doctors to work in. The ability to work 
from remote locations may be particularly helpful in recruiting to traditionally hard-
to-staff geographical regions or subspecialties. 
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1.5.3.6 Ergonomic advantages 
One of the largest implementations of digital pathology to date was initiated to 
improve workplace ergonomics, because a member of staff was unable to perform 
conventional microscopy due to neck pain. 7 Conventional microscopy is linked to a 
range of workplace-based morbidities including neck and back problems.33Digital 
pathology allows greater diversity in working positions for pathologists, as neck 
position does not have to be fixed, and a range of ergonomic input devices can be 
used, tailored to pathologist preference and any existing musculoskeletal problems. 
Further work is needed to understand the long-term ergonomic and other health 
effects of using digital pathology display equipment. 
 
1.5.4 Improving service quality 
 
1.5.4.1 Improved information sharing and collaboration 
As already discussed, digital pathology allows for streamlined sharing of images, both 
within and between departments, allowing rapid access to second opinion, or double 
reporting of difficult cases. In a study by Manion et al, in which over 5000 referral 
cases were reviewed and reported by a second pathologist, 11.3% of reviews had 
minor or major differences in diagnosis with the original diagnosis and 1.2% of all 
reviews would have resulted in a change in patient management. 34 A survey of 
laboratories in the USA noted that 6.6% of all histopathology cases were reviewed 
before sign out, suggesting second opinions are often obtained in clinical practice, 
especially in challenging areas such as breast disease.35Digital pathology renders 
second opinion and double reporting of specimens faster and more efficient, which 
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may help lower the threshold for seeking a second opinion, improving the quality of 
diagnosis and patient care. 
The Royal College of Pathologists tissue pathways for gastrointestinal disease state 
that double reporting of slides is advisable in cases of dysplasia in inflammatory 
bowel disease, dysplasia in Barrett’s oesophagus and cancers from bowel cancer 
screening patients. 12Digital slides are easily marked and annotated, further speeding 
up the process of obtaining an answer to a specific question, for example, are these 
cells in a blood vessel? If the process of sharing cases is made simpler, it is likely that 
pathologists will reduce their threshold for sharing cases, which may lead to better 
quality diagnosis for the patient. 
The introduction of biomedical scientist prereporting and screening also requires 
double reporting during training, and pathologist review of certain cases, which could 
be expedited with digital pathology.36 
 
1.5.4.2 Improved access to archived slides 
As discussed previously, streamlining access to a patient’s previous histology is likely 
to lower the threshold for pathologists to review previous specimens, with the 
potential to improve the quality of the diagnosis for that particular patient. 
Direct comparison of a current tumour biopsy with a previously resected tumour 
from the same patient may allow the pathologist to avoid costly further 
immunohistochemical investigation of the new tumour. 
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1.5.4.3 Ability to perform synchronous analysis of slides 
Multiple digital slides can be viewed simultaneously on one screen, allowing 
synchronised assessment of conventional H and E histology with multiple 
immunohistochemical stains or special stains. The images can be aligned and locked 
in the same position, making assessment of complex stains and their distribution in 
tissue far more accurate and simple to perform. The time to physically load and 
unload multiple glass slides for a relatively rapid assessment (of gross tumour 
positivity or negativity) is a significant part of the task of immunostain scoring 
process, suggesting that this task could be more rapid with a digital platform. 
 
1.5.4.4 More convenient cancer staging 
Minimum datasets for cancer cases required careful measurement of tumour volume 
and surgical margins. These measurements often form the basis of tumour staging, 
and can dictate further treatment decisions for the patient. Making measurements 
on the light microscope is time consuming, and there can be considerable 
interobserver variability in measurements taken by different pathologists. Digital 
slide viewers can use on-screen measurement tools which enable multiple 
measurements to be made and recorded in a few keystrokes or mouse clicks. More 
accurate and reproducible measurement of tumour size and margin status will allow 
more accurate staging of tumours, and the selection of more effective treatment 
options for patients. 
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1.5.4.5 Clearer diagnostic audit trails 
Digital pathology software allows for automatic and comprehensive diagnostic audit 
trails including data on who has viewed slides, when, where and for how long. It also 
facilitates annotation of regions of interest, which have formed the basis of a 
diagnosis. Some systems also incorporate these images of these regions of interest 
into the pathology report.27 
 
1.5.4.6 Research and development opportunities 
A digital pathology image archive represents a valuable resource, with diagnostic 
images made readily available for research purposes. Rapid transfer and availability 
of diagnostic slides will encourage collaboration and pooling of resources between 
diagnostic departments and higher education facilities, facilitating participation in 
national and international studies and clinical trials. In addition to providing rapid 
access to slides for academic purposes and clinical trial review, large volume 
databases of digital slides can be used in the development of new computerised 
algorithms for the rapid detection of new quantitative diagnostic and prognostic 
markers in tumours. 
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Figure 4. The benefits of digital pathology can be appreciated at multiple levels. 
Reproduced from Williams BJ, et al. J Clin Pathol 201727 The individual patient, the 
pathologist, the institution and the region can all potentially gain from deployment. 
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1.6 Financial benefits of digital pathology 
In addition to quality and service benefits, there are a number of potential financial 
benefits for the clinical pathology department, although there is little published 
evidence to support these at present.  
 
1.6.1 Potential cost savings 
1.6.1.1 Locum pathologist costs 
Locum pathologists are still widely used by many NHS Trusts to cover shortfalls in 
manpower due to retirement, maternity and carer leave, long-term sick leave, and 
so on. The overall cost of this is substantial (£140 per hour). Improved productivity 
and utilisation of the existing pathologist workforce using digital pathology, allied 
with easy transferability of cases should substantially reduce reliance on locum 
cover. 
 
1.6.1.2 Reduced costs of referral to commercial laboratory services 
Considerable sums (estimated at £35 per case) are spent by many NHS Trusts in order 
to keep abreast of their workloads. The turnaround times of cases outsourced to 
agencies can be prolonged, given the need for work to be physically transported 
elsewhere. 
 
1.6.1.3 Transport savings on tissue/slide exchange between institutions/sites 
There would be reductions in the logistical costs of relay of slides to reference sites 
for second/specialist opinions and their subsequent return. 
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1.6.1.4 Microscope/camera purchase 
Consultant pathologist microscopes currently cost around £25,000 each. If cameras 
are also added this can rise to £30,000 and height-adjustable benching to provide the 
appropriate ergonomic posture for microscopy can add further costs. Although they 
have a long ‘shelf-life’ it has been common practice in many hospitals to provide new 
consultant pathologist staff with a new microscope to ensure the stock of the 
department is refreshed. Such regular purchases would no longer be necessary. 
 
1.6.1.5 Reduced slide archiving and retrieval costs 
Although unlikely to have an impact initially, it is highly likely that costs associated 
with slide/tissue storage may be avoided in the future. Where these are off-site and 
commercially supported these costs are not insignificant. 
 
1.6.1.6 Reduced staff travel costs 
The technology provides consultant pathologists with the ability to work at a distance 
from their laboratories/MDT meeting venues. This could include agile home-working 
(to cover future 7-day working initiatives) and satellite site working (for MDT 
attendances).  
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1.6.2 Cost avoidances 
1.6.2.1 Reduced financial penalties 
Avoidance of financial penalties due to cancer breaches relating to delays in 
obtaining pathological diagnostic opinion (currently £1000 per cancer breach47) 
 
 
1.6.2.2 Reduced litigation costs 
Although cases are rare, where institutions have been prosecuted due to diagnostic 
error relating to pathology, these have proved to be extremely expensive. Post-event 
analysis has shown that such cases could often have been avoided had there been 
improved quality assurance checking, often including a second/ specialist opinion. 
Apart from the financial aspects, the reputational damage to the institution and the 
pathology departments can also be severe.47 
 
1.6.2.3 Earlier diagnosis of disease 
Digital imaging can provide quicker turnaround times for cases that require referral 
to external institutions for regional MDT review, which could result in cost-savings 
related to treatment costs and hospital stays. 
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1.6.2.4 Time savings for pathologists 
There are indicative data suggesting productivity improvements for pathologists 
when they have adopted digital imaging of between 10% and 15%.30 Specific areas 
where time is saved relate to immediate availability of slides without need to wait 
for delivery, faster measurements and annotations and easier preparation and 
compilation of cases for MDT meetings. 
 
 
1.6.2.5 Delayed clinical workforce expansion costs 
As cancer workloads continue to grow, hospitals need to expand their pathologist 
workforce and are experiencing recruitment difficulties. Increased productivity of the 
existing workforce will help offset these pressures. Applied conservatively this might 
give an expectation that institutions would be able to absorb an additional workload 
of at least 5%. Consultant annual workload is roughly estimated to be approximately 
3000 cases. A 5% increase in capacity would equate to an extra 150 cases per annum 
per consultant for the region. Theoretically at least this could increase the number of 
cases that could be examined by the overall existing pathologist workforce of our 
region by as much as an additional 12,000 cases per annum. 
 
1.6.2.6 Delayed laboratory workforce expansion costs 
Considerable laboratory staff time is undertaken to support current ways of working 
that could be significantly reduced if digital imaging were adopted. These are as 
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follows: case assembly, case retrieval, case filing, packing and unpacking dispatched 
slides, time spent chasing missing/ overdue slides, time re-cutting/re-staining 
lost/damaged slides, time delivering slides to consultants. 
 
1.6.3 Potential income generation 
Digital slides create the ability for sites to provide remote clinical diagnosis from 
images generated anywhere, and will open up insourcing opportunities. Pathologists 
could undertake work for other institutions within the region, and there is also a 
market nationally and internationally. 
 
1.6.4 The commercial case 
Digital pathology is already recognised as a having a key role to play in the future of 
health services, and many NHS suppliers have already formed commercial 
partnerships with scanner, software and biomarker supplier to offer complete digital 
solutions, which could integrate with Laboratory Information Systems (LIMS) and 
electronic patient records. These partnerships may be broadened to include image 
access and storage solutions, such as vendor neutral archives, where pathology 
images could be stored alongside radiology images, photographs, electocardiogram 
traces etc.  
Pathology services in the UK are increasingly utilising managed service contracts for 
the provision of laboratory equipment, and it is likely that digital pathology hardware 
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will be embraced in a similar fashion, allowing for more effective use of finance, and 
allowing for hardware refreshment as contractual periods approach their end points.  
A digital pathology scanning and reporting solution also offers a platform for the use 
of spin-off technologies, including computer assisted scoring of 
immunohistochemistry and triaging of specimens.  
 
1.7 Future perspectives – image analysis and artificial intelligence 
The field of digital pathology is progressing rapidly, with innovative diagnostic and 
prognostic tools on the market and in development, with the potential to lead to 
further benefits in patient care. Algorithms for detecting regions of interest, which 
direct the pathologist to areas of abnormality, and programmes designed to quantify 
immunohistochemical staining can streamline screening and triage of cases, while 
tools for automated mitotic counting, tumour grading and microorganism detection 
could remove some of the more onerous, time-consuming tasks from the 
pathologists workload, leaving them to engage with the more intellectually 
challenging areas of diagnosis and clinicopathological correlation. 93 
It is likely that in the future, image analysis of digital slides will become part of routine 
practice, allowing for further streamlining of the diagnostic process, and enabling 
junior staff and non-clinical staff to report and sign out screened and triaged cases. 
 
1.8 Barriers to adoption 
Digital pathology uptake in the clinic has followed a classic adoption curve, with initial 
niche applications (including remote reporting of frozen section specimens, 
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education, research and second opinions ) followed by larger scale, broader 
spectrum deployment in a small number of “early adopter” clinical sites.37 In the 
course of my period of PhD study, progress has been made in most of these domains, 
although significant implementation barriers persist and are slowing translation of 
DP from academia to clinical settings. 
 
1.8.1 Lack of evidence of diagnostic equivalence with conventional light microscopy 
If digital pathology is to be implemented for primary diagnosis on a large scale, 
regulatory bodies, both international and national; departmental heads; and 
individual pathologists will have to be confident that a diagnosis made on a digital 
microscope is equivalent to a diagnosis made by the same pathologist on a light 
microscope. Efforts to validate WSI diagnosis against the gold standard of 
conventional light microscopy have been hampered by the innate subjectivity and 
variability of histopathological diagnosis.  
In 2016, the author undertook was part of a group which undertook a systematic 
review of these studies in which study quality was assessed.38 38 studies were 
identified, and reported and a mean diagnostic concordance of WSI and light 
microscopy, weighted by the number of cases per study, of 92.4% was observed. Of 
the 30 studies quoting concordance as a percentage, 60% showed a concordance of 
90% or greater, of which 10 showed a concordance of 95% or greater. There was a 
trend for increasing concordance in the more recent studies, reflecting the evolution 
of hardware and software. The review found evidence to support a high level of 
diagnostic concordance for WSI overall, and the conclusions can be interpreted as 
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encouraging for a diagnostic department that is considering a primary diagnostic 
digital adoption. However, the review is limited by the quality of the source studies. 
Included studies utilised experimental methodologies that may not accurately reflect 
the breadth and depth of histopathological diagnosis, or the environmental and 
psychological factors that exist in real world clinical pathology services.  
 
1.8.2 Lack of regulatory approval 
At the time this work commenced, there was no widespread regulatory approval for 
the use of WSI for primary diagnosis, and many medical institutions would be 
uncomfortable taking on the medicolegal risks of implementing an unapproved 
healthcare technology. The first WSI system was CE marked for primary diagnosis in 
201239. The European CE mark in itself does not necessarily persuade the pathology 
profession that digital diagnosis is valid, although it was a step towards acceptance 
of technology. FDA approval is a more rigorous process, and requires a higher level 
of evidence. In 2017, the FDA approved the Philips Intellisite WSI system for primary 
diagnostic use in US, but additionally specified that pathologists must keep their 
microscopes for situations where, in their clinical judgment, it would be best to defer 
to glass slide review. Approval for a second WSI device, the Leica AT2 was granted in 
2018. These approvals represent major milestones in the acceptance and validity of 
WSI for primary diagnostics. 
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1.8.3 Pathologist attitudes 
Published studies of the use of digital slides tend to present positive perceptions of 
WSI technology, but these studies tend to be based in early adopter institutions, 
where clinical adoption has been accelerated by a handful of enthusiastic individuals.  
There is very limited data available about the acceptability of digital pathology to 
general pathology audiences. A study of Canadian pathologists in 2013 found that 
71% of respondents believed there was a need for digital slide telepathology in their 
practice, but that its use should be reserved for teaching and consultation services, 
with cost and image quality issues implicated as barriers to wider clinical use.40   
One of the fears quoted by many pathologists is that digital pathology could result in 
loss of work, as slides can potentially be transferred anywhere in the world for 
diagnosis. 41 This transferability is one of the great strengths of the WSI as the mode 
of diagnosis, but care would need to be taken to ensure quality of diagnosis and 
integrity of patient data are maintained.  
There are also concerns that WSI, as an enabler of AI could result in job losses for 
pathology consultants, or remove the need for human diagnosticians at all. Given the 
current shortages of human pathologists, and the relatively limited applications of AI 
algorithms currently in development, this is unlikely to be the case in the near future. 
42 
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1.8.4 Diagnostic speed compared with the light microscope 
One very practical barrier to deployment in clinical settings is the perceived 
inefficiency of DP versus conventional light microscopy. A survey in the United States 
found that whilst 59% of respondents felt the benefits of digital pathology 
outweighed their concerns with its use, speed of diagnosis on digital slides was a 
major barrier to use in the clinic. 43 A small number of studies have attempted to 
compare diagnostic time on the light microscope with the digital microscope, 
including a study in Norway suggested that digital pathology was faster than light 
microscopy diagnosis in some diagnostic scenarios, but the study only reported the 
experience of a single pathologist. 31 A study by Hanna et al with a more experimental 
design used eight different pathologists, and found an overall mean loss of efficiency 
of 19% for WSI compared with glass slides.44 
A pathologist in the UK will have completed at least 5  years postgraduate training on 
the light microscope,  and may have twenty or thirty years clinical experience with 
this diagnostic tool. Whilst the diagnostic assessment is essentially the same on the 
digital microscope, the interface is very different. The pathologist needs to learn to 
use the image management and image viewing software, how to navigate through 
multi-slide cases and perform small object tissue search tasks at high magnification. 
Initial experiences of digital reporting are likely to be slower and more cumbersome 
than light microscopy practice until the pathologist has reached a level of 
comfortable familiarity with the WSI system implemented. The user interface is 
another factor likely to influence diagnostic speed on the digital microscope, with 
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both slide viewing software design and display resolution implicated in enabling 
efficient diagnosis. 10 
 
1.8.5 Lack of training and educational support 
An interview based study conducted by Randell et al questioned a sample of 12 
histopathologists on their views regarding barriers to clinical usage of DP.  A key 
concern was lack of familiarity with the technology, and lack of confidence in their 
diagnostic skills with this new medium. The findings emphasise the need to ensure 
adequate training and support and the potential benefit of allowing parallel use of 
glass slides and digital while pathologists are on the learning curve.45  
 
1.8.6 Lack of support for digital pathology from professional bodies 
The Royal College of Pathologists’ position on digital pathology implementation has 
altered significantly within the time frame of this PhD. As recently as 2016, RCPath 
president Suzy Lishman stated that there was “not yet sufficient evidence to support 
wholesale adoption”. In 2017, the College published a strategy suggesting that digital 
pathology offers potential efficiency and quality benefits, and advertised for its first 
lead for diagnostic digital pathology1. Following formation of a committee, the group 
published guidance recommendations for the implementation of DP in the clinic.  
Whilst the Royal College supports the safe and considered use of DP in the clinic, 
Public Health England (PHE), the body responsible for the UK cancer screening 
programmes for breast, bowel and cervical specimens does not sanction the use of 
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DP for primary diagnosis of screening programme specimens. 46 As screening patients 
are symptom free, “healthy”populations, lower levels of risk of misdiagnosis are 
deemed acceptable than for symptomatic patient groups, where the likelihood of 
disease is greater. This will be discussed in greater detail in chapter 7. 
 
1.8.7 Financial Constraints 
Deployment and running costs for a digital pathology system will vary greatly 
between institutions dependent on their size, workloads, workforce, existing IT 
infrastructure and data storage capacity.  
Indicative costs suggest a stand-alone, single hospital deployment as part of a 
managed service contract might cost in the region of £100,000 -£200,000 per annum 
depending on the size of the workload, including data storage and interfaces with the 
laboratory information system (LIMS). These costs would be reduced if a regional 
purchase strategy was adopted, especially if purchase of hardware and peripherals 
made use of existing NHS IT suppliers on NHS framework agreements. 47 
Compensating savings could mitigate against these costs, and provide a longterm 
return on investment. Digital pathology fits well with national and regional funding 
opportunities to support the adoption of digital technologies and improved early 
diagnosis.  
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1.9  Conclusion 
In an era when histopathology services are under increasing pressure to produce 
more work, of greater complexity and quality, in a shorter timeframe, digital 
pathology systems offer a flexible platform for service improvement and 
development. The benefits of digital pathology, in improving patient safety, 
improving workflows, improving workforce factors and improving service quality can 
be felt by all stakeholders in the process, from the patient and pathologist, through 
to the institution and the wider clinical network in which it operates. 
Timely adoption of digital pathology offers opportunities to future proof 
histopathology services in a time of emergent demand: capacity mismatching. Failure 
to embrace technology and modernisation could compromise the ability of pathology 
service providers to produce accurate diagnostic work for patients. 
 
A number of key barriers to implementation have been identified in the literature, 
some of which, including lack of regulatory approval and lack of support from the 
Royal College of Pathologists have been overcome since the start of this piece of 
work.  
At the time of commencement of this work, it was decided it was important to 
identify trends in clinical digital pathology adoption, and identify the key obstacles to 
real world implementation. In chapter 2, the results of a nationwide survey of clinical 
and academic pathology departments are presented, the results of which shaped the 
direction of this body of work, and indicated some of the key areas where the clinical 
pathology community required reassurance or guidance.  
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Chapter 2 Digital Pathology Access, Usage and Attitudes in the United Kingdom 
 
This chapter contains content published in: 
 
Williams BJ, Lee J, Oien KA, et al Digital pathology access and usage in the UK: 
results from a national survey on behalf of the National Cancer Research 
Institute’s CM-Path initiative 
 
Journal of Clinical Pathology 2018;71:463-466. 
 
 
2.1 Introduction 
 In chapter 1, the benefits of and barriers to digital pathology implementation in the 
clinic were discussed. It is important to consider what progress is being made in terms 
of clinical uptake of digital pathology in the UK, contemporary attitudes to DP usage, 
and perceived barriers to digital pathology.  In chapter 2, the design and results of a 
nationwide survey of DP are explained and discussed.  
2.2 Aim  
The aim of the study was to canvass the UK pathology community to ascertain 
current levels of digital pathology usage in clinical and academic histopathology 
departments, and prevalent attitudes to digital pathology. With this in mind a 
national survey was developed on behalf of the National Cancer Research Institute’s 
(NCRI) Cellular Molecular Pathology (CM-Path) initiative. 
2.3 Methods 
A survey was written and disseminated on behalf of the membership of the 
technology and informatics workstream of the NCRI’s CM-Path initiative. The survey 
comprised 15 items and assessed:  
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(1) access to and ownership of digital pathology hardware;  
(2) current and predicted usage of digital pathology; 
(3) prevailing attitudes to digital pathology. 
 
The survey was initially circulated to the whole CM-Path membership (a research 
focussed group of pathologists working in clinical and academic settings) using the 
SurveyMonkey online survey tool (www.surveymonkey.com) with specific 
instructions for completion of forms. As the aim was to assess national trends in 
digital pathology uptake and attitudes, responses were sought at a departmental or 
institutional level. Where possible, departmental heads were approached and asked 
to complete the survey, or forward it to the most relevant individual in their 
department. Data were collected over a 6-month period from February to July 2017. 
Reminder emails were sent out during this period, and survey invitations were 
extended to academic and clinical pathology departments without a CM-Path 
member. Simple summary statistics were calculated for each questionnaire item. Not 
all questions were mandatory, and some questions allowed more than one response 
to be selected per respondent, so denominators are shown for the results on a per 
question basis. 
 
2.4 Results 
A total of 41 questionnaires were completed, representing 41 institutions in 
England, Wales and Scotland, with no duplications. 
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2.4.1 Respondent demographics 
Respondent demographics are shown in table 1. The majority of respondents 
represented National Health Service (NHS) clinical pathology departments (85%, 
34/40), with the remaining 15% (6/40) of responses from university academic 
pathology units. Of the 34 clinical pathology departments that responded, 10 were 
based in district general hospitals, and 24 in tertiary referral centres. 
 
Type of institution % of responses No. of responses 
NHS - tertiary referral centre 60.0 24 
NHS- district general hospital 25.0 10 
University academic department 15.0 6 
Total  40 
 
Table 1. Respondent department characteristics 
 
The clinical departments surveyed varied greatly in size, with the number of whole 
time equivalent consultants ranging from 4 to 47, and the estimated number of 
histopathology cases accessioned per year ranging from 2000 to 90000. 
 
2.4.2 Access to and ownership of digital pathology hardware 
60.0% (23/39) of participating institutions had access to a digital pathology scanner. 
Of these institutions, 34.8% (8/23) had an NHS-owned scanner, 43.5% (10/23) had a 
university-owned scanner and 21.7% (5/23) had access to a scanner owned by 
neither the NHS nor the university (see figure 5). 
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60.0% (24/40) of institutions had access to a digital pathology workstation, but only 
46.2% (18/39) had access to a digital slide archive or library. 
 
 
 
 
Figure 5. Access to and ownership of digital pathology hardware. Availability of NHS and 
non NHS owned digital slide scanners, workstations and archives.  
 
2.4.3 Current digital slide usage 
 
58.8% (20/34) institutions reported that they do not currently produce any digital 
slides. Of the institutions that currently produce scanned slides, the annual total 
ranged from 50 slides to 30 000 slides. 
The most popular applications of digital pathology in current use were 
undergraduate and postgraduate teaching, research and quality assurance. 
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Experience with direct clinical use of digital pathology was less widespread, but 31% 
of departments indicated they use digital slides for primary diagnosis and 36% for 
secondary diagnosis, in a proportion of cases (see figure 6).  
 
 
Figure 6 Current usage of digital slides. Digital slides are used for a variety of purposes, 
ranging from education and research to primary diagnosis. 
 
2.4.4 Predicted digital slide usage 
When asked to predict their institution’s projected usage of digital pathology in 
1 year’s time, an increased proportion of institutions predicted that digital slides 
would be used always or often for all digital slide use types (see figure 7). 
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Figure 7 Projected usage of digital slides. Departmental predictions of usage in one year’s 
time. 
 
2.4.5 Image analysis usage 
41.0% of institutions (16/39) report that they currently use image analysis on digital 
slides, with immunoscoring, tumour environment assessment, basic measurements, 
tumour cell proportions and tumour segmentation given as examples of current 
usage. 
 
2.4.6 Attitudes to digital pathology adoption and usage 
The majority of departments (24/41, 58.5%) listed the investigation and use of 
digital pathology as a high or essential priority at their institution (see table 2). 
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Digital pathology prioritisation % of responses Number of responses 
Not a priority 9.8 4 
Low priority 14.6 6 
Neutral 17.1 7 
High priority 43.9 18 
Essential priority 14.6 6 
Total  41 
 
  
Table 2 Prioritisation of digital pathology for institutions 
 
 
When asked about the perceived benefits of digital pathology for their department, 
the majority of respondents agreed or strongly agreed that digital pathology would 
improve efficiency, turnaround times, reporting times and collaboration in their 
institution (figure 8). Overall laboratory costs and safety were the only parameters 
that the majority of respondents did not think would be improved by introducing 
digital pathology. 
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Figure 8 Perceived benefits of digital pathology. The potential benefits of digital 
pathology, as viewed by participating institutions. 
 
 
2.4.8 Perceived barriers to digital pathology adoption 
Respondents were next asked what they perceive to be the barriers to wider digital 
pathology adoption. 82.5% of respondents agreed or strongly agreed that initial 
financial cost was a barrier to wider digital pathology usage at their institution, while 
only 15% agreed that safety concerns were impeding more widespread use of digital 
slides (see figure 9). 
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Figure 9 Perceived barriers to digital pathology. The barriers to digital pathology, as 
reported by the participant institutions. 
 
 
 
 
2.4.9 Factors facilitating digital pathology usage 
Access to funding for initial hardware, software and staff outlay, training for 
pathologists and guidance from the Royal College of Pathologists were identified as 
factors that could enable respondent institutions to increase their digital pathology 
usage (see figure 10). 
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Figure 10. Factors that could enable digital pathology usage. Key factors enabling digital 
pathology, as indicated by participating institutions. 
 
The following additional enabling factors were identified by respondents, and 
included as free text: 
 Relevant UK data proving cost savings. 
 Public Health England (PHE) approval for screening specimens. 
 NHS England taking a clear and strong stance on digital pathology. 
 Improved internet connections. 
 Algorithms which improve reporting standards. 
 A change in attitude from managers. 
 Information technology infrastructure and personnel support. 
 
 
2.5 Discussion 
This NCRI’s CM-Path survey was the first attempt to gather national data on access 
to and usage of digital pathology in NHS and academic pathology departments in the 
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UK. Sixty per cent of respondents had access to WSI scanners, with ownership of 
these devices split between the NHS and linked university departments. 41.2% 
of institutions reported that they currently actively produce digital slides in their 
department, with the most popular applications being for education, research and 
quality assurance purposes. Interestingly, 31% of respondents indicated that they 
currently use digital slides for primary diagnosis in a proportion of cases, and 36% 
use digital slides for secondary diagnosis, indicating that pathology departments are 
finding utility for the use of digital slides in certain aspects of clinical practice. 
Predictions for slide usage 1 year from now suggest more departments will be using 
digital pathology for diagnostic work, and for a greater proportion of cases in the 
near future. 
One of the most interesting findings of the survey was reported level of prioritisation 
for digital pathology adoption or investigation in the respondent institutions, with 
the majority of respondents listing it as a high or essential priority. Participants were 
optimistic that digital pathology could help improve diagnostic efficiency and 
turnaround time, and 97.6% agreed or strongly agreed that digital pathology could 
improve collaboration in their department. Interestingly, patient safety aspects of 
digital reporting were not emphasised by the survey respondents, despite the 
potential to reduce patient misidentification errors by creating a paper-light or 
paper-free workflow. 
The most prevalent existing barrier to wider digital adoption for the survey 
respondents was financial cost to their department. There have been long economic 
arguments in favour of the introduction of digital pathology in many contexts, but 
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there is undoubtedly significant initial outlay, in terms of hardware and software, and 
ongoing training, maintenance and personnel costs. The time required to set up and 
deploy a system, train staff and ongoing staff time costs to run scanners was also 
implicated as a barrier for some departments. Clearly, these barriers would need to 
be counterbalanced by the potential major benefits for diagnostic workflow, 
workload and workforce issues, and service quality and safety. Little concern was 
expressed regarding the safety and accuracy of digital pathology diagnosis versus 
conventional slide diagnosis, which may reflect the evolving evidence base for digital 
and glass slide diagnostic concordance.  A recent systematic review, published by a 
group including myself38 found a glass:digital concordance rate of 92.4%. 
92.5% of respondents agreed or strongly agreed that funding was required to aid 
increased uptake of digital pathology in their institution, and 78% wanted guidance 
from the Royal College on digital pathology usage. Interestingly, more people 
identified Royal College guidance as a digital pathology enabler than a randomised 
controlled trial of digital pathology accuracy, and this may help more departments 
evaluate the opportunities and risks of digital pathology adoption in their 
department. In free-text statements, respondents also indicated that a need for 
direction from NHS England and an approval from Public Health England (PHE) were 
needed to enable them to move forward with digital pathology adoption. 
The results of the survey suggest that interest in digital pathology adoption in the UK 
is high, and that an increasing proportion of pathological diagnosis will be made on 
digital slides in the immediate future. Furthermore, the recently published Life 
Sciences Industrial Strategy recognises the need for increased adoption of digital 
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pathology within the NHS,19citing that digital pathology will allow the use of artificial 
intelligence that could provide prognostic insights that are currently unavailable. To 
support this adoption, pathology departments would value clear guidelines and 
statements from key national healthcare, professional and regulatory bodies 
regarding their position on digital pathology in the clinic, and the necessary steps to 
take to ensure any adoption maintains or improves on current standards of quality 
and safety. 
With this in mind, in chapter 3 the evidence base for the diagnostic accuracy for 
digital pathology is analysed, with the aim of identifying key safety and educational 
points which could inform the design of a digital pathology training and validation 
protocol. 
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Chapter 3. Evaluating the evidence for the safety of primary digital 
diagnosis 
This chapter summarises work by the author from the following publication: 
Williams BJ, DaCosta P, Goacher E, Treanor D. 
A Systematic Analysis of Discordant Diagnoses in Digital Pathology Compared with 
Light Microscopy 
Archives of Pathology and Laboratory Medicine 2017:141:1712-1718 
 
3.1 Introduction 
The review of the literature outlined in chapter 1, and the results of the national 
survey described in chapter 2 suggested that pathologists were seeking support and 
advice with education and training in digital pathology.  
Clinical adoption of digital pathology at scale requires more than the approval of 
regulatory bodies and departmental heads and decision makers. It requires that 
individual pathologists can be confident that a diagnosis they make on the digital 
microscope is equivalent to a diagnosis they make on the conventional light 
microscope.  Achieving this level of confidence is likely to be a different journey for 
different individuals, but a core part of this is feeling that personal educational and 
professional development needs have been met. 
 
3.1.1 Systematic Review of the concordance of WSI and light microscopy 
A limited number of studies have compared the diagnostic concordance of WSI and 
traditional light microscopy. In 2016, the author was part of a team that undertook a 
70 
 
systematic review of diagnostic accuracy studies of WSI, in which the quality of 
studies was explored .38 Thirty-eight qualifying studies were identified, consisting of 
6 crossover studies (16%), 19 prospective comparative reviews (50%), and 13 
retrospective retrieval and review studies (34%). The mean number of cases within 
the included studies was 140. Sixteen studies (42%) used participants trained in using 
WSI systems. Washout periods between comparisons ranged from none to more 
than 12 months. Eight WSI scanner manufacturers were represented in the studies, 
with Aperio (Aperio, Vista, California) scanners used in the majority of the studies (n 
= 23; 61%). Interobserver agreement was measured in 6 studies (16%), whereas 32 
studies (84%) measured intraobserver agreement. The most commonly studied 
individual organ system was the gastrointestinal system (n=7; 18%). Ten studies 
(26%) were a mix of 2 or more distinct organ systems.  
The study reported a mean diagnostic concordance of WSI and light microscopy, 
weighted by the number of cases per study, of 92.4%. Of the 30 studies quoting 
concordance as a percentage, 60% showed a concordance of 90% or greater, of which 
10 showed a concordance of 95% or greater. There was a trend for increasing 
concordance in the more recent studies. Concordance levels were higher in studies 
which explicitly documented that participant pathologists had been trained in the 
use of the WSI system.  The review found evidence to support a high level of 
diagnostic concordance for WSI overall.  
 
3.1.2 A systematic analysis of discordant digital diagnosis 
The conclusions of the systematic review can be interpreted as encouraging for a 
diagnostic department that is considering a primary diagnostic digital adoption; 
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however, if one inverts the statistic, 92.4% concordance equates to 7.6% 
discordance. It can be argued that discordances are more valuable than 
concordances in analysing the potential patient safety impact of digital diagnosis, and 
an evaluation of the type, severity, unexpectedness, and root cause of these 
discordant diagnoses can allow us to explore safety aspects of digital pathology 
adoption and identify potential pitfalls—areas of digital diagnostic interpretation 
that may require more attention or practice before full digital adoption for primary 
diagnosis. Experience in analysing error rates and types in telepathology, including 
that published by Dunn et al,48 has contributed greatly to our understanding of the 
limitations and strengths of this diagnostic medium, and gathering and analysing 
similar data from WSI studies is likely to prove equally beneficial.  
The primary aim of this review and analysis was to systematically examine the 
published literature on discordant pathologic diagnoses rendered by WSI compared 
with those rendered by light microscopy, and to identify areas that may be 
problematic to diagnose using digital microscopy.  
 
3.2  Materials and methods 
A systematic review protocol that had been used in our  previous systematic review 
of WSI concordance was used.38 The review protocol is registered with the PROSPERO 
database (registration number CRD42015017859). 
 
3.2.1 Search Strategy 
An electronic search was instigated on the databases Medline, Medline in Progress, 
EMBASE, and the Cochrane Library between 1999 and December 2015, using the 
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previously published systematic review methodology. 38  A search of clinicaltrials.gov 
(Bethesda, Maryland) was performed to identify any ongoing studies. Included 
studies underwent manual reference searching and citation tracking through 
PubMed and Google Scholar. Corresponding authors were contacted, where 
possible, to identify subsequent or ongoing research. 
 
3.2.2 Paper Screening 
Two pathologist reviewers independently subjected the abstracts of papers to the 
previously used systematic review screening algorithm.38 In cases of disagreement, a 
third independent pathologist reviewer was consulted. Full texts of all papers that 
fulfilled the initial screening algorithm were retrieved and reviewed. Only published 
journal articles were included in the review. 
 
3.2.3 Data Extraction and Analysis 
A standardised data extraction protocol was applied to all included studies. Pairs of 
discordant diagnoses were extracted (preferred diagnosis with discordant diagnosis) 
and were stored in a spreadsheet in which the source study and the method of 
diagnosis (glass or digital) used to render each diagnosis were concealed from the 
reviewers. A team of 3 discordance reviewers was assembled, all of whom were 
professional diagnostic pathologists, with 6, 18, and 34 years of pathology 
experience. 
The 3 discordance reviewers evaluated each diagnostic pair and assigned it a 
category based on the Royal College of Pathologists System of Categorisation for 
Discrepancies.49 In this system, discordances are assigned a letter code depending on 
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the type of error (ie, errors in macroscopy, microscopy, clinical correlation, failing to 
seek a second opinion, misidentification). For this study, the B category, 
discrepancies in microscopy, was the most relevant. The B category errors are then 
stratified depending on how unexpected or understandable the error is (Table 3 ).  
 
Category Description 
A Inadequate dissection, sampling or macroscopic description 
 
B1 Discrepancy in microscopy – a diagnosis that one is surprised to see 
from any pathologist 
 
B2 Discrepancy in microscopy – a diagnosis that is clearly incorrect, but 
that one is not surprised to see a small percentage of pathologists 
suggesting 
 
B3 Discrepancy in microscopy – a diagnosis where interobserver 
variation known to be large (eg. difficult diagnosis, difference 
between 2 tumour grades) 
 
C Discrepancy in clinical correlation 
 
D Failure to seek a second opinion in an obviously difficult case 
 
E Discrepancy in report (includes misidentification) 
 
Table 3. Summary of Royal College of Pathologists system of categorisation for 
discrepancies. Each discrepancy is assigned an alphanumeric code indicating the type of 
error. 
 
 
Next, each reviewer assigned each discordant diagnostic pair a category 
corresponding to the potential for patient harm to be caused, from the Royal College 
of Pathologists guide to duty of care reviews (Table 4).50 The spectrum of harm ranges 
from no clinical impact, no harm, which is categorised as 1, to severe harm, 
categorized as 5. Dimensions such as delay in diagnosis, unnecessary further 
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diagnostic efforts, delays in therapy, unnecessary therapy, and resultant levels of 
morbidity or mortality were considered. All discordances were reviewed 
independently by the 3 discordance reviewers.  
 
 
Category Description 
1 No impact on care. 
 
2 Minimal harm, no morbidity. Delay in diagnosis or therapy only, of 
less than 3 months. Unnecessary noninvasive further diagnostic 
efforts. Unnecessary therapy without morbidity.  
 
3 Minor harm, minor morbidity. Delay in diagnosis or therapy only, of 
more than 3 months. Unnecessary invasive further diagnostic efforts. 
Delay in therapy with minor morbidity. 
 
4 Moderate harm, moderate morbidity. Due to delay in diagnosis, due 
to otherwise unnecessary diagnostic efforts, due to otherwise 
unnecessary therapeutic efforts. 
 
5 Major harm, major morbidity. Loss of limb, organ, or function of 
organ system due to unnecessary therapeutic efforts. Death. 
 
Table 4. Summary of Royal College of Pathologists categorisation of discrepancies for 
duty of care reviews. Each discrepancy is assigned a category number indicating the 
potential for harm to be caused to a patient. 
 
For the potential for harm categorisations, the Royal College categories 2 and 3 
(minimal harm, no morbidity, and minor harm, minor morbidity) were merged into a 
single category of minimal/minor harm, and categories 4 and 5 (moderate harm, 
moderate morbidity, and major harm, major morbidity) were merged into a single 
category of moderate/major harm. Where reviewers disagreed on the categorisation 
of a diagnostic discordance, cases were discussed and a consensus reached. Expert 
opinion was sought on the renal transplant biopsy data, as the review team did not 
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feel they had sufficient subspecialty expertise in this area (Dr Carole Angel, MB, ChB, 
Leeds Teaching Hospitals NHS Trust).  
 After all cases had been categorized, the lead researcher reunited the discordant 
pairs with source study data. For each individual discordance, the source paper was 
examined to extract data determining whether glass or digital slides yielded the gold 
standard or consensus diagnosis; the type of diagnosis required; the type of 
discordance; any specific diagnostic tasks, objects, or features that would have 
enabled the pathologist to make the true diagnosis; and detail from the paper of any 
particular difficulties/observations encountered by the study pathologists. See Table 
5 for an example of a discordance analysis. 
 
Parameter Example 
True diagnosis Focal active colitis 
 
Discordant diagnosis Normal colon 
 
Gold standard diagnostic modality Glass 
 
RCPath expression of concern code B2 (clearly incorrect, but would expect 
a small proportion of pathologists to 
make the same error) 
 
RCPath potential for harm code 2 (minor harm, minor morbidity) 
 
Discordance type Missed diagnosis 
 
Diagnostic tasks/objects/features Finding and identifying small objects 
(neutrophils) 
 
Details from paper Granulocytes difficult to discern on 
digital. Improved at 40x. 
 
Table 5. Example of a discordance analysis for a colonic biopsy. In this case, the gold 
standard, “true” diagnosis was made on the glass slide, and a discrepant diagnosis was 
made on the digital slide. 
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3.3 Results 
3.3.1 Study Demographics 
One thousand three hundred abstracts were checked and 39 full-text papers 
extracted. Of these, 23 contained detailed, extractable discordant diagnostic pair 
data.51-73 Publication dates ranged from 2006 through 2015, with the majority of 
studies published post-2010. These 23 papers included 8069 instances of a glass 
diagnosis and a digital diagnosis being compared. Out of these 8069 glass-digital read 
pairs, 335 instances of discordance were recorded, which represents 
approximately 4% of 8069 glass-digital comparisons. The included studies used a 
range of scanners from 7 different vendors. Viewing hardware varied greatly both 
within and among studies. Many studies provided little information on viewing 
hardware/scanners or failed to standardise viewing hardware. The majority of 
studies scanned slides at a routine magnification of 20x, with more recent 
publications tending to use 40x, and some varying the scanning magnification 
depending on the type of case, for example, diagnostic specimens at 40x and 
therapeutic specimens at 20x. 
The majority of included studies scanned a mixture of cases from a number of 
histopathology subspecialties. Ten studies were a mix of 2 or more distinct organ 
systems, which was termed a case mix, with gastrointestinal and skin the most 
popular single pathology specialties examined. The majority of recorded 
discordances occurred in gastrointestinal, skin, genitourinary, and gynaecological 
cases. Unfortunately, many of the source studies lacked a sufficiently detailed 
breakdown of case types included, but it is likely that cases from these organ systems 
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are overrepresented in the source studies. They are certainly all high-throughput 
specialties. 
 
3.3.2 Severity and Implications of Discordance 
Of the 335 reported discordances, glass was the preferred diagnostic modality in 286 
cases (85%). Interestingly, the digital diagnosis was preferred in 44 cases (13%), with 
an equivocal response in the remaining 6 (2%). The largest specific category of 
discordance was missed diagnosis of malignant/dysplastic/atypical conditions, where 
malignant tissue was given a benign diagnosis. In these cases, glass was the preferred 
diagnostic modality in 66 of 77 cases (86%). There were also 25 cases where benign 
tissue was erroneously diagnosed as malignant/atypical. Here glass was the 
preferred diagnostic modality in 23 cases (92%) (Table 6).  
 
The second greatest discordance type (70 cases) was where a case was recognised as 
malignant/atypical but incorrectly typed or graded. Here again, glass was the 
preferred diagnostic modality in 67 cases (96%). Discrepancies in the diagnosis of 
inflammation were also common. Most discordances (169 cases) fell into the 
category of B3, areas of appreciable diagnostic difficulty and recognised 
interobserver variation, such as the difference between 2 adjacent grades of a 
malignant condition. In total 21 B1 diagnoses were recorded. These would be 
regarded as surprising errors using the Royal College of Pathologists’ System of 
Categorisation for Discrepancies.49 One type E discordance was recorded—a 
misidentification error, where digital was the preferred diagnostic modality (Table 7).  
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Discordance type Glass preferred Digital preferred Total 
Missed malignant/ 
atypical diagnosis 
 
66 11 77 
Erroneous malignant 
diagnosis 
 
23 2 25 
Difference in malignant 
diagnosis (including 
grading/subtype 
differences) 
 
67 3 70 
Missed inflammation 
 
40 2 42 
Erroneous diagnosis of 
inflammation 
 
6 2 8 
Difference in diagnosis 
of inflammation 
(including 
subtype/degree) 
 
15 2 17 
Invasion missed 
 
2 5 7 
Erroneous invasion 
 
4 0 4 
Other 
 
63 17 80 
Total 286 44 330 
Table 6. Types of discordance 
 
 
Category and description Glass preferred Digital preferred Total 
B1 Surprising error 
 
19 2 21 
B2 Expect small number of 
pathologists to make this 
type of error 
 
123 16 139 
B3 Area of appreciable 
difficulty/interobserver 
variation 
 
144 25 169 
E Misidentification 0 1 1 
 
Table 7. Types of discordance classified by the Royal College system for discrepancy 
classification. 
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The majority (242; 72%) of the 335 discordances reported had the potential to cause 
minimal or minor harm to patients. This represents 3.0% of all glass-digital 
comparisons (242 of 8069). Only 28 of 335 (8%) had the potential to cause moderate 
or major harm to patients. This represents 0.35% (28 of 8069) of all glass-digital 
comparisons. For these, glass was the preferred diagnosis in 26 (93%). Digital was 
preferred in 2 of 28 cases (7%) with the potential for moderate/major harm (Table 
8).  
 
Harm category Glass preferred Digital preferred Total 
No impact 
 
51 9 60 
Minimal/minor 
harm 
 
209 33 242 
Moderate/major 
harm 
 
26 2 28 
 
Table 8. Potential for harm in discordant case scenarios. 
 
Table 9 shows specific instances of major/moderate harm recorded on diagnoses 
made using digital and conventional glass slides. Instances where the glass slide 
diagnosis was preferred included benign breast tissue erroneously reported as 
invasive carcinoma on the digital read and a benign lung biopsy erroneously 
diagnosed as non–small cell carcinoma. Examples where malignant diagnoses were 
missed on the digital read of a case included gastric adenocarcinoma called acute 
gastritis, metastatic melanoma missed in a lymph node, and chronic lymphocytic 
leukaemia missed in a skin biopsy. Digital was the preferred diagnostic modality for 
2 cases with the potential for moderate/major harm: a carcinoid tumour that was 
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missed in the glass examination of an appendix, and benign breast tissue erroneously 
diagnosed as ductal carcinoma in situ on glass. 
 
Preferred diagnostic 
modality 
Discordant diagnosis True diagnosis 
Glass Invasive carcinoma with 
lobular features 
 
Benign breast tissue 
Glass Non-small cell lung 
cancer 
 
Chronic bronchitis 
Glass Acute gastritis 
 
Adenocarcinoma 
Glass Lymph node, no 
abnormality detected 
 
Metastatic melanoma 
Glass Dermatitis Skin infiltration with 
chronic lymphocytic 
leukaemia 
 
Digital Acute appendicitis Goblet cell carcinoid 
tumour 
 
Digital Ductal carcinoma in situ Fibrocystic change 
 
Table 9. Examples of diagnostic scenarios with the potential to cause major/moderate 
harm 
 
 
3.3.3 Types of Discordance 
3.3.3.1 Dysplasia Diagnosis 
The included studies reported 108 of 335 discordances concerning the diagnosis of 
dysplasia, representing 32% of all reported discordances. These were predominantly 
cases from the upper gastrointestinal tract and the cervix. Dysplasia is an area of 
appreciable interobserver and intraobserver variation, but nonetheless, dysplasia 
discordances seemed to be particularly prevalent. The majority of discordances were 
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instances of missed diagnosis, where dysplastic tissue was diagnosed as benign or 
reactive tissue. Fifty-one cases of this type were reported, and they represented 47% 
(108) of all dysplasia related discordances. Interestingly, where there were 
differences in grading, dysplastic lesions tended to be undercalled (undergraded or 
missed diagnosis as opposed to overgraded or erroneously diagnosed) on the digital 
microscope (33 cases undercalled, 8 cases overcalled). There were also errors in the 
other direction, with erroneous dysplasia diagnosed in benign tissue (14 cases) and 
a smaller number of overcalls in grading (10 cases). Of all the discordant dysplasia 
diagnoses, glass diagnosis was preferred in 101 of 108 cases (94%). This indicates that 
diagnosis and grading of dysplasia may be a pitfall of digital diagnosis (Table 10). 
 
 
Dysplasia 
discordance type 
Glass preferred Digital preferred Total 
Missed diagnosis 
 
47 4 51 
Grading undercall 
 
33 0 33 
Erroneous 
diagnosis 
 
13 1 14 
Grading overcall 
 
8 2 10 
Total 101 7 108 
 
Table 10. Summary of discordant dysplasia diagnoses 
 
3.3.3.2 Locating Small Diagnostic Objects/Features. 
Another common diagnostic feature implicated in discordance is the ability to find or 
not find a small diagnostic/prognostic object. Thirty-nine discordances of this type 
were recorded, with glass the preferred diagnostic medium in 30 of 39 (82%). The 
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majority of these discordances would be classified as B2 errors in microscopy, which 
one expects to see in a small proportion of cases as a matter of course. Three small 
object location discordances were classified as surprising errors based on the 
context. In total, 5 of the small object location discordances could have resulted in 
moderate/major patient harm. The types of small object missed included a range of 
malignant and benign features. Perhaps the most concerning of these are small 
tumors, metastases, and microsatellites. The most common small objects missed 
were foci of inflammation, more specifically cryptitis in colon biopsies. The detection 
of microorganisms was also a theme raised in the literature. (Table 11). 
 
Category Object Glass 
preferred 
Digital 
preferred 
Neoplasia Small primary tumour 
 
1 2 
 Lymph node metastasis 
 
3  
 Tumour microsatellite 
 
1  
 Focal tumour invasion 
 
3 3 
Inflammation Focus of inflammatory 
activity 
 
8  
 Granuloma 
 
3  
Micro-organisms Helicobacter pylori 
 
2  
 Candida 
 
3  
Sparse cells Reed-Sternberg cells 
 
2  
Focal benign features 
 
 5 2 
Focal immunopositivity 
 
 1  
 
Table 11. Discordances related to difficulty locating diagnostic objects 
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3.3.3.3 Specific Problematic Entities Reported in the Literature 
 
Granulocytes were mentioned in 27 of 335 instances of discordance (11%). 
Disparities in detection of granulocytes, particularly eosinophils, may relate to 
differences in the colour of the cells on digital and their refractile textures. Similar 
issues with detection of other eosinophilic, refractile objects (nucleated red blood 
cells and eosinophilic granular bodies) were reported. Difficulties were also described 
identifying 2 entities commonly recognised on the grounds of subtle textural and 
tinctorial qualities: blue mucin and amyloid. In the 2 reported cases of difficulty with 
amyloid,73study participants were unable to detect the textural quality of amyloid on 
digital slides, which would have alerted them to examine the original glass slides with 
a polariser (Table 12). 
 
Object/feature No. of cases 
Neutrophils 19 
Eosinophils 7 
Mast cells 1 
Nucleated red blood cells 8 
Eosinophilic granular bodies 1 
Amyloid 2 
Blue mucin 1 
 
Table 12. Objects and features that caused difficulty on digital slide review. 
 
3.3.3.4 Misidentification Errors 
There was one confirmed misidentification error, where the reader providing a glass 
diagnosis viewed the wrong slides, and the digital read rendered the correct 
diagnosis. 
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3.4 Discussion 
The use of digital pathology in the clinic is increasing, with many departments piloting 
digital pathology in primary diagnostic settings. In light of this, guidance is needed 
regarding potential safety implications for patients. A number of validation studies 
have been reported in the literature, but as the published systematic review 
indicated,38 these vary greatly in terms of the number and types of participants and 
cases, the methodology, and the technologies examined. In the absence of a 
multicentre clinical trial, a systematic review remains the highest level of digital 
pathology concordance evidence available for those engaged in regulatory efforts. 
Goacher et al38 found a mean diagnostic concordance of WSI and light microscopy, 
weighted by the number of cases per study, of 92.4%. In this study, the aim was to 
complement this work with a systematic analysis of the discordant diagnoses 
reported in the validation literature, in the hope that this analysis would allow a more 
precise evaluation of primary digital diagnosis. 
 
3.4.1 Dysplasia 
The diagnosis and grading of dysplasia is implicated as a possible pitfall of digital 
diagnosis. Most papers emphasise blurring of nuclear detail on digital scans, and 
implicate poor focus, exacerbated by compression artefact. These explanations focus 
on high-power diagnosis, but one should also consider low power. In cervical 
biopsies, dysplasia is often focal, and if focal abnormality is not picked up on the low-
power assessment of the epithelium, confirmatory nuclear detail cannot be 
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appreciated on high. One may also need to consider the effect of scanning 
magnification and viewing hardware quality.  
What potential strategies do pathologists have to mitigate the risks of diagnosing 
dysplasia digitally? The first thing that can be done is to ensure pathologists are 
aware that dysplasia is a potential pitfall. Ordi et al68 describe an increase in glass-
digital concordance for cervical dysplasia as their study progressed, suggesting that 
there is a significant learning curve effect for digital dysplasia diagnosis. This is an 
area of diagnosis that may need a longer settling-in period before pathologists can 
confidently and safely sign out digital cases. 
Pathologists working in relevant specialties might want to consider a self-validation 
procedure, with digital-glass reconciliation of dysplasia diagnoses while they 
establish satisfactory glass-digital concordance. Alternatively, there might be a role 
for optional or mandatory checks on glass following a digital assessment in particular 
scenarios—for example, diagnosing dysplasia in Barrett oesophagus, a practise used 
in some digital pathology deployments (Anna Boden MD, Linkoping; David Snead, 
MB, BS, Coventry; verbal communications, January 2016). Some authors describe 
limited improvement in digital dysplasia diagnosis with slides scanned at 40x, so 
there may be justification for mandatory scanning of selected specimens at 40x (eg, 
cervical biopsies, upper gastrointestinal biopsies). Unfortunately, there are 
insufficient data at present to judge whether scanning at 20x versus 40x has a 
significant impact on overall discordance rates, and this is an area that deserves more 
attention in future studies. 
 
3.4.2 Locating Small Diagnostic Objects/Focal Diagnostic Features 
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Locating small diagnostic objects is highlighted as a potential problem on digital slide 
reads. Navigation is certainly implicated, both within and among slides, and the 
effects of display resolution and scanning magnification also warrant consideration. 
In many studies, authors explicitly state that pathologists found navigating cases 
cumbersome. Specific training in safe and efficient navigation strategies using digital 
software should be available to pathologists who are expected to use digital images 
clinically. Appropriate use of whole slide and whole case thumbnails can aid 
navigation, and safety features such as indicator lights to warn pathologists of missed 
slides/regions could help. There may be a case for modifying workflows to 
incorporate a mandatory glass check, at least in the initial phases of digital 
deployment, for specimens such as sentinel lymph nodes, where detection of 
micrometastases should be optimal. There is little evidence in the literature 
regarding minimum specification for viewing hardware or standardization of viewing 
hardware. Many authors found diagnostic biopsies, particularly where detection of 
inflammatory disease is important, were best scanned at 40x, with Snead et al69 
recommending 60x in cases where detection of micro-organisms is a priority. 
 
3.4.3 Specific Objects/Features Causing Diagnostic Difficulty 
Examination of the literature highlights a number of specific entities, including 
granulocytes, nucleated red blood cells, and amyloid, which were reported as having 
a different appearance on glass and digital slides. The importance or relevance of 
identifying these entities will vary among different subspecialties, and possibly 
among different pathologists, but it is important to mention areas where 
investigators have noticed an appreciable difference in appearance.  
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Specialty pathologists need to be aware of specialty specific diagnostic pitfalls and 
decide how important these features are to their own practice. Bauer and Slaw58 
report that scanning gastrointestinal biopsies at 40x improved the ability of their 
pathologists to detect and correctly categorize granulocytes. Colour calibration may 
potentially play a role. 
 
3.4.4 Misidentification Errors 
A single case of misidentification error was reported in the review source literature. 
In this case, the correct diagnosis was rendered on the digital slide, and the glass slide 
reviewer viewed the incorrect glass slide. It perhaps reminds us of the potential 
digital technology provides us to avoid the type of pathology error that should never 
occur: the misidentification of specimen, slides, or reports. The types of study design 
used in the source material for this analysis are unlikely to expose the full extent of 
misidentification errors, which should be considered when evaluating the total 
impact of digital versus glass technology on diagnostic error rates. 
 
3.5 Conclusions 
Given the increasing trend towards using digital pathology for clinical diagnosis, 
including primary diagnosis, the need for evidence-based digital pathology guidelines 
and a systematic evaluation of the available evidence is paramount. In this analysis 
of 8069 comparisons of glass and digital diagnoses, 335 discordances were found. Of 
these, only 28 had the potential to cause moderate or major patient harm. 
A number of problem areas in digital diagnosis were found that warrant further 
exploration and explanation; namely the identification and grading of dysplasia, the 
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location of small diagnostic objects and features, and the identification of certain 
specialty-specific diagnostic features. This information can be used to inform safe 
departmental or institutional adoption of digital pathology and to help design 
systems and process to address these areas in the future. Although digital 
deployment for primary clinical diagnosis is in its infancy, it is important to collect 
and share data on pitfalls and problem cases. To this end, it might be helpful to create 
a centralised database of problematic cases, recorded in a standardised format. 
Education and continuing professional development of pathologists on an individual 
level is vital to ensure a safe and responsible rollout of digital microscopy. 
Pathologists should be encouraged to gain confidence in risk-free or risk mitigated 
diagnostic environments before adopting a 100% digital workflow. The perceived 
success or failure of digital pathology in a specific laboratory will stand or fall based 
on the competency and confidence of individual pathologists, and it is therefore 
important that pathologists understand the strengths and limitations of the WSI 
systems. The studies included in this analysis used a wide variety of different 
scanners, with different characteristics that could affect diagnostic interpretation of 
slides. In light of this, it can be argued that it is important that diagnostic departments 
perform their own whole-system validations for WSI, to evaluate the strengths and 
weaknesses of the combination of hardware and software components they propose 
to use for primary diagnosis.  
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Chapter 4. Developing a training and validation protocol for primary 
histopathological diagnosis using digital pathology 
 
4.1 Background  
For digital pathology to be accepted by the clinical pathology community for standard 
reporting practice, pathologists will need to feel confident in their abilities to 
diagnose using digital slides. From the author’s experience working with the Leeds 
pathology cohort, and visiting other facilities in the UK and Europe, departments 
generally have an even mix of 3 types of pathologist when it comes to digital 
adoption: “enthusiasts”, “uncertains” and “sceptics”. The enthusiasts are the typical 
early adopters, who embrace technology with enthusiasm and positivity – they are 
eager to deploy and use digital pathology as soon as possible. At the other end of the 
spectrum are the sceptics, who are quick to identify potential problems with 
digitisation and its impact on their working day, service delivery and the profession. 
Members of both groups are usually vocal in their opinions, and can exert influence 
over the third group, the “uncertains”. 
These are individuals that tend to resist any attempts to engage them in discussions 
or planning meetings regarding digital pathology. Their worries and concerns are 
harder to elicit. A comprehensive departmental training programme for digital 
pathology should provide a useful and meaningful experience for members of all 
three groups, not just the enthusiasts, and equip them with skills and approach to 
report digital cases safely and confidently.  
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4.2 General principles and overview 
Digital pathology remains a relatively novel technology, and while the literature 
suggests it is safe, there is limited experience of its use in clinical practice. In light of 
this, a cautious, safety focused approach, where microscopes are still readily 
available for slide review where needed would seem prudent.  
Any histopathology department will usually house a mixture of enthusiasts and 
sceptics, and pathologists are a heterogeneous population in terms of their 
background computer skills, attitude to technology and attitude to risk. A pathologist 
needs to reach a state where they are not just competent, but confident in their use 
of the digital pathology reporting system and the validity of their digital diagnosis. A 
number of approaches are possible, but a successful training and validation 
procedure should result in: 
-  Pathologists that are confident in their abilities and their limitations with 
digital diagnosis. 
- Pathologists that are familiar with their hardware and software and can 
recognise and report performance issues. 
-  A department with a shared understanding of and investment in their digital 
pathology system. 
-  A department that can develop bespoke ways of using digital to improve its 
outputs, workflows and working environment. 
The College of American Pathologists validation guidelines advises that a minimum 
of 60 cases per “use case” should be viewed on digital and glass, with a washout 
period of at least 2 weeks between reads and diagnostic concordance rate 
observed.74 This experimental validation design can help a department confirm that 
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their digital pathology system produces diagnostic grade images, but does not offer 
the individual pathologist an opportunity to gain competence and confidence in 
digital reporting. The Royal College of Pathologists recommends training and 
validation which reflects ‘real world’ diagnosis, with the emphasis on individual 
professional development.1 The validation protocol  developed at Leeds Teaching 
Hospitals NHS Trust combines a brief period of hardware and software 
familiarisation, followed by focused training using cases relevant to the pathologists 
workload which test potential ‘pitfalls’ of digital diagnosis and a period of dual 
reporting, with initial digital assessment followed by a safety check on glass slides.  
 
Pathologists can train singly or in small cohorts, ideally grouped by subspecialty. 
Ideally, a departmental ‘trainer’ should oversee the validation of colleagues. This 
could be a consultant or suitably enthusiastic trainee. Alternatively, pathologists 
could self-train and self-validate, although discussion with peers is recommended 
where possible, as this facilitates sharing of and access to a wider range of ‘difficult 
cases’ and early discussion of departmental workflows. 
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Validation stage Overview 
Training (T) One to one formalised training in digital 
microscope use 
Observed practice with feedback 
Validation – training cases (V1) Training set of approximately 20 
challenging and informative cases 
relevant to the individual pathologists 
regular workload. 
Participant views the cases as WSI, makes 
notes on diagnosis and diagnostic 
confidence in a workbook, then 
immediately checks the glass slides of the 
case, and records any change in their 
assessment of the case. 
Allows identification and mitigation of 
pitfalls. 
Validation – live reporting (V2) All cases scanned prospectively. Diagnosis 
made on WSI, with reconciliation with 
glass slides before case sign out. 
Pathologist aims to complete 
approximately 2 months whole time 
equivalent workload. Difficulties reported 
and discussed. Library of problematic 
cases assembled and reviewed. 
Summary and recommendations (S) Validation document produced for 
individual pathologist documenting 
concordance and diagnostic confidence 
throughout the validation.  
Recommendation made for scope of 
digital reporting practice or further 
training. 
 
Table 13. Summary of the validation and training protocol for primary digital diagnosis. 
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4.3 The protocol phases in detail 
4.3.1 Training phase 
The aim of the training phase is to allow the pathologist to familiarise themselves 
with the hardware and software components of their departmental digital pathology 
system and provide feedback on the pathologist’s use of that system to optimise 
their initial experience of digital reporting. An initial training package could include a 
group or individual teaching session based on a powerpoint presentation. This 
presentation should include the following: 
- Description of the components of the departmental digital pathology system 
(scanners, image management software, reporting workstations including 
diagnostic screens, slide viewing software).- 
- Stepwise description of the validation/training protocol (outlined in table 1). 
-  Description of digital pathology workflows in the laboratory. 
-  Description and examples of common digital image artefacts/ system 
performance issues and how to report these to appropriate team members. 
- Commonly encountered areas of diagnostic difficulty on digital slides (these 
will be discussed later in this thesis). 
- Contact details of key team members who can answer queries regarding 
digital pathology training, validation, scanning and so on. 
At this stage, pathologists can be given access to a digital copy of the training 
presentation, standard operating procedures (SOPs) for digital pathology validation, 
an SOP for digital reporting and a guide/instruction manual to using the digital 
pathology slide viewer. After this, it is useful to have an individual session with the 
pathologist, in which trainer and pathologist open and view training cases. These 
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should include larger, multislide cases which require navigation between slides. The 
trainer can observe the pathologist’s use of the mouse/other input device and offer 
suggestions for ergonomic and efficient navigation of slides and specimens. Basic 
features of the viewing software, including use of zoom and measurement and 
annotation tools should be demonstrated, until the pathologist is happy to open, 
navigate and assess cases without the assistance of the trainer. 
 
4.3.2 .Validation training cases (V1) 
In this part of the validation, the pathologist views a set of pre-prepared educational 
cases, which are selected to reflect areas of expected diagnostic difficulty on digital 
and represent learning targets. The slide sets should be assembled from local 
departmental archives, so they represent the histology and staining protocols from 
the participant’s own laboratory/laboratories. Case sets should be assembled which 
reflect the practice of the individual pathologist – for instance, a breast pathologist 
should just view breast cases, someone that reports that lung and skin should view a 
mixture of both topographies. Care should be taken to include a range of tissue types, 
diagnoses and stains. It may be helpful to recruit a trainee pathologist to help 
assemble cases and create topographical training sets— these are also a fantastic 
resource for trainees to view. A maximum of 20 cases would seem prudent to balance 
training needs and time constraints of pathologists. ‘Cases’ can be a mixture of 
complete, multislide cases and single representative slides of particular entities. 
Inclusion of complete resection cases allows the pathologist to test their digital slide 
navigation skills and competence in use of digital measuring tools, while single slide 
cases can be used to demonstrate the digital appearance of particular diagnostic 
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features (eg, amyloid, weddelite) and to assess their skills in digital dysplasia grading 
and mitotic scoring.  
Once collected, the glass slides for the training cases should be scanned using the 
departmental scanning protocol. At Leeds, scanning at 40× equivalent magnification 
is recommended  for primary diagnostic work. The pathologist should be given access 
to the digital slides for the cases and the relevant clinical information pertaining to 
the case. The pathologist should view the digital slides for a case, record their 
diagnosis in a workbook and record their confidence in that diagnosis on a Likert scale 
of 1–7. They should then immediately consult the corresponding glass slides of the 
case and directly compare the glass slide and digital slide representation. This form 
of validation by direct comparison allows the pathologist to appreciate subtle 
differences in the representation of the case on digital and glass slides and become 
confident in their interpretation of the digital slide. The pathologist should record 
any change in their assessment of the case after consulting the glass and again record 
their diagnostic confidence. Once the pathologists have viewed all the cases, they 
can discuss these with the trainer and their colleagues and will hopefully have 
identified some key areas to concentrate on as they move on to the live reporting 
phase of the validation. 
 
4.3.3 Validation—live reporting phase (V2) 
In this phase of the validation, the pathologist is asked to make all their live diagnoses 
on digital slides, using their own workload. The pathologists make their diagnosis on 
the digital slides, but with immediate glass reconciliation prior to case sign-out. A 
whole time equivalent of 2 months allows the pathologist to view an appropriate 
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breadth and depth of cases, including an appropriate mix of biopsies and resections. 
The length of time needed to gain confidence in digital reporting is likely to vary by 
pathologist, and some may take longer to navigate the learning curve than others. 
The pathologist should record all cases viewed and record any alterations made to 
diagnoses following glass slide review on a spreadsheet. The pathologist should be 
given regular opportunities to discuss discordant or difficult cases with the 
trainer/their peer group. Discordant cases should be collected and used to create a 
library of ‘difficult on digital’ training cases, which can be used as a departmental 
resource for further training.  
 
4.3.4 Validation summary and recommendations (S) 
When the pathologists have completed a suitable period of live reporting, their 
spreadsheet data should be reviewed and concordance and discordance statistics 
calculated and put into a report. Data reports should include: 
- Record of all training meetings. 
- Training set concordance rate as a %. 
- Detailed description of discordances from the training set. 
- Total number of cases viewed in the live reporting phase. 
-  Number and percentage of concordant cases. 
- Detailed description of discordances from the live reporting phase. 
Following review of the data, the pathologist and trainer should reach a mutual 
decision on the result of the validation procedure. There are three possible 
outcomes: 
1. Fully validated for primary digital diagnosis in the specified diagnostic area. 
97 
 
2. Validated for primary digital diagnosis in the specified diagnostic area, with some 
exceptions. 
3. Not validated for primary digital diagnosis in the specified diagnostic area at this 
time. 
In the majority of cases, an outcome ‘2’ will be the most appropriate designation. In 
this case, the pathologist and trainer should agree on the scope of digital practice 
and mandate glass slide checks for particular diagnostic scenarios/case types outside 
of the scope. For instance, if at the end of the validation procedure, the pathologists 
still lack confidence in mitotic scoring, they could agree to safety net glass slide 
reconciliation before sign-out for cases with borderline/critical mitotic count scores. 
As the pathologist gains experience post-validation, the scope and exceptions can be 
reviewed and modified as appropriate. 
 
 
4.4 Conclusion 
The validation protocol was developed with the needs of all 3 categories of 
pathologist in mind: the enthusiasts, uncertains and sceptics. (See figure 11). 
The enthusiasts get to experience real-world digital reporting as soon as they have 
completed their brief training set in V1. The period of glass slide checking in V2 allows 
some time for reflection and appreciation of difficulties they may not have 
anticipated. The “uncertain” pathologists get the assurance of a safety net – they can 
explore the technology and its capabilities in a risk modified setting, without 
committing to full digitisation. The more sceptical members of a department get to 
put the clinical WSI system through its paces, and will be able to provide focussed 
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feedback on parts of the system and workflow that succeed, and those that are in 
need of modification.  
 
 
 
Figure 11. Categorisation of pathologists. Experience at Leeds Teaching  Hospitals suggests 
that pathologists can be divided into 3 categories: the enthusiasts, the uncertains and the 
sceptics. 
 
Following development of the protocol, the decision was made to trial it on a cohort 
of 3 specialist breast histopathologists. This group was chosen for a number of 
reasons. Firstly, breast pathology is an area with appreciable inter- and intraobserver 
variation, where diagnosis is often dependent on tasks that my systematic analysis 
(chapter 3) suggested might be difficult on digital slides (eg. nuclear dysplasia, mitotic 
counts, weddelite detection. Secondly, for historical reasons, the breast pathologists 
are located in a separate wing of the hospital at St James’ University Hospital from 
the histology laboratory and the rest of the diagnostic pathologists. Reporting of glass 
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slides was dependent on infrequent, often unpredictable delivery of glass slides by a 
porter from the laboratory, to this separate wing. WSI reporting could offer early 
benefits to this group, allowing more timely, continuous transfer of slides for 
reporting. Finally, and fortuitously, a pre validation questionnaire distributed to the 
group suggested that the three pathologists represented all 3 categorisations – 
enthusiast, uncertain and sceptic, and would be a representative group for trial of 
the protocol. In the next chapter, data from the first instances of real world use of 
the validation protocol will be presented.  
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Chapter 5 Validation in practice 
This chapter summarises work by the author from the following publications: 
Williams BJ, Hanby A, Millican-Slater R, Nijhawan A, Verghese E, Treanor D 
Digital Pathology for the Primary Diagnosis of Breast Histopathological Specimens: 
an Innovative Validation and Concordance Study.  
Histopathology 2018;72:662-671. 
 
Williams BJ, Ismail A, Chakrabarty A, Treanor D 
Clinical Digital Neuropathology: Experience and Observations from a Departmental 
Digital Pathology Training Programme, Validation and Deployment 
 Journal of Clinical Pathology 2020; doi: 10.1136/jclinpath-2019-206343. [Epub 
ahead of print] 
 
In this chapter, the first two instances of clinical use of the digital pathology validation 
protocol outlined in chapter 4 are described. Firstly, with a cohort of 3 breast 
histopathologists, and then with a neuropathology team, composed of 2 consultant 
histopathologists. Both studies were performed in the histopathology department of 
St James University Hospital, Leeds, United Kingdom, a large academic institution and 
tertiary cancer centre with full histopathologist subspecialisation, which processes in 
the region of 250,000 H&E stained histology slides per annum. 
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5.1 Primary Diagnosis of Breast Histopathology 
5.1.1 Background 
52000 new breast cancers are diagnosed each year in the UK, accounting for 15% of 
all new cancer diagnoses, and making this the most common cancer in the UK. 75 
Diagnosis of breast cancer, and its differentiation from benign breast diseases is 
dependent on the histopathological examination of tissue biopsies under the 
microscope. The use of whole slide imaging in clinical breast pathology is very limited. 
Digital slides are utilised by medical students and junior doctors in undergraduate 
and postgraduate medical education, with breast histopathology images accessible 
online at sites including the online Atlas for Breast Pathology76 and the virtual 
microscopy website of the University of Leeds. 77 In research, digital slides allow for 
simplified centralised review of breast cancer material in large multicentre studies, 
an option explored by the Prospective Study of Outcomes in Sporadic versus 
Hereditary breast cancer (POSH) cohort study, amongst many others78, 79. In the 
LORIS trial, which aims to address the overtreatment of screen detected ductal 
carcinoma in situ, trial entry depends on real time review of digital slides rather than 
glass slides to assess eligibility. 79 
 
In clinical pathology breast pathologists are under increasing pressures in terms of 
breast cancer case volume, case complexity, and the need for rapid evaluation and 
review to meet cancer diagnostic and therapeutic targets. A small number of digital 
pathology validation studies have focused on the use of whole slide images for the 
diagnosis of breast biopsies. Al-Janabi et al demonstrated a 93% concordance rate in 
a single reader study of 100 breast biopseis56 whilst Campbell et al found 
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intraobserver concordance rates between digital and glass diagnosis of 85 breast 
biopsies for 3 pathologists was 95.4%.60 Both studies identified discordant diagnoses 
regarding a select group of diagnostic scenarios: differentiation between hyperplasia 
and atypical ductal hyperplasia (ADH), the differentiation of benign phyllodes 
tumours from fibroadenomas, and the identification of foci of 
microinvasion/lymphovascular invasion. In their validation study, Reyes et al found 
digital:glass variation in diagnosis varied between 1% and 4% for their 3 pathologists, 
and in all cases of discordance, the diagnostic issue was the differentiation of ductal 
hyperplasia from atypical hyperplasia.80 
 
The majority of breast digital pathology validation studies in the literature focus on 
biopsy specimens, whilst in real practice, a large proportion of the pathologist’s time 
is spent viewing resection specimens, where a checklist of histological parameters of 
an excised tumour need to be assessed and recorded. Shaw et al published their 
experience reviewing both glass and digital slides of breast cancers from the POSH 
breast cancer cohort study78. 9 pathologists collected data items from digital slides 
of breast tumours, and then reviewed the glass slides at a later date. Diagnostic 
performance with the digital slides was comparable to conventional light microscopy. 
There was better agreement on degree of tubule formation between different 
reviewers using digital slides than glass slides. The authors suggest that this supports 
the assertion that the whole slide view provided in digital pathology permits superior 
assessment of the architecture of a lesion compared with light microscopy. A recent 
non inferiority study compared reads of 299 breast cases by 4 pathologists, and found 
103 
 
no significant difference in the incidence of major discordances using digital 
microscopy versus light microscopy.81 
Leeds Teaching Hospitals NHS Trust made the decision to pilot digital pathology for 
the primary diagnosis of breast histopathology specimens, utilising the novel 
validation protocol outlined in chapter 4. This protocol offered participant 
histopathologists digital microscopy training, exposure to challenging cases, and a 
risk mitigated early conversion to a full digital slide workload.  
 
5.1.2 Methods  
3 consultant breast histopathologists with 35 years of combined practice were 
recruited to participate in the validation study. Scanning of all breast histopathology 
glass slides prior to laboratory send out was initiated prior to the study period, as 
part of the departmental digital pathology deployment roadmap. Scanning was 
performed using a single Aperio AT2 scanner for standard dimension slides (Leica 
Aperio, Vista, US), and a single CS2 scanner (Leica Aperio, Vista, US) for large slides. 
Standard slides were scanned at 40x equivalent magnification, and large slides at 20x 
equivalent magnification, all with JPEG2000 compression. Automated scanning 
processes (selection of scanning area, placement of focus points) were quality 
checked and repeated manually by a laboratory technician where necessary. 
 
 Digital images were stored in a remote digital archive, along with relevant clinical 
information, including a scanned copy of the original request form, and retrieved 
using e-Slide Manager software (Leica Aperio, Vista, US). Images were viewed by 
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consultant pathologists using Leeds Virtual Microscope viewing software (University 
of Leeds, Leeds TH NHS Trust) on medical grade Coronis Fusion 6 MP, 30.40 inch 
screens (Barco, Kortrijk, Belgium). (See figure 12 for an image of a digital pathology 
workstation using during the validation) 
 
 
 
 
 
Figure 12. A digital pathology workstation in use during the breast histopathology 
validation. The central screen is medical grade, and used for slide viewing. The screens to 
either side are used to display patient information in the LIMS, and the reporting software. 
 
 
 
 
The validation structure consisted of 3 phases, a training phase (T), a validation 
training set phase (V1), a live reporting validation phase (V2) and a summary phase 
(S). (See table 13 in chapter 4 for an overview of the validation procedure). 
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 Prior to the initiation of training, each participant completed a questionnaire 
detailing their prior experience of, and attitude towards digital pathology. The 
pathologists expressed a range of views, with one expressing strong enthusiasm for 
digital pathology, one admitting they were sceptical, and one uncertain about their 
attitude to digital reporting. 
 
5.1.2.1. Training Phase (T1)  
 
In T1, each participant received a one hour individual session in basic use of the 
digital pathology slide viewer (LVM)10, and the image management software ( e-Slide 
Manager, Leica Aperio), and was issued a user manual. Participants were observed 
opening and evaluating cases, and given feedback regarding effective use of input 
modalities (mouse and keyboard shortcuts). Participants could request additional 
training as required, but none elected for this.  
 
5.1.2.2 Validation 1 – Training set (V1)  
 
In V1, each participant received a training set of 20 breast histopathology cases, in 
glass slide and digital slide formats. The training set was designed to encompass the 
breadth of breast diagnosis, and confront the participant with cases which might be 
challenging to diagnose digitally. The cases were chosen based on clinical relevance 
to our department, and the challenging digital cases were selected based on my 
systematic analysis of digital discordance (chapter 3). The cases are detailed in table 
14. Participants viewed the training set in their own time. For each case, the digital 
slides were viewed first, then the pathologist recorded their diagnosis, and their level 
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of confidence in their diagnosis, on a Likert scale from 1-7, where 1 corresponded to 
no not at all confident, and 7 to very confident.  
 
The pathologist then viewed the glass slides for the same case, immediately after the 
digital read, and recorded any alteration in their diagnosis, and their confidence in 
their glass slide diagnosis. When all participants had completed the training set, the 
results were discussed in a group with the researcher, and all participants reviewed 
discordant cases on glass and digital slides. Pathologists identified the types of case 
they found problematic on digital, so that they could ensure they were vigilant for 
these type of error in the next phase, V2.  
 
 
Case Diagnosis Domains explored 
1 Benign phyllodes tumour Diagnosis (benign fibroepithelial) 
2 Fibrocystic change, weddelite 
calcification 
Diagnosis (benign tissue), 
identification of weddelite 
calcification 
3 Fat necrosis Diagnosis (benign/inflammatory 
condition) 
4 Sparse residual ductal carcinoma, 
post chemotherapy 
Diagnosis (malignant epithelial), 
grading, immunohistochemistry 
interpretation (sparse tumour cells) 
5 Invasive ductal carcinoma, grade 
2, neuroendocrine features 
Diagnosis (malignant, epithelial), 
grading, immunohistochemistry 
interpretation, identification of 
neuroendocrine features 
6 High grade ductal carcinoma in 
situ with small, grade 1 invasive 
component 
Diagnosis (malignant 
epithelial)grading, identification of 
small invasive component 
7 Atypical ductal hyperplasia, flat 
epithelial atypia, 
microcalcification, sclerosed 
papilloma 
Diagnosis (benign and atypical 
epithelium, papillary lesion), 
identification of microcalcification  
8 Invasive ductal carcinoma, grade 
3 
Diagnosis (malignant epithelial) 
grading, immunohistochemistry 
interpretation 
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9 Paget’s disease of nipple Diagnosis (malignant epithelium), 
immunohistochemistry, special stain 
interpretation 
10 Fibroadenoma with ductal 
carcinoma in situ 
Dual diagnosis (malignant 
epithelium and fibroepithelial 
lesion) 
11 High grade ductal carcinoma in 
situ, no calcification 
Diagnosis (malignant epithelial), 
grading, identification that no 
calcification is present 
12 Benign sclerotic lesion Diagnosis (benign lesion), 
immunohistochemistry 
interpretation 
13 5mm lymph node metastasis Diagnosis (locate metastasis) 
14 Organising haematoma Diagnosis (benign/inflammatory) 
15 Apocrine metaplasia with atypia Diagnosis (borderline lesion) 
16 Lymph node with 
micrometastasis 
Diagnosis (locate micrometastasis) 
17 Nipple dermatitis Diagnosis (benign dermatosis) 
18 Mucinous carcinoma, grade 1 Diagnosis (malignant epithelial), 
grading, identification of mucin 
19 Pleomorphic lobular carcinoma, 
grade 2 
Diagnosis (malignant epithelial), 
grading, identification of 
pleomorphic lobular content 
20 Invasive lobular carcinoma, grade 
2 
Diagnosis (malignant epithelial), 
grading, identification of classic 
lobular features 
 
Table 14. Training cases for breast histopathology primary digital diagnosis 
 
5.1.2.3 Validation 2 – Live cases (V2)  
 
In V2, the totality of each participants breast pathology workload was scanned 
prospectively. The pathologists made their primary diagnoses on digital slides, 
recording them in a spreadsheet, along with their confidence in their diagnosis, 
expressed on a 7 point Likert scale. All cases were then checked on glass before final 
reporting, and any modification to the diagnosis was recorded, along with the glass 
slide confidence in diagnosis, and the preferred diagnostic medium for each case. 
Pathologists were also asked to record any technical failures – i.e. out of focus digital 
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slides, or those with any digital artefact which might preclude confident or safe 
diagnosis.  
All discordances were discussed at weekly to fortnightly validation meetings, were 
digital and glass slides were reviewed by all available participants and the researcher. 
When each participant had viewed 2 months whole time equivalent workload 
(estimated at approximately 200 cases based on departmental data), their diagnostic 
spreadsheets were analysed by the researcher, and concordance and discordance 
data was summarised. This data was discussed between each participant and the 
researcher, and the scope of that pathologist’s future digital pathology practice was 
agreed upon, with specific criteria documented for cases which require a check on 
glass before final sign out.  
 
5.1.3 Results 
5.1.3.1 Validation 1 – Training set (V1)  
 
Each participant viewed the same 20 training cases on digital slides and glass, 
consisting of 60 slides in total. Mean diagnostic concordance for all participants was 
92% (range 80% - 100%). Discordant cases concerned the following areas of 
diagnosis: mitotic count component of invasive tumour grading, failure to detect 
weddelite calcification, micrometastasis detection, and the recognition of ductal 
atypia. (see figure 13 for examples of discordant cases from the training phase of the 
validation.) 
109 
 
                                        
                                         
 
Figure 13. Missed diagnostic objects.Top image shows weddelite calcification, and 
bottom image a micrometastasis, both missed by multiple participants in the V1 
stage of validation. 
 
 
5.1.3.2 Validation 2 – Live cases (V2)  
 
The three participants viewed a total of 694 complete breast histopathology cases, 
consisting of 15,000 slides. The cases were representative of the specimen type and 
diagnostic category mix found in the departmental breast workload. (See tables 15 
and 16).  
 
Specimen type Number of cases 
Vacuum assisted biopsy 159 
Core biopsy 397 
Wide local excision 28 
Mastectomy 27 
Other excision 55 
Immunostains/special stains only 28 
Total 694 
 
Table 15. Specimen types included in the V2 caseload. 
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Diagnostic category Number of cases 
Normal tissue 
 
85 
Benign lesion 
 
308 
Lesion of uncertain malignant potential 
 
51 
Suspicious 
 
5 
Malignant – in-situ 
 
43 
Malignant – invasive 
 
145 
Lymph node specimen – no lymphoid tissue 
 
1 
Lymph node specimen – benign lymphoid 
tissue 
 
22 
Lymph node specimen – malignant, 
metastatic carcinoma or other 
 
5 
Other 
 
29 
Total 694 
 
Table 16. Types of diagnosis included in the V2 caseload. 
 
In the course of the validation, a technical failure rate of 1.0% was observed - these 
were cases where scanning artefact or focus issues with digital slides resulted in the 
pathologist rejecting the digital slides and making a diagnosis on glass. There was 
complete clinical concordance between the glass and digital impression of the case 
in 98.8% of cases. Only 1.2% of cases had a clinically significant difference in 
diagnosis/prognosis on glass and digital slides. (See table 17) 
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 Pathologist 1 Pathologist 2 Pathologist 3 All 
pathologists 
Technical 
failure rate 
(%) 
0.7 1.4 1.0 1.0 
Complete 
concordance 
(%) 
95.0 96.2 97.4 96.2 
Any 
observable 
difference (%) 
5.0 3.8 2.6 3.8 
Complete 
clinical 
concordance 
(%) 
99.3 99.1 98.5 98.8 
Clinically 
significant 
observable 
difference (%) 
0.7 0.9 1.5 1.2 
 
Table 17. Pathologist concordance and discordance percentages in V2. 
 
 
All discordances were reviewed on glass and digital by the validation group and 
trainer. Clinically significant discordances concerned the mitotic count component of 
invasive tumour grading, identification of weddelite calcification, identification of 
isolated tumour cells, assessment of a fibroepithelial lesion for cellularity, and 
identification of focal epithelial atypia. (See figure 14 for example images). 
 
 
 
 
112 
 
                                    
                                     
Figure 14. Slides that were difficult to interpret on the digital microscope. Top – a tumour 
in which a participant had difficulty identifying mitotic figures and bottom – a fibroepithelial 
lesion, both of which were difficult to assess on digital slides. 
 
The 2 most significant discordances both concerned the diagnosis of DCIS. In one 
case, a small focus of DCIS was missed on the digital read of an otherwise B3 
screening case, whilst in another case, a small focus of DCIS was correctly diagnosed 
on the digital slide in a large, multi-slide case, but missed on the initial glass review 
of the case. The pathologist had to revert to the digital case to locate the 
corresponding glass slide, and was then able to identify the DCIS on the glass, which 
had been overlooked. Use of glass slides only for this case could have resulted in 
misclassification of a B5a case as B2. (See table 18).  
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Specimen Digital diagnosis Glass slide 
diagnosis 
Preferred 
diagnosis (gold 
standard) 
Core biopsy Grade 2 invasive 
ductal carcinoma 
Grade 3 invasive 
ductal carcinoma 
Glass 
Vacuum biopsy Benign phyllodes 
tumour 
Fibroadenoma 
with inflammation 
Glass 
Vacuum biopsy Columnar cell 
change 
Columnar cell 
change plus 
atypical 
intraductal 
proliferation 
Glass 
Vacuum biopsy Sclerosing 
adenosis 
Sclerosing 
adenosis, small 
focus of ductal 
carcinoma in situ 
Glass 
Vacuum biopsy Microcysts Microcysts and 
weddelite 
calcification 
Glass 
Vacuum biopsy Benign Isolated tumour 
cells 
Glass 
Vacuum biopsy Columnar cell 
change 
Columnar cell 
change, single 
focus of atypical 
cells 
Glass 
Vacuum biopsy Small focus of 
ductal carcinoma 
in situ 
Benign Digital 
 
Table 18. Clinically significant discordances documented during V2. 
 
 
 
5.1.3.3 Diagnostic confidence and diagnostic modality preference  
 
Mean diagnostic confidence (on a Likert scale from 0-7) was similar for each 
pathologist for digital slides and for glass slides. (See table 19), although the range of 
diagnostic confidence scores was dramatically different for one pathologist (0-7 on 
digital, versus 6-7 on glass).  
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 Digital Slides Glass slides 
 Mean 
confidence  
(0-7) 
Range Mean 
confidence   
(0-7)         
Range 
Pathologist 1 6.70 4-7 6.80 4-7 
Pathologist 2 6.90 4-7 6.90 4-7 
Pathologist 3 6.79 0-7 6.99 6-7 
 
Table 19. Pathologist confidence in digital and glass slide diagnosis in V2 
 
All of the participant pathologists identified a proportion of cases for which they 
preferred to use glass slides over digital slides, although digital slides were judged to 
be superior or equivalent to glass slides in the vast majority of cases. (See figure 15) 
Cases where glass slides were preferred all involved mitotic counting, weddelite 
detection and lymph node searches.  
 
 
Figure 15. Pathologist reporting modality preferences in V2. For each case in the validation, 
pathologists recorded if they preferred the glass or digital to make their diagnosis, or had no 
preference. 
 
 
 
5.1.3.4 Beliefs about digital pathology efficiency  
 
Prior to their validation procedure, the pathologist group predicted that viewing 
digital slides would be slightly slower than viewing glass slides, and that breast 
0 50 100 150 200 250
Pathologist 1
Pathologist 2
Pathologist 3
Prefer glass No preference Prefer digital
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resections would be much slower to report on digital. After the validation procedure, 
the pathologists reported that they perceived their digital reads of resection cases 
and large/multi-level biopsies to be much faster using digital slides rather than glass 
slides, and resections to be either slightly faster or much faster on the digital 
microscope.  
Prior to the validation procedure, pathologists believed the most relevant barriers to 
digital pathology adoption were increased time to view digital slides compared with 
glass slides, pathologists’ lack of exposure to digital pathology and pathologists’ 
resistance to change. Following the validation procedure they identified the chief 
barriers to digital pathology adoption were financial cost to the department and the 
time taken to scan slides in the laboratory.  
When asked to list the principal benefits of digital slides over glass slides, pathologists 
listed ease of access to previous biopsies/linked specimens, more efficient diagnosis 
of large cases/multi slide biopsies, diagnostic utility of the low power overview of the 
slide, more efficient delivery of digital slides to the pathologists desktop, enhanced 
opportunities to teach trainees and ergonomic benefits.  
 
5.1.4 Discussion  
 
Digital pathology has the potential to transform the way in which breast pathology 
services are delivered. Rapid transfer of images across geographical boundaries can 
allow for more efficient dispersal of pathology workload between linked hospitals, 
and make best use of pathologist manpower. Rapid access to second opinion on 
challenging cases, and increased collaboration between pathologists on cases could 
lead to significant improvements in the quality of pathology diagnosis.  
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Successful adoption of digital pathology for primary diagnosis in a department is 
dependent on individual pathologists, many with decades of experience reporting on 
a light microscope, engaging with a new technology, educating themselves on its 
limitations, and actively learning how to use software and hardware efficiently. As 
with the adoption of any new diagnostic procedure, patient safety should be 
paramount. The US Food and Drugs Administration guidance to manufacturers 
recommends that medical devices (including whole slide imaging systems) should be 
able to demonstrate established safety and effectiveness.82 The digital pathology 
guidelines published by the Royal College of Pathologists also describe the need for 
individual pathologists to be validated with sufficient rigour to satisfy an internal or 
external observer that safety and clinical effectiveness are maintained. The 
document also emphasises that validation should occur in a real world context. This 
study documents the first instance of use of the novel validation and training protocol 
for digital primary diagnosis of histological specimens, which has since been 
recommended as an example of best practice in the Royal College of Pathologist’s 
Guidelines for Digital Pathology 1.  
The philosophy of this validation protocol is slightly different from the approach of 
the College of American Pathologists (CAP) Guideline74 and of other non-inferiority 
studies, largely because of the intended purpose of the validation procedure. The 
CAP validation intends to validate that a WSI system produces images of sufficient 
quality for correct diagnoses to be made. The aim of the Leeds validation protocol is 
to allow individual pathologists to validate their own digital slide practice against 
their conventional light microscopy practice. The protocol is centred on the individual 
pathologist rather than a department as a whole, and it is competence driven rather 
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target driven. This approach takes into account the variability in IT competencies, 
diagnostic experience and enthusiasm for technology between pathologists, and 
allows all members of a department, whether enthusiasts or sceptics to develop 
digital pathology skills and gain confidence in their abilities. Three specialist breast 
pathologists viewed 694 complete “live” breast cases, including large format slides, 
stained with haematoxylin and eosin, immunohistochemistry and special stains. 
Complete clinically significant concordance was observed in 98.8% of cases, 
indicating excellent agreement between digital primary diagnosis and glass slide 
review. Our findings suggest that pathologists, given access to digital pathology 
training, and a risk mitigated diagnostic environment to gain real world digital 
reporting experience, can competently and confidently use digital pathology for 
primary diagnosis as standard practice.  
The training and validation process allowed the participant pathologists to identify 
and discuss areas of digital diagnosis they found more challenging, and identify 
subtypes of breast case which warrant glass review of digital slides, in order to 
maintain patient safety and allow for further education of the pathologist and 
navigation of specific learning curves (eg. for confident identification of mitotic 
figures or navigation of lymph nodes). Identification and counting of mitotic figures 
was consistently highlighted as an area of difficulty for pathologists. Our pathologists 
perceived two causes of this difficulty in digital reporting: firstly they suggested that 
less contrast between chromatin and the background on digital slides made mitoses 
harder to identify, and secondly, they were unable to fine focus on suspected mitotic 
figures on digital slides, a function they often perform on glass slides to confirm the 
identity of mitoses. A number of workarounds and strategies to mitigate this 
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difficulty could be considered, including use of immunohistochemistry to highlight 
mitoses, the use of image analysis software to automate mitotic counts, or 
mandatory checks of mitotic count on glass slides prior to specimen sign out, in cases 
where mitotic score would affect overall grading of an invasive tumour.  
Our pathologists reported perceived greater efficiency in reporting multi-slide 
biopsies and large resections on digital slides, which they attributed to a number of 
factors. This was partly because they no longer had to load and reload glass slides on 
the microscope stage, and could move swiftly between slides. In addition, they found 
the full screen low power view of individual slides enabled them to assess lesional 
architecture with greater ease, and they were able to make measurements using 
digital tools efficiently and accurately. The relative diagnostic efficiency of 
pathologists using digital versus glass slides deserves further attention, especially 
now that there is a growing cohort of pathologists with significant digital microscopy 
experience to compare fairly with conventional light microscopy . Others benefits of 
digital reporting noted by our pathologists included rapid access to previous biopsy 
specimens when reviewing resections, more engaging education and training of 
junior colleagues, and ergonomic benefits.  
As a consequence of this validation study, our validated breast pathologists now 
report all cases on digital slides as standard, reverting to glass following digital 
examination only for cases fulfilling set criteria (invasive cancers where differences 
in mitotic score could affect overall grade, cellular fibroepithelial lesions, cases with 
radiological confirmation of calcification but no calcium identified on digital, and any 
challenging case not encountered in the validation phase.) On the basis of the 
validation pilot in breast pathology, it was decided that the laboratory at Leeds 
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Teaching Hospitals NHS Trust would commence scanning all histopathology slides for 
all specialties, and that all consultants would complete a validation procedure for the 
relevant diagnostic subspecialty. As the validation process is completed for each 
specialty, more data can be gathered on challenging areas of digital diagnosis. It is 
important that individual departments share their experiences with digital 
pathology, and highlight areas of potential difficulty which can be prioritised in the 
digital training of their colleagues to ensure a safe transition from glass slide to digital 
slide reporting.  
 
5.2 Validation of neuropathology for primary diagnosis  
 
Following a successful pilot in primary digital diagnosis of breast histopathology, 
Leeds Teaching Hospitals NHS Trust decided to initiate training and validation in 
primary neuropathological diagnosis and frozen section evaluation. 
 
5.2.1 Background 
 
As arguably one of the most specialised diagnostic topographies, and with only 70 
practitioners in the UK83, neuropathology stands to benefit a great deal from 
digitisation. Networked digital pathology systems allow more flexibility in who 
reports what and where, and can help ensure that complex histology slides are 
transferred to a suitably experienced neuropathologist for frozen section analysis, 
primary diagnosis or secondary opinion instantaneously, regardless of the 
geographical location of the specimen.  
There is little data regarding diagnostic safety in digital neuropathology, as the 
majority of published validation studies have excluded neuropathology specimens, 
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or only included them in small numbers.38 One multi-specialty study identified a 
single major discrepancy between glass and digital diagnoses, which related to a 
neuropathology case.57 A pilot digital neuropathology study 84 found individual 
digital:glass concordance rates for two neuropathologists of 94.9% and 88%, and 
identified two common causes of glass:digital discrepancy: identification of mitoses 
and assessment of nuclear detail.  
 
5.2.2. Methods 
 
The study was performed in the histopathology department of St James University 
Hospital, Leeds, UK, a major NHS cancer centre. Leeds provides neuropathology and 
ophthalmic pathology services to the West Yorkshire region, encompassing a 
population of approximately 3 million, and includes multidisciplinary team meetings 
for adult, young adult and paediatric central nervous system tumours, and adult and 
paediatric neurology. The department receives approximately 2750 brain, 
ophthalmic, nerve and muscle specimens per annum, and an additional 300 frozen 
sections. The department’s two specialist neuropathologists, with combined 
consultant experience of 34 years (20 years and 14 years) were recruited to train in 
digital diagnosis, and validate their primary diagnostic practice using a digital 
pathology system. 
 
5.2.2.1 Primary diagnostic validation 
 
All neuropathology histopathology glass slides, including H and E, 
immunohistochemistry and special stains were scanned prior to laboratory sign-out, 
before distribution to participating pathologists. All slides were scanned on one of six 
Aperio AT2 scanners. (Leica, Vista, CA, US). Standard H and E and special stains were 
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scanned at x40 equivalent magnification, whilst immunohistochemistry was 
captured at x20 equivalent magnification.  
Automated tissue detection and scanning point placement provided by the scanner 
were utilised, and quality checked by the scanner operator (a trained biomedical 
scientist) as per departmental protocol. The diagnostic images were stored in a 
remote digital archive, and retrieved with e-Slide Manager software (Leica, Vista, CA, 
US). The scanner operator performed a final quality control check on the captured 
images to detect scanning artefact and major focusing issues. Images were viewed 
by consultant neuropathologists using Leeds Virtual Microscope slide viewing 
software (University of Leeds, Leeds TH NHS Trust, UK) on medical grade 8 MP 
screens (Eizo, Hakusan, Japan). Figure 16 depicts one of our neuropathologists at 
work on their digital workstation during their validation. 
 
Figure 16. A neuropathologist at work during their validation. The slide is viewed on an 8 
Megapixel medical grade screen. 
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The validation protocol described in chapter 3 was utilised, consisting of a training 
phase (T), Validation – Training Cases (V1), Validation – Live reporting (V2) and 
summary phase (S). 
5.2.2.3 Training Phase 
The training phase, (T), consisted of an hour-long individual session covering basic 
digital pathology skills including use of the image management software (e-slide 
manager) and the viewing software (Leeds Virtual Microscope). Participants were 
observed opening and navigating cases, and were given feedback regarding their use 
of input modalities (gaming mouse ergonomics and use of keyboard shortcuts). 
Participants were able to request additional training as required, and provided with 
user manuals for the software, and standard operating procedures for the validation 
protocol and for departmental digital reporting.  
 
5.2.2.4 Validation 1 - Training Set (V1) 
In V1, each pathologist received a training pack consisting of a set of 20 challenging 
and educational neuropathology cases, all presented in both digital slide and glass 
slide formats. The training set was designed to encompass a broad range of diagnoses 
and tissue types, and to expose the pathologist to types of case that might be 
problematic to a novice digital diagnostician. The cases selected are documented in 
table 20.  All cases/ specimen types selected which were relevant to departmental 
practice, and the challenging cases were selected based on my review of the relevant 
discordance literature for neuropathology (chapter 3).4  
Participants were allowed to take as long as they needed to complete the training set 
comfortably. Pathologists were asked to view the digital slides first for each case, 
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recording both their diagnosis, and their confidence in that diagnosis (on a Likert 
scale from 1-7, where 1 corresponded to not at all confident, and 7 to very confident) 
in a workbook, which also contained the relevant clinical details for the case. 
Pathologists then viewed the glass slides for the case immediately after the digital 
read, and recorded any alteration in their assessment of the case, as well as their 
confidence in their glass slide diagnosis.   
Following completion of the training set by both participants, the results were 
discussed in a group with the trainer, and all participants reviewed cases that had 
caused difficulty. Pathologists identified the types of case they found problematic on 
digital slides, and progressed to the next phase, V2, armed with this information.  
Case Diagnosis Domains explored 
1 Oligodendroglioma Diagnosis, grading 
2 Metastatic carcinoma - breast 
primary 
Diagnosis, immunohistochemistry 
interpretation 
3 Schwannoma Diagnosis 
4 Pilocytic astrocytoma Diagnosis 
5 Giant cell glioblastoma multiforme Diagnosis, grading 
6 Diffuse astrocytoma Diagnosis, grading 
7 Pituitary adenoma Diagnosis, immunohistochemistry 
interpretation 
8 Epithelioid GBM Diagnosis, grading 
9 Metastatic carcinoma - lung primary Diagnosis, immunohistochemistry 
interpretation 
10 Pituitary adenoma Diagnosis, immunohistochemistry 
interpretation 
11 Rhabdoid meningioma  Diagnosis, subtype recognition, 
grading 
12 Anaplastic glioma WHO Grade 2 Diagnosis, grading 
13 Lymphoma Diagnosis, atypical lymphocytic 
proliferation identification 
14  Myositis Diagnosis, special stain 
interpretation 
15 Temporal arteritis Diagnosis, granuloma detection 
16 Giant cell glioblastoma multiforme Diagnosis, subtype recognition 
17 Acute and chronic inflammation. No 
evidence of malignancy. 
Diagnosis, confident exclusion of 
malignancy 
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18 Microcystic meningioma Diagnosis, subtype recognition 
19 Mature teratoma Diagnosis, tissue type recognition 
20 Benign melanosis - conjunctival 
specimen. 
Diagnosis, benign melanocytic 
lesion 
 
Table 20. Validation training cases for neuropathology primary diagnosis 
5.2.2.5 Validation 2 - Live Cases (V2) 
In V2, all departmental neuropathology cases were scanned prospectively. The 
pathologists made their live primary diagnosis on the digital slides, and recorded the 
diagnoses, and their diagnostic confidence on an Excel spreadsheet. All cases were 
then reviewed on glass prior to final sign out, and any modification to the digital 
diagnosis was recorded, in addition to the pathologist’s confidence in the glass slide 
diagnosis. A record was also kept of any technical failures – e.g. out of focus regions 
on slides or the presence of digital striping artefact.  
When each pathologist had viewed approximately 2 months whole time equivalent 
workload (estimated at 150 histology cases on the basis of departmental data), their 
diagnostic spreadsheet was analysed, and concordance and discordance data were 
summarised (Summary phase - S). These data were discussed with the participant, 
and the scope of that pathologist's future digital pathology practice was agreed upon.  
 
5.2.3 Results 
5.2.3.1. Validation 1 – Primary diagnostic training set (V1) 
Each participant viewed the same training set of 20 neuropathology cases on digital 
slides and glass slides. The diagnostic concordance between digital and glass slide 
reads was 85% (17/20) for both participants. The discordances encountered are 
described in table 21, and frequently concerned mitotic figure detection and grading. 
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In all cases of discordance, group review of the glass slides confirmed that these held 
the ground truth diagnosis. 
Participant Case 
number 
Digital slide 
diagnosis 
Glass slide diagnosis Comment 
1 8 Likely reactive, 
differential 
diagnosis to include 
GBM 
Definite GBM Mitoses 
hard to see 
on digital. 
GFAP 
difficult to 
interpret, 
very dark on 
digital. 
1 11 Meningioma (WHO 
1) 
Atypical 
Meningioma (WHO 
2) 
On digital 
read, missed 
focal 
pleomorphic 
cells and 
mitoses. 
1 12 Diffuse glioma, 
unable to grade 
High grade glioma On digital 
read, 
mitoses 
difficult to 
assess, 
nuclei very 
dark. 
2 6 Diffuse 
glioma/astrocytoma 
WHOII 
Anaplastic 
glioma/astrocytoma 
WHO III 
 
Mitotic 
figures 
difficult to 
discern on 
digital – 
nuclei very 
dark. 
2 8 Glioblastoma 
multiforme WHO 
IV, epithelioid 
component 
Glioblastoma 
multiforme, WHO 
IV 
Vascular 
proliferation 
mistaken for 
epithelioid 
component 
on digital 
2 12 Anaplastic glioma 
(WHO II) 
Anaplastic glioma 
(WHO III) 
Mitotic 
figures 
difficult to 
discern on 
digital 
Table 21 . Discordant cases from the training phase of validation. 
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5.2.3.2 Primary Diagnosis Validation 2 – Live cases (V2) 
The participants viewed 340 complete neuropathology cases between them. The 
cases were representative of the specimen type and diagnostic category mix found 
in the departmental neuropathology workload, and included diagnostic biopsies and 
excisions, and included brain, muscle, nerve and ophthalmic specimens. 
The pathologists had to defer full digital assessment in 16 cases due to quality issues. 
These instances all related to muscle biopsies, and in all cases the haemotoxylin and 
eosin slides were assessable on digital, but the crucial Gomori and ATPase stains were 
unreadable. (See figure 17 for an example.) 
 
Figure 17. Example of a digital slide of Gomori stained muscle which could not be 
interpreted. The slide was too dark for the contrasting stain to be seen.  
 
When these cases are excluded from the total, there was complete clinical 
concordance between the glass slide and digital slide reads in 98.1% of cases 
(318/324). Only 1.8% of cases had a clinically significant difference with the potential 
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to affect diagnosis/prognosis between digital and glass slide reads. See table 22 for a 
breakdown of concordance statistics for the 2 pathologists. 
 
 
Table 22. Live reporting validation statistics 
 
All discordant cases were reviewed on glass and digital by the participant and the 
trainer. In all cases, the glass slides were judged to hold the ground truth. Clinically 
significant discordances concerned identification of mitotic figures, and confident 
identification of malignant lymphoid proliferations. (See table 23 for a summary of 
all discordances.) (See figure 18 for an example). 
 Pathologist 1 Pathologist 2 Combined 
Total number of 
cases 
125 215 340 
Technical deferral 
to glass 
9 7 16 
Clinically 
significant 
observable 
difference 
2 4 6 
Complete 
diagnostic 
concordance 
 98.3% (114/116) 98.1% (204/208) 98.1% (318/324) 
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Figure 18. Example of a digital slide of a brain tumour where identification of mitotic 
figures was challenging. The green arrow indicates a mitotic figure which was not identified 
on the initial digital assessment of the case. 
  
Digital diagnosis Glass diagnosis Comment 
Low grade glioma High grade glioma Mitotic figures 
difficult to discern on 
digital 
Small round blue cell 
tumour 
Lymphoma Malignant lymphoid 
cells clearer on glass 
slides 
Astrocytoma WHO 3 Glioblastoma 
multiforme WHO 4 
Mitotic figures 
difficult to discern on 
digital  
Meningioma Atypical meningioma Mitotic figures 
difficult to discern on 
digital 
Glioma WHO 2 Glioma WHO 3 Mitotic figures 
clearer on glass 
Lymphoid tissue - 
??malignant/?? 
reactive 
Malignant lymphoid 
proliferation 
consistent with 
lymphoma 
Nuclear features/fine 
detail clearer on 
glass slides 
 
Table 23. Discordant cases from the live reporting phase of validation (V2) 
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5.2.3.3 Diagnostic confidence and diagnostic modality preference 
The mean diagnostic confidence, on a Likert scale from 1-7 was similar for each 
pathologist for digital slides and for glass slides (see table 24), although the range of 
diagnostic confidence varied between digital and glass. Both pathologists detected a 
proportion of cases (4% for pathologist 1, 3% for pathologist 2) where they clearly 
preferred the glass slide presentation of the case. These cases all involved borderline 
mitotic counts. 
Pathologist Mean diagnostic 
confidence on digital 
Mean diagnostic 
confidence on glass 
1 6.7 (Range 3-7) 7.0 (Range 7-7) 
2 6.9 (Range 5-7) 7.0 (Range 6-7) 
Table 24. Pathologist diagnostic preferences 
5.2.4. Discussion 
Digital pathology is a transformative technology, with the potential to revolutionise 
the way in which neuropathology services are delivered. Digitisation of slides allows 
for rapid transferability, enabling the establishment of robust, efficient diagnostic 
networks for intra-operative diagnosis and consultations. In addition to streamlining 
diagnosis and referral, remote reporting of scanned slides could allow more 
equitable access to specialised neuropathological opinion. It is also likely that 
digitisation of the specialty could aid recruitment and retention of neuropathologists, 
by supporting flexible and remote working. 
This study documents the first use of the Royal College of Pathologists’ approved 
validation and training protocol1 for the diagnosis of neuropathological specimens. 
This approach is focussed on the training needs of the individual pathologist, and is 
competence driven rather than target driven. Two specialist neuropathologists 
viewed 340 complete neuropathological cases, including H and E, 
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immunohistochemistry and special stains. Complete clinical concordance was 
observed in 98.1% of cases, indicating excellent agreement between digital primary 
diagnosis and glass slide assessment. This statistic is similar to the published 
validation findings using the same protocol for breast histopathology (see above).85  
Our findings suggest that suitably trained and validated pathologists can competently 
and confidently use digital pathology for standard primary neuropathology reporting 
practice.  
Our pathologists reported a number of key benefits to digital reporting, including: 
- Instantaneous access to previous biopsies in the digital archive for 
comparison with new metastases, and ability to compare these directly on 
screen. 
- Greater efficiency assessing multi-slide cases, especially cases with large 
immunohistochemistry panels. 
- Easier navigation between small pieces of tissue on a slide for fragmented 
specimens. 
- More efficient preparation and selection of cases for multidisciplinary team 
meetings (MDTM) and tumour boards. 
- More secure, convenient MDTM and tumour boards. (Negating the need to 
physically transport glass slides from the histopathology department to the 
MDT suite in a separate institution.) 
- Enhanced training experience for junior pathologists and trainees. Pathology 
trainees can be directed towards neuropathology cases with optimum 
educational value in the digital slide archive, facilitating more equitable 
distribution of training cases between a training group, and allowing the 
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trainer to personalise cases to the needs of the trainee.  Use of digital slides 
by the consultant histopathologist frees the glass for the student, who can 
study them, or the digital slides at leisure, without compromising turn-around 
times for the patient by delaying definitive diagnosis.  
- Review of digital slides allows for a more engaging teaching experience, and 
allows a single pathologist to interact with a group of trainees, gathered 
around a screen, without the need for a multi-headed microscope.  
In the course of their validation procedure, our pathologists identified key areas of 
digital reporting they found more difficult on digital slides, particularly in the early 
stages of the validation, and both appreciated a “learning curve” for mitotic figure 
detection in particular. Two causes for this can be proposed: firstly an observation 
that there was less contrast between chromatin and the nuclear background on 
digital slides, rendering the nuclei dark and difficult to interpret, and secondly the 
inability to adjust the fine focus of potential mitotic figures. In our experience, our 
validation procedure of direct comparison of digital and glass slide images allowed 
our pathologists to reconcile the appearance scanned mitoses with the glass slide 
image, and they soon gained confidence in digital mitotic scoring. Given the initial 
difficulty, and the importance of mitotic scoring in accurate tumour grading, the 
group decided that post-validation, any cases with “borderline” mitotic counts 
should be reviewed on glass before sign out, to ensure maintenance of diagnostic 
quality. In the future, the use of image analysis software could support the work of 
the pathologist by providing rapid, reproducible mitotic scoring for scanned digital 
pathology slides. 
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Since completion of the validation period in 2018, our neuropathologists now report 
all cases on digital slides as standard, deferring to glass slides only when they wish to 
confirm mitotic count in borderline lesions, or where special stains are too dark for 
easy digital assessment.  
 
5.3 Conclusion 
In this chapter, the results of two digital pathology validation pilots are presented – 
for breast and neuropathological primary diagnosis. Specialist pathologists working 
in both topographies were able to achieve high levels of diagnostic concordance 
between their glass slide and digital slide histology interpretations, and both cohorts 
of pathologists now practice digital pathology as standard at Leeds Teaching 
Hospitals NHS Trust. Interestingly, both groups of pathologists could identify areas of 
digital practice in which they still lacked confidence following their validation period, 
and elected to mandate glass slide checks of particular cases. Following completion 
of the two pilots, it was decided that Leeds Teaching Hospitals would roll the  
protocol out to all remaining histopathology subspecialty reporting groups 
(Gastrointestinal, hepatobiliary, skin and soft tissue, cardiothoracic, gynaecological, 
urological and head and neck), who are currently in the process of V1 and V2 phases 
of validation. Pathologists are progressing at different rates, reflecting differing levels 
of comfort with IT, and acceptance of digital pathology. One issue that has emerged 
is the extra time commitment that validation requires from the participant. Our pilot 
pathology groups estimated that the validation process required an additional 10% 
WTE for completion of the protocol. This time includes performing additional glass 
slide “safety checks” before signout of V2 cases and completing data collection 
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sheets documenting cases viewed and concordance/discordance rates. Some of the 
pathologists that started the protocol more recently are reporting an approximate 
doubling of time in their diagnostic sessions, attributable to “double reading” of 
cases on the digital and light microscope. This extra workload commitment would be 
unacceptable to the pathologist population, and result in major backlogs in a clinical 
department. Discussion with these pathologists revealed that they were completely 
re-reading every case in its entirety on glass slides following their initial digital slide 
read. Advice was re-issued to pathologists that after a few initial weeks of 
familiarisation, when they may want to check every slide, only the index slides 
pertinent to the diagnosis need to be reviewed on glass, or cases where the diagnosis 
is very uncertain on the digital read. 
All the pathologists involved in the pilot were able to recognise key benefits of digital 
pathology in their clinical area, and were keen to expand their use of WSI to 
applications beyond the primary diagnosis of histology, including frozen section 
assessment and MDT presentation for the neuropathologists, and review of 
cytopathology specimens for the breast pathologists.  
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Chapter 6 Validation of digital diagnosis for non-primary diagnostic 
use cases 
 
In the course of the Leeds Digital pathology deployment, it soon became apparent 
that there was a need to adapt the validation protocol for specific scenarios and use 
cases apart from primary diagnosis. Firstly, the author was approached by the 
neuropathologists who had taken part in the primary diagnostic validation pilot, who 
felt there was a clinical need for digital frozen section capability. Secondly, there was 
interest from both the laboratory and pathologists in streamlining access to 
immunohistochemistry slides, especially those requested as ancillary studies after 
assessment of the primary histology for the case. Re-uniting these slides with the 
relevant histology cases and sending them out to pathologists was viewed as 
cumbersome and time consuming, and the results of these tests were often needed 
in a short time frame for MDT presentation.  
 
6.1  Frozen section assessment 
Frozen section assessment is the process of providing an intra-operative pathological 
opinion on a biopsy. This could provide a differential diagnosis of an unexpected, 
incidental lesion, or provide the surgeon with feedback on completeness of lesional 
resection.  In both scenarios a rapid assessment of a sub optimal histology slide is 
used to direct further surgical management of the patient rather than provide a 
definitive diagnosis. Preservation of nuclear and cytological detail is poor in a frozen 
section compared with conventional histology, and opinion is often based on grosser, 
architectural features.  
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6.1.1 A validation protocol for digital frozen sections 
A simplified frozen section training programme was devised for the two 
neuropathologists who had already completed their primary diagnostic validation. 
Ten frozen section cases were selected from the glass slide archive, and scanned 
using an Aperio CS2 scanner (Leica, Vista, CA, US). This low throughput scanner was 
chosen for frozen sections because slides can be loaded and scanned without 
interrupting scanning programmes on the larger, high throughput scanners utilised 
for the primary diagnostic clinical deployment. 
All slides were scanned at 40x equivalent magnification and subjected to JPEG2000 
compression. Tissue detection software was not employed, so the entire scannable 
area of each glass slide was scanned, to ensure all tissue, however dispersed on the 
glass slide, was represented on the digital slide. 
The ten cases were selected to represent commonly encountered frozen section 
scenarios in our department. Each pathologist was provided with the digital slides for 
each case, presented alongside all relevant clinical information available to the 
original reporting pathologist. The cases selected can be viewed in table 25. The 
pathologist was asked to make their frozen assessment on the digital slides, record 
this, and then immediately compare the digital slides with the glass slides for the 
same case, documenting any change in their assessment or their confidence in their 
report. Diagnostic confidence was measured using a 7-point Likert scale for both 
digital and glass slide reads.  
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Case Archive frozen section report 
diagnosis 
Ground truth following definitive 
evaluation 
1 High grade astrocytoma Gemistocytic astrocytoma 
2 High grade glioma Glioblastoma mulitforme 
3 Suspicious for malignancy Abscess/inflammatory lesion 
4 Normal brain tissue Normal  brain tissue 
5 Metastatic cancer Metastatic squamous cell carcinoma 
6 Meningioma Meningioma 
7 Malignant tumour Glioblastoma multiforme 
8 Inflammation Benign inflammatory infiltrate 
9 Low grade glioma Pilocytic astrocytoma 
10 Melanoma metastasis Melanoma metastasis 
 
Table 25. Frozen section training set. The neuropathology set consists of 10 cases covering 
a range of clinical scenarios. 
 
6.1.2  Results 
There was 100% clinical concordance between the digital slide and glass slide 
assessment of frozen section cases for each pathologist, and these assessments 
corresponded with the ground truth diagnoses obtained from examination of 
definitive histology. Pathologists demonstrated equal confidence in their digital and 
glass slide assessments of frozen sections. 
As a result, both participant neuropathologists decided that digital slides could be 
used in place of glass slides for remote frozen section reporting in cases of clear 
clinical need, when no on-site neuropathologist is available. When a pathologist is 
on-site, it is more expedient to examine the freshly prepared glass slides, and this is 
the preferred option. To date, the neuropathologists have not needed to utilise 
digital slides for this purpose.  
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6.2 Immunohistochemistry assessment  
The assessment and interpretation of IHC slides sometimes requires the pathologist 
to make a simple distinction between a positive and a negative result, but can be 
complex, requiring detailed localisation of the staining and correlation with the 
H&E-stained slide or grading of the proportion of stained cells, or the intensity of the 
staining. In light of this, the department wanted to ensure our pathologists had 
sufficient training and familiarity with digital IHC slide use before they started using 
digital IHC slides in routine practice.  
 
6.2.1  A validation protocol for digital immunohistochemistry assessment 
A digital IHC training and validation protocol was developed, which is a simplified and 
streamlined version of the digital primary diagnostic training and validation protocol 
recommended by the Royal College of Pathologists in their best practice guidance.1 
See table 26 for an overview of this protocol. 
Phase Aim Description 
1. Basic Skills Pathologist 
familiarisation with 
digital pathology 
software 
30-60 minute session 
Observed practice with 
feedback 
2. Validation and 
training cases 
Pathologist 
familiarisation with 
digital IHC images 
Identification of 
challenging cases 
Identification of IHC 
types that require 
routine 40x scanning 
Pathologist views a set of 
approximately 10 
relevant training cases 
covering a range of stains 
and scenarios 
Discussion and feedback 
 
 
3. Ongoing 
surveillance 
Clinical governance of 
digital reporting 
Assessment of scanning 
requirements for new 
stains/scenarios 
Adhere to local/national 
clinical governance 
guidelines 
Consider yearly audit of 
IHC digital reporting 
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Table 26. Summary of validation protocol for immunohistochemistry assessment 
6.2.1.2 Phase 1: basic skills training 
The aim of this stage is to train each pathologist in the use of the digital pathology 
system. This stage can be truncated or omitted for pathologists who are already 
experienced in using the digital pathology system. It consists of a short (30 min–1 
hour) training session in which the pathologist learns from an experienced user of 
the system (a trainer). Access to a help manual and training slides is required. 
The pathologist is taught: 
- The basic digital pathology workflow and layout of the software. 
- How to use the system to open a case/slide and pan and zoom 
- How to use the system to annotate a case and other advanced functions 
- How to access the documentation for the system. 
- How to identify gross scanning artefacts 
The trainer observes the pathologist open and read a small number of training cases 
and provides feedback. 
 
6.2.1.3 Phase 2: validation and training cases 
The aim of this stage is to train the pathologist on the appearance of digital IHC slides. 
It includes exposure to cases anticipated to be challenging to diagnose digitally, and 
encompasses a variety of case types and stains as defined in the validation scope. 
Discussion with pathologists prior to validation can be used to identify stains and 
scenarios that are potentially difficult to diagnose on the digital platform or those 
that have important therapeutic implications for patients. 
139 
 
 
A set of slides was prepared for each subspecialty, comprising a set number of IHC 
cases for each specialty (this varied from 6 to 15 cases, and individual case size varied 
from 1 to 15 immunostains). Glass slides, digital slides and clinical information were 
made available to the pathologist. The cases included slides from a variety of relevant 
tissue types, covering a range of IHC stains and diagnostic scenarios. The cases were 
selected to allow the pathologist to explore specific aspects of digital IHC, which were 
relevant to that individual pathologist’s practice and have experience of viewing a 
range of features on the digital microscope. As the scope of the validation protocol 
is to train and validate the pathologist's use of digital for IHC assessment only, and 
did not extend to primary diagnosis, it was felt that a relatively small validation set 
of cases should be prepared for each specialty, in contrast with the Royal College of 
Pathologists’ Guidance on primary diagnostic validation case numbers1 and the 
College of American Pathologist’s guidelines74 (approximately 2 months whole time 
equivalent caseload and a minimum of 60 cases, respectively). A typical ‘case’ for 
these purposes can consisted of a few representative slides and does not have to 
include all material from a complete clinical case.  
 
The pathologists were asked to review their personalised training set, in their own 
time, over a short period of time (eg, up to 2 weeks). For each case, they made notes 
on their digital slide diagnosis. Then they immediately review the glass slides for the 
same case and noted their diagnosis. They were able to make comments on the case 
on a proforma, including their diagnostic confidence using both the digital and the 
glass slides for the case, expressed on a numerical Likert scale from 1 to 7 (where 
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1=not confident at all and 7=very confident). This allows the pathologist and trainer 
to distinguish between slides that the pathologist finds difficult to assess on any 
diagnostic medium, and slides that are particularly difficult to assess confidently on 
the WSI. At the end of the training set, the results were discussed at a small group 
training meeting. This included discussion of the pitfalls noted in the test set and 
explicit identification of the cases/features known to be difficult. If any particular 
type of stain or scenario was found to be problematic on digital slides, and this was 
not resolved following review of digital slides and discussion within the training 
group, the researcher  provided more examples for training and where appropriate, 
offered to rescan cases at ×40 equivalent magnification. 
Once the pathologist and trainer were both satisfied that the pathologist was familiar 
with the operation of the system and its use in the training cases, the pathologist was 
allowed to view and assess their IHC using digital slides as default. If any areas of 
diagnostic difficulty were identified, certain glass slides could be protocolled for 
scanning at higher magnification, or a mandatory glass check prior to case sign out 
could be mandated. 
 
6.2.1.4 Phase 3: ongoing surveillance 
Once a pathologist has completed their training for digital IHC reporting in a 
particular specialty, ongoing quality assurance procedures should be followed as part 
of normal departmental clinical governance procedure. Local incident reporting 
procedures should be adhered to, as they would for conventional 
microscopic practice. Cases should be peer reviewed for multidisciplinary team 
meetings, and difficult/challenging cases should be shared for second opinion, or 
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discussed at existing intradepartmental meetings, in settings where both glass and 
digital images can be studied. The department should consider introducing audit 
protocols to allow a random review of a proportion of an individual pathologist’s 
digital cases on a rolling basis. 
 
6.2.2 Validation and training outcomes 
A total of 24 pathologists completed the digital IHC training and validation exercise, 
representing 11 histopathology reporting subspecialties. The number of IHC cases 
viewed per specialty varied from 6 to 15 cases, and individual case size varied from 
1 to 15 immunostains. A total of 1480 slides were viewed and assessed in the course 
of the validation by all participants. The mean satisfaction score with digital IHC 
slides, expressed on a Likert scale of 1–7, where 1=not at all satisfied, and 7=very 
satisfied, was 5.91. The range of observed responses was 2–7 (see figure 19). 
 
 
 
Figure 19. Pathologist reported satisfaction with digital IHC training slides. Satisfaction is 
reported on a Likert scale from 1-7 (x –axis), where 1 is not at all satisfied, and  7 is very 
satisfied indeed. 
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There was complete IHC assessment clinical concordance for all cases and all 
observers across the validation study, with no clinically significant difference in IHC 
interpretation observed. Across the validation, the average confidence score for 
digital slide IHC assessment was 6.1 (range, 2–7), compared with 6.9 (range, 6–7) for 
glass slides. Cases scoring low confidence values on digital slide assessment 
contained particular IHC stains, which pathologists almost universally reported as 
being difficult to assess on digital in free-text comments. 
 
6.2.3 Free-text comments 
Pathologists were encouraged to support their scoring for satisfaction with digital 
slides, and confidence in diagnosis on digital versus glass slides with free-text 
commentary. Cases scoring high confidence marks on digital slides (6 or 7), and 
pathologists rating their satisfaction with digital slides as high (6 or 7) gave the 
following feedback: 
- Found digital as quick and as easy as the glass slide. 
- Found it easier to spot areas of concern at low power on the 
             digital slides than on glass. 
- Positive results are spotted more quickly on the digital slide. 
- I find it easier to assess a multislide case digitally. I can see all the IHC 
requested at one glance, then quickly zoom in to check staining pattern. 
- Easy to use and interpret. 
- Quicker looking at digital images. 
- Digital IHC seems more crisp. 
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Cases scoring low confidence marks on the digital slides anything below 6) and 
pathologists rating their satisfaction with digital slides as low (anything below 6) 
provided the following feedback: 
- Screening large volumes of tissue for rare positive cells gave me a headache. 
- It took me longer to scroll through all the tissue at high power than on my 
light microscope. 
- Need higher magnification scanning for some stains. 
- Helicobacter pylori blurry and difficult to spot. 
In addition, the pathologists identified a number of immunostains that they found 
difficult to interpret with confidence using standard images captured at ×20 
equivalent magnification. These immunostains belong to a category of stains that 
either require some form of advanced assessment (eg, quantification, complex 
location) and/or would have direct therapeutic implications for the patient (eg, 
decision to offer or not offer a drug therapy). See table 27 for a list of these stains. 
Stain Rationale 
Her2 Requires quantification of intensity and 
volume 
Therapeutic relevance 
ER, PR for breast and gynaecological 
tumours 
Requires quantification of intensity and 
volume 
Therapeutic relevance 
Helicobacter pylori Requires tissue search for small, 
sometimes sparse diagnostic objects 
Ki67 Requires quantification, can be key part 
of tumour grading and hence prognosis 
and therapeutic management 
Sv40 Difficult to locate and localise in renal 
biopsies 
CMV Difficult to locate and localise in renal 
biopsies 
Table 27. Immunohistochemical stains pathologists identified as difficult to interpret at 20x 
magnification 
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Scanning this selection of immunostained slides at ×40 equivalent magnification 
improved the ability of our pathologists to make a confident diagnosis, and direct 
comparison of ×20 and ×40 captured images demonstrated appreciable difference in 
the appearance of the slides. As a result of this, these slides are now mandated for 
×40 equivalent scanning, while the remainder of the IHC workload is scanned at ×20. 
Pathologists can request repeat scanning at ×40 of any immunostained slide which 
they are not confident to assess at ×20, following initial ×20 assessment. 
 
6.2.4 Conclusions 
This study demonstrated complete concordance of WSI and glass slide assessment of 
IHC using digital images capture at ×20 equivalent magnification. While this is 
reassuring, it is important to consider the pathologist’s confidence in their WSI 
assessment, and the efficiency and ease with which the diagnosis is rendered too. 
The majority of pathologists were satisfied and confident to use digital IHC slides 
rather than glass slides to report live cases, but they did highlight individual 
immunostains and diagnostic scenarios that were difficult to assess on standard ×20 
captured WSI. The approach highlighted the need for careful assessment of a digital 
pathology system and scanning protocols before pathologists are expected to 
transfer from the light microscope to the digital microscope for routine IHC 
assessment. A small number of immunostains requiring more sophisticated 
assessment in terms of localisation and quantification of staining were problematic 
for our pathologists, who were unable to reach a confident diagnosis. For these cases, 
routine scanning at ×40 was beneficial. 
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The assessment of IHC is becoming an increasingly complex and time-consuming 
process, as more diagnostically and therapeutically useful antigens are identified and 
incorporated into the workload of the clinical pathologist. Pathology services are 
under increasing pressure to provide detailed, accurate IHC assessments within short 
turn-around-times (TAT), at a time when many institutions are suffering from a 
shortage of pathologists. The judicious development and use of artificial or 
augmented intelligence to read and interpret IHC stained slides could provide 
diagnostic support to the 21st-century pathologist, allowing them to concentrate on 
the morphology, while algorithms locate and quantify immunopositive regions of IHC 
slides. 
 
6.3 Conclusion 
The fundamental principles of the digital pathology validation protocol outlined in 
chapter 4 can adapted to scenarios beyond primary diagnostics. The core principles 
of selection of evidence based training targets, individualisation at the level of the 
pathologist, and consolidation of learning and experience through direct comparison 
of digital and glass slides are retained, whilst the protocol is truncated to reflect the 
relatively narrow scope, and lower risk of the clinical scenario considered (IHC or 
frozen section assessment). 
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Chapter 7. Maintaining quality and safety with digital diagnosis 
This chapter summarises work by the author from the following publications: 
Williams BJ, Knowles C, Treanor D 
Maintaining quality diagnosis with digital pathology: a practical guide to ISO 15189 
accreditation 
Journal of Clinical Pathology 2019;72:663-668. 
 
Williams BJ, Treanor D 
Practical guide to training and validation for primary diagnosis with digital pathology 
Journal of Clinical Pathology Published Online First: 29 November 2019 
doi: 10.1136/jclinpath-2019-206319 
 
Williams B, Hanby A, Millican-Slater R, Verghese E, Nijhawan A, Wilson I, Besusparis J, 
Clark D, Snead D, Rakha E, Treanor D.   
Digital pathology for primary diagnosis of screen-detected breast lesions – experimental 
data, validation and experience from 4 centres. Accepted for publication February 2020, 
Histopathology.  
 
Interest in the deployment of clinical digital pathology systems for primary diagnosis 
has increased dramatically in the timeframe of this body of work, fuelled by the 
evolution of hardware and software solutions on the market, and the need for 
pathology services to tackle ever-increasing workloads, with a dwindling workforce, 
while maintaining quality and timeliness of diagnosis.27 Many departments have 
either deployed scanning technology or have planned or initiated a deployment, to 
harness the flexibility of digital images and potentially improve service capabilities. 
In this chapter, three key areas pertaining to safety and acceptability of clinical digital 
pathology services will be discussed – ISO accreditation, detailed guidance on digital 
pathology training, and the use of WSI in the UK cancer screening programmes. 
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7.1 ISO accreditation for digital pathology services 
 ‘ISO 15189 Medical laboratories—Requirements for quality and competence’ is an 
international standard that specifies the quality management system requirements 
pertinent to medical laboratories.86Successful laboratory accreditation with national 
bodies (including UKAS in the UK, CLIA in the USA and SWEDAC in Sweden) should 
reassure patients and clinicians that the staff who carry out diagnostic and prognostic 
tests are competent, and that the equipment and processes they use are safe and fit 
for purpose. The deployment and integration of digital pathology diagnostic systems 
in a clinical histopathology department represents a departure from standard 
laboratory procedures, and the scope of accreditation will have to include 
examination of hardware and software, calibration of tools and devices, and the 
training and competence of laboratory staff and diagnosticians. 
In order to prepare for the Leeds Teaching Hospitals ISO inspection of digital 
pathology output in Summer 2018, procedures and documentation had to be 
presented to a team of  inspectors to demonstrate measures taken to ensure safety 
and reliability in the laboratory and the diagnostic office. At this time, there was no 
formal guidance available for pathology departments on the specific types of 
evidence required for successful digital pathology accreditation. This could be a key 
barrier to implementation for many clinical departments, as planning for an 
inspection is a time consuming process.  Preparation for accreditation inspection 
always requires effort and exertion on the part of the laboratory. The novelty of 
digital pathology, and laboratories’ relative inexperience using it, can make the 
process even more daunting. Stress can be minimised by careful planning in the early 
stages of a deployment, so the groundwork can be layed for safe, responsible 
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practice from day one. Our preparations at Leeds resulted in successful UKAS 
accreditation of primary digital diagnosis in our department. Details of the approach 
developed with the assistance of Chloe Knowles, biomedical scientist have been 
disseminated and published to aid other departments in their inspections. 87 
 
7.1.1 General principles of UKAS inspection 
The first formal assessment for accreditation is an ‘initial assessment’, conducted by 
a Lead Assessor supported by technical assessors able to cover the scope of the 
application (including digital pathology).88 The assessment involves detailed review 
of relevant departmental records, interviews with staff and managers and the 
witnessing of key activities, which may include digital diagnosis and slide scanning. It 
is important to identify key individuals, both in the laboratory, and among pathology 
diagnostic staff who will take responsibility for the delivery of core aspects of the 
accreditation procedure, and keep regular track of progress. 
Original article 
7.1.2 Laboratory considerations 
ISO 15189 requires validation (assurance that a system meets the needs of 
stakeholders) and verification (evaluation of whether a system complies with 
regulation, requirement and specification) for any new process or technique that has 
been implemented in a laboratory. For digital pathology deployment, assessors will 
need to view a written document, supplemented with evidence, which addresses a 
number of key aspects of the implementation: 
-  Change control 
-  Risk assessment 
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-  Verification and acceptance 
-  Comparability and reproducibility 
-  Training and competency 
-  Uncertainty of measurement 
 
7.1.3 Change control 
Change control, the systematic management of all changes to a system or process, is 
a vital part of a digital pathology deployment, and ensures that all changes are 
documented, no unnecessary changes are made, resources are utilised efficiently 
and existing services are not unnecessarily disrupted. A full change control 
procedure, complete with documentation, must be developed and adhered to if 
digital pathology is being implemented into the laboratory as a new process. It is 
essential for ISO 15189 and ensures all aspects of the implementation are assessed 
and managed appropriately. It allows key people to be identified to ensure 
appropriate stakeholder engagement and that all evidence is submitted correctly and 
in a timely manner. If an initial accreditation inspection raises findings that need to 
be addressed or resolved prior to the next assessment, it also simplifies the process 
of resubmitting evidence. Key personnel to engage during the change control process 
might include the clinical lead, representatives of departmental management 
(business, operations and service), the departmental health and safety officer, 
quality control manager, members of laboratory staff of all grades, and a change lead. 
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7.1.4 Risk assessment 
The health and safety risks of the proposed digital pathology process need to be 
scoped and assessed before it can be implemented. The departmental health and 
safety representative will be an invaluable resource to advise and assist in carrying 
out risk assessments. Types of assessment include: 
- Equipment usage (scanners, computer workstations etc). 
- Proposed processes and workflows 
- A general risk assessment to include the environment in which the equipment 
will be sited, and how the laboratory staff will work safely the equipment. 
- New screen display assessments for all staff will be using new screens either 
in the laboratory or the diagnostic office. 
 
7.1.5 Verification and acceptance 
Verification for ISO 15189 in the laboratory requires evidence to show that the 
scanners and software have been adequately tested for their intended use, and are 
working as required, and as the manufacturer states. This includes the scanners, any 
software provided by the company and any databases used. A written document 
detailing the evaluation methods and results must be submitted as evidence. A good 
way of providing this is to run internal tests against the initial manufacturer's 
installation and verification checklist from when the scanners were first installed. 
 
7.1.6 Comparability and reproducibility 
If multiple scanners are being utilised as part of the digital pathology system, ISO 
15189 requires evidence to demonstrate that all scanners used produce images that 
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are of equal diagnostic quality. This can be done by scanning a test set of slides on 
each of the scanners and asking a suitably experienced and validated digital 
pathologist to assess them. Suitable cases might include a malignant breast core 
biopsy for tumour grading, a bowel cancer screening specimen and a sentinel lymph 
node. 
Factors to consider when assessing the images would be: 
- Is the background clear? 
- Is the image in focus? 
- Is the staining crisp and clear? 
- Are the images comparable across all scanners? 
- Is there a significant difference in the interpretation of key diagnostic features 
in images obtained from different scanners? 
Inter-laboratory assessment schemes are common for standard glass slide histology, 
and are likely to be adopted for digital pathology whole slide images too. This would 
involve departments exchanging whole slide images, and asking pathologists to 
assess images produced in different laboratories. As digital pathology is a new 
technique, it may be difficult to share images from one department to another. An 
alternative to an inter-laboratory scheme is to rescan a case previously scanned and 
ask the reporting pathologist to reassess the case and compare their assessment with 
the original report. 
 
7.1.7 Training and competency 
152 
 
All parts of the digital pathology process need formal documentation in the form of 
quality managed standard operating procedures (SOPs). Laboratory staff should be 
familiar with these documents, and able to access them easily for reference. 
Examples of SOPs include the following: 
- How to operate the scanners. 
- How to operate the image software and database. 
- Troubleshooting—both for the scanners and workflow. 
- Maintenance of the scanners. 
To complement the content of the SOPs, relevant training booklets and competency 
assessments need to be documented and regularly reviewed. To ensure staff feel 
safe to work in digital pathology without supervision, a suitable training programme 
should be delivered to all new users of digital pathology in the laboratory. These SOPs 
and training materials will require regular updates to reflect changes in practice and 
the acquisition of new and updated hardware and software. 
7.1.7 Uncertainty of measurement 
If digital measurement software is being utilised as part of clinical diagnosis, one 
needs to tackle the question of uncertainty of measurement. A calibration slide with 
predefined values can be used to assess whether scanned objects are captured to 
scale, and this should be audited within the department.  An example of a calibration 
slide (Applied Image, NY, USA) is shown in figure 20. It contains a marked area with 
a predetermined height and width, with expected measurement given by supplier's 
calibration data. Suppliers should provide a calibration certificate with this slide. A 
width and height measurement should be recorded using the proposed clinical 
measurement tool and monitored for any changes that are deemed out of the 
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reference range. Scanner suppliers will differ in their approach, but is important to 
check the scanner's documentation to determine the reference ranges the 
measurements can fall under, for example, ±0.15 mm. This process should be 
repeated for all scanners used to scan slides for primary digital diagnosis, and any 
measurements falling outside of the manufacturer's acceptable reference range 
should be reported. As with any other equipment used for measurement in a medical 
laboratory, the calibration slide itself needs to be calibrated. The process and 
frequency of this will differ between suppliers, so it is important to check how often 
this should be done. 
 
 
To satisfy a clinical department, and an accreditation assessor that digital 
measurements taken on WSIs using slide viewing software are safe for clinical use, 
one needs to demonstrate that measurements taken on diagnostic images are 
accurate and reproducible. A relatively simple approach to this is to carry out and 
document an audit of clinically relevant measurements appropriate for the scope of 
the intended digital diagnostic practice. A small set of glass slides encompassing 
tumour measurements/margin assessment/tumour thickness, etc, can be 
assembled, and pathologists can be asked to make repeat measurements on glass 
and digital once a day for week or two. In this way, variability in measurement on 
both glass and digital slides can be documented, using both inter-observer and intra-
observer comparisons. 
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Figure 20. An example of a commercially available calibration slide from Applied Image, 
NY, USA. The slide contains objects of known dimensions, which can be measured and 
compared with certified measurements made by the manufacturer. 
 
7.1.8 Post-accreditation monitoring 
At this point in time, based on the Leeds Teaching Hospitals experience of digital 
pathology implementation, and existing national benchmark frequencies (eg, annual 
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External Quality Assurance schemes, annual appraisal), yearly audit/quality 
assurance benchmarks for digital pathology systems would seem advisable. As 
experience in digital pathology accumulates, and it becomes standard practice, the 
need for audit may reduce, as pre-existing departmental accuracy audits will simply 
be performed on digital slides as standard. 
 
7.2 Clinical and diagnostic considerations 
All the SOPs and workflows established in a laboratory should ensure that  
diagnosticians are presented with quality whole slide images in a safe and timely 
manner. This rigour needs to be matched with appropriate training and validation in 
the diagnostic office. 
 
7.2.1 Validation and training 
Meaningful digital diagnosis training and validation should result in: 
- Pathologists that are confident in their abilities and their limitations with 
digital diagnosis. 
- Pathologists that are familiar with their hardware and software, 
             and can recognise and report performance issues 
- A department with a shared understanding and investment in the digital 
pathology system 
- A department that can develop bespoke ways of using digital to improve its 
outputs, workflows and working environment 
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7.2.2 Preparing clinical pathologists for accreditation 
Consultants should have ready access to their own data, documenting their individual 
training and validation for digital reporting, copies of relevant SOPs and protocols, 
and user guides/manuals for the software they use. A specific personal folder 
containing this information for each consultant could be stored on a shared 
departmental drive, and accessed via a desktop shortcut. 
 
Each pathologist should be able to demonstrate how they report a case to the 
assessor, and how they would recognise and report issues with digital slides, such as 
out of focus regions or digital artefact. Depending on local departmental SOPs, 
technicians may protocolise reflex rescanning of inadequate slides (digital slides on 
which the pathologist is not prepared to make a diagnosis for quality reasons), or 
deferral to glass slides in this situation. All quality issues should be reported and fed 
back to the laboratory, regardless of whether the pathologist can make a diagnosis 
or not on the suboptimal slide. Examples of suboptimal slides are presented in figure 
21. 
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Figure 21. Examples of suboptimal digital slides. In each case, the pathologist would need 
to exercise their judgement in deciding whether the artefact precludes safe diagnosis. Top 
– Tissue folding in the original glass slide is replicated in the digital slide. Bottom – 
“Striping” artefact introduced during scanning. 
 
Pathologists that are reporting digitally should be familiar with, and able to access 
departmental SOPs for digital slide reporting, training and validation in digital 
reporting, and the relevant user guides for the software/slide viewer they use for 
primary diagnosis. They should be able to access their individual validation 
documentation, and talk through the implications of this validation, describing any 
situations in which they would defer to glass slide reporting. It can be helpful to 
circulate spreadsheets/templates for pathologist to record data on cases where they 
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need to defer to glass, or where digital slides are suboptimal for assessment, which 
can be fed back to the laboratory on a regular basis. 
 
 
7.2.4 Post-accreditation monitoring 
Accreditation is an ongoing process, and departments must continuously monitor, 
and strive to improve the quality and safety of their digital pathology service. In light 
of this, it is important to continue to audit and evaluate digital diagnosis after 
successful ISO accreditation. This should include documentation and investigation of 
scanning issues (eg, out of focus slides/ slide regions, incidence of digital artefact) 
and diagnostic issues (eg, frequency and reason for deferral to glass). Digital 
diagnosis can be audited on an annual or 6 monthly basis, by retrieving a random 
sample of archived cases, and reviewing the diagnosis. This could incorporate 
comparison with glass slides, providing the pathologist participating in the audit with 
an opportunity for continuing professional development. 
 
7.2.5 Training points for primary digital diagnosis 
Experience from Leeds Teaching Hospitals NHS Trust deployment, and the pilot 
validations detailed in chapters 5 and 6 has identified a number of key areas where 
novice digital pathologists can experience difficulty. Diagnosis of all types of case is 
possible on the digital microscope, but confident and efficient sign out of all cases 
will take time and experience. ‘Safety nets’ such as the use of adjunct 
immunohistochemistry or glass slide deferral in particular circumstances or for 
particular types of case can be used and should not be viewed as ‘failure’ of the digital 
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system. As pathologists’ digital reporting experience grow, they will find that the 
proportion of cases they are comfortable to sign out increases. While relatively little 
is known about what the minimum specification should be for a digital pathology 
workstation for primary diagnosis, use of quality, high resolution screens can improve 
pathologists’ ability to assess some of the more challenging cases and features 
described below. 
 
7.2.5.1 Detection of small diagnostic and prognostic objects 
The smooth and efficient navigation of digital cases, both between slides in a 
multislide case and within a slide that requires a high magnification search can be 
problematic. The initial low magnification, whole slide image displayed on the 
computer screen can provide a fantastic ‘spot diagnosis’ of a predominantly 
architecture-based diagnosis, for example, adenomatous polyp, fibroadenoma, but 
it can also provide false reassurance. One of the most common diagnostic 
discordances that can occur when a novice starts digital diagnostic training is missing 
a small diagnostic or prognostic object. 89 Examples of this include missing 
a metastasis or micrometastasis in a sentinel lymph node case (see figure 22) or 
failing to identify a single focus of cryptitis in a multislide colonic biopsy series. It is 
vitally important that pathologists have sufficient time to adapt and develop their 
own navigation strategies on the digital microscope. The tried and tested 
‘lawnmower’ technique to ensure complete high power coverage of a slide on the 
light microscope is difficult to replicate on the digital microscope. Judicious use of 
whole slide and whole case thumbnails can aid navigation of a digital case, and 
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features such as indicators that warn pathologists of missed slides/regions of slides 
can help, particularly in the early stages of digital training. 
 
                       
Figure 22. Assessment of a sentinel lymph node on the digital microscope. A pathologist 
might be reassured by the benign appearance of the extreme low power view (top image) 
but zooming in to just 5x equivalent magnification reveals a micrometastasis which would 
have affected patient management.  
 
7.5.2.2 Dysplasia 
The diagnosis and grading of dysplasia on the digital microscope is a recurrent theme 
in the WSI discordance literature and is a potential pitfall for the new digital 
pathologist. There are two areas of concern here: diagnostic issues at ‘low power’ 
and ‘high power’. Discordance can result from a failure to detect a focal region of 
dysplasia on the initial low power assessment of epithelium (eg, in a cervical biopsy). 
This type of problem is discussed above. The other issue implicated in the 
misdiagnosis/grading of digital dysplasia relates to the rendering of nuclear detail on 
digital scans, with some authors implicating poor focus, exacerbated by compression 
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artefact and the limited dynamic range of the WSI58. There is a definite learning curve 
for digital dysplasia assessment, and a validation procedure involving direct 
comparison of a pathologists digital and glass assessment of dysplasia cases can help 
the pathologist reconcile their digital and glass dysplasia identification and grading. 
Routine use of 40× scans for diagnostic biopsies and a high contrast, high resolution, 
medical grade display can also improve confidence in diagnosis of tricky or borderline 
cases. 
 
7.5.2.3 Mitotic figure counting 
Accurate identification and counting of mitoses is another recurrent theme in the 
digital pathology discordance literature. 61,62,73,79 In the absence of z-stacking, 
pathologists have to rely on an image captured at a single best plane of focus and 
cannot adjust this to focus through the depth of the nucleus for chromatin 
assessment. 
Similarly to assessment of dysplasia, there is a learning curve for digital mitotic 
counting. In cases of uncertainty, where the mitotic count on digital is at a critical 
cut-off level, which would affect overall grading and treatment for a patient, a 
confirmatory glass slide check should be encouraged. Mitotic counting is an area 
where artificial intelligence and computer assisted diagnosis could assist the digital 
pathologist in the near future. 
 
7.5.2.4 Specific diagnostic items and features 
Examination of the literature89 highlights a number of diagnostic/ prognostic items 
and features which may have a subtly different appearance on a WSI. Many of these 
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items share common features: they are often eosinophilic, refractile entities. Other 
items of particular note include the weddelite form of calcification in breast biopsy 
specimens and amyloid. Both entities can be viewed on standard WSI images, but 
experience from validation studies suggests that there is a learning curve for 
confident recognition on the digital slide. 
 
7.5.2.5 Potential pitfalls 
Table 28 summarises some of the potential pitfalls of digital diagnosis in different 
diagnostic subspecialties, as evidenced by the validation literature and practical 
experience of validation. These potential pitfalls should form the basis of digital 
primary diagnostic training. 
 
Histopathology subspecialty Potential pitfalls 
General 89 Identification and grading of dysplasia 
 Identification of lymph node metastasis and 
micrometastasis 
 Identification and quantification of mitotic figures 
 Identification of granulation tissue 
 Identification of micro-organisms 
 
Breast 38,43,56,60,80,85 Identification and grading of nuclear atypia 
 Identifying microinvasion and lymphovascular 
space invasion 
 Identification of lobular carcinoma 
 Grading invasive cancers (mitotic count 
component) 
 Identification of weddelite calcification 
 Identification of sentinel lymph node 
metastasis/micrometastasis 
 
Skin and soft tissue 51,55,70,89 Identification and grading of squamous dysplasia 
 Micro-organism detection 
 Granulomatous inflammation 
 Melanocytic lesions 
 Granulocyte identification and classification 
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 Identification of sentinel node metastasis 
 Identification of amyloid 
 Identification of lymphoproliferative 
disease/malignancy 
 
Endocrine89 Identification of granulomata 
 Identification of lymph node metastasis 
 Identification of amyloid in medullary carcinoma 
of the thyroid 
 Classification of thyroid neoplasms- identification 
of cellular papillary features 
 Identification of mitoses and atypical mitoses 
 
Genitourinary52,59,62,66,69 Identification and grading of urothelial dysplasia 
 Identification of micro-organisms 
 Identification of granulomatous inflammation 
 Identification and classification of inflammatory 
cells (especially granulocytes) 
 Identification of amyloid 
 Identification of lymphoproliferative 
disease/malignancy 
 Grading renal carcinoma (nuclear features) 
 
Gastro-intestinal54,58,62,64,65,67 Identification and grading of oesophageal 
dysplasia 
 Identification of focal activity in inflammatory 
bowel disease 
 Identification of eosinophils in oesophageal 
biopsies 
 Identification of granulomata 
 Identification of micro-organisms – particularly 
Helicobacter pylori 
 
Gynaecological 68,89 Identifying and grading cervical dysplasia 
 Identifying metastasis/micrometastasis 
 Assessing endometrial atypia 
 Identifying mitotic figures (particularly in soft 
tissue uterine lesions 
 Identifying mucin 
 
Head and neck 89 Identification and grading of squamous dysplasia 
 Identification of micro-organisms including fungal 
forms 
 Identification of granulomata 
 Identification and typing of inflammatory cells 
 
Hepatobiliary/pancreatic 89 Interpretation of liver special stains 
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 Identification of dysplastic epithelium 
(particularly gall bladder) 
 Identification and typing of inflammatory cells 
 Identification of granulomata 
 
Cardiothoracic 89 Identification of dysplasia/malignancy in small 
biopsy specimens 
 Identification of micro-organisms including 
mycobacteria 
 Identification of granulomatous inflammation 
 Identification of micrometastasis in EBUS 
specimens 
 
Table 28. Potential pitfalls of digital diagnosis organized by topography 
 
7.2.6 Continuing surveillance and audit 
Following introduction of digital primary diagnosis, data should be collected routinely 
on: 
- frequency and root cause of poor quality/out of focus/artefact containing WSI 
- frequency and details of instances when pathologists defer to glass slides. 
WSI diagnosis can be audited in a similar way to existing departmental glass slide 
diagnostic audit, with a random sample representing a proportion of the diagnostic 
workload reviewed by a second pathologist. 
 
7.2.7 Conclusion 
The body of work detailed in this thesis has formed the basis of a practical guide to 
advise clinical histopathology departments on how to train and validate their 
pathologists for primary digital diagnosis, which summarises the key steps and 
considerations and provides a detailed list of evidence-based ‘potential pitfalls’ and 
training targets for digital reporting. Digital pathology technology and our 
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appreciation of the scope and limitations of digital practice continue to evolve, and 
with this in mind, it is important that the pathology community continues to prioritise 
the quality and safety of our diagnosis with the introduction of new technologies and 
techniques. 
 
7.3 Digital pathology and patient safety for cancer screening programmes  
 In clinical pathology, breast pathologists are experiencing increasing pressure in 
terms of breast cancer case volume, case complexity, and the need for rapid 
evaluation and review to meet cancer diagnostic and therapeutic targets. Within this, 
one of the most challenging areas facing the NHS breast screening programme 
(NHSBSP) is the identification of pre-cancers, atypia, and early stage cancers. This 
area involves the identification of subtler morphologies, and the increasing use of 
adjunctive immunohistochemistry. Digitisation of slides could be of benefit to the 
NHSBSP, allowing more streamlined distribution of screening cases to pathologists, 
and faster access to archived cases for comparison, but also must be able to 
accurately classify the atypias and other borderline lesions of potential significance.  
   
Interest in the use of DP for the primary diagnosis of histological specimens is 
flourishing, with a number of laboratories using digital images for primary diagnosis 
in at least a proportion of cases. For DP to be accepted and adopted on a large scale, 
regulatory bodies, diagnostic departments, and individual pathologists will have to 
be convinced that a diagnosis made by a particular pathologist on a digital 
microscope is non-inferior to a diagnosis made by the same pathologist on a 
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conventional light microscope, and that no systematic error is introduced into the 
diagnostic process as a result of the technology.   
   
The UK Royal College of Pathologists has published guidelines supporting the use of 
DP for primary diagnosis by pathologists who have received adequate training and 
validated their DP diagnosis1, but at present, Public Health England (PHE), which is 
responsible for the NHSBSP, does not allow the use of digital slides for the primary 
diagnosis of screening programme specimens.  
   
 In this chapter, the results of a comprehensive review of the literature regarding DP 
safety are presented, particularly in the context of breast histopathology, and new 
concordance data from four European centres comparing conventional light 
microscopy diagnosis with DP diagnosis is presented.  In addition, 3 types of 
complementary data are presented in order to provide the reader with a 
comprehensive overview of digital breast cancer diagnosis: (1) experimental 
diagnostic concordance data, (2) direct comparison diagnostic validation data and (3) 
experimental intraobserver variation data. 
 
7.3.1. Experimental data  
   
To provide a comprehensive assessment of digital primary diagnosis for breast 
specimens, data were collated from 3 types of experiments performed across the 
contributing institutions. The complementary data from these are described 
separately below.  
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7.3.1.1 Experimental concordance data  
   
7.3.1.1.1 Aim  
To establish if digital slides are diagnostically equivalent to the glass slides they 
represent.   
   
7.3.1.1.2 Materials and methods  
The study was performed in the histopathology departments of University Hospitals 
Coventry, and the Centre for Pathology, Vilnius, Lithuania. Fully qualified consultant 
histopathologists with specialist experience reporting breast specimens were 
recruited to participate. Each centre utilised their own departmental digital 
pathology hardware and scanning protocols, detailed in table 29.  
   
    University Hospitals 
Coventry  
Centre for Pathology, 
Vilnius  
Scanning hardware  Omnyx  Leica Aperio Scanscope  
Scanning magnification  40x  20x  
Viewing hardware  DELL standard desktop 
screen, non medical 
grade, 1920p x 1080p 
resolution  
DELL standard desktop 
screen, non medical 
grade, 1920p x 1080p 
resolution  
Viewing software  Omnyx VL4  Aperio ImageScope  
Number of consultant 
participants  
2  1  
   
Table 29. Digital pathology scanning and viewing specifications – experimental data. 
 
Complete breast pathology cases, including immunohistochemistry and special stains 
where applicable, were selected from departmental archives and scanned. 
participants viewed digital breast pathology cases and recorded their diagnoses, as 
they would in their routine practice. These diagnoses were then compared with 
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archived light microscopy reports for the same cases. In cases of disagreement of 
discordance, both glass slides and digital slides were reviewed by an expert 
consensus panel to establish ground truth. A discordance was classified as any 
material difference in the diagnosis, regardless of whether this would have affected 
patient prognosis or treatment. Full details of each discordance were recorded, but 
discordances were not classified as minor or major, to reflect differences in practice 
in the different centres. 
   
7.3.1.1.3 Results  
Pathologists at the 2 sites viewed a total of 475 complete breast pathology cases. 
(View table 30 for a breakdown of the data by site).  
   
   University 
Hospitals 
Coventry  
Centre for 
Pathology, 
Vilnius  
Combined 
results for 
both sites  
Number of cases  250  225  475  
Complete 
concordance  
249  216  465  
Discordances  1  9  10  
Concordance rate 
(%)  
99.6  96.0  98.7  
   
Table 30. Experimental digital pathology versus light microscopy concordance data.  
 
The clinical concordance rate for combined data across both sites was 98.7%. Only 
10 clinically significant discordances were observed, the majority of which were 
differences in invasive tumour grading attributable to differences in mitotic count 
scoring. (See table 31 for a detailed list of discordances, and the corresponding 
diagnostic B-codes.) Please refer to table 32 for a description of National Health 
Service B codes. These are alphanumeric codes used to categorise breast biopsy 
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diagnoses, and correspond to different management options. A difference between 
B codes e. g B2 versus B5a, could result in differences in further management of a 
patient, whilst a difference in tumour type (lobular versus ductal carcinoma) or grade 
(2 versus 3) would not lead to differences in further management, as it is likely the 
correct diagnosis would be appreciated in the resection specimen.  
 
Digital diagnosis  Digital 
diagnostic B 
code  
Glass slide 
diagnosis  
Glass slide 
diagnostic 
B code 
Ground 
truth  
Grade 2 IDC B5b  Grade 3 IDC  B5b  Glass  
Grade 2 IDC B5b  Grade 3 IDC B5b  Glass  
Grade 1 IDC B5b  Grade 2 IDC B5b  Glass  
Grade 1 IDC B5b  Grade 2 IDC B5b  Glass  
Hamartoma  B2  Adenosis  B2  Glass  
Grade 2 IDC B5b  Grade 1 IDC B5b  Glass  
Grade 2 IDC B5b  Grade 1 IDC B5b  Glass  
Grade 1 ILC B5b  Grade 2 ILC  B5b  Glass  
Normal lymph 
node  
N/A  Reactive lymph 
node  
N/A  Glass  
Grade 1 IDC B5b  Grade 2 invasive 
ductal carcinoma  
B5b  Glass  
 
Table 31. Experimental discordances encountered  
 
Breast biopsy diagnostic 
B code 
Description 
B1 Normal 
B2 Benign 
B3 Uncertain malignant 
potential 
B4 Suspicious 
B5a Malignant in situ 
B5b Malignant invasive 
B5c Malignant not assessable 
Table 32. Diagnostic B codes for breast biopsy specimens (NHS, UK) 
 
7.3.2 Direct comparison validation data  
7.3.2.1 Aim  
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To train and validate individual pathologists for the primary digital diagnosis of breast 
pathology using a direct comparison method endorsed by the Royal College of 
Pathologists, and evaluate clinical concordance rates throughout the validation 
process.  
 
7.3.2.2 Materials and methods  
The study was performed in the histopathology departments of Leeds Teaching 
Hospitals NHS Trust, and United Lincolnshire Hospitals NHS Trust. Five fully qualified 
histopathologists with specialist experience reporting breast specimens were 
recruited to participate. Each centre utilised their own departmental digital 
pathology hardware and scanning protocols, detailed in table 33.  
   
   Leeds Teaching Hospitals 
NHS Trust  
United Lincolnshire 
Hospitals NHS Trust  
Scanning hardware  Leica Aperio AT2 and 
CS2  
Omnyx VL120  
Scanning magnification  40x  40x  
Viewing hardware  Barco 6MP medical grade  Not specified  
Viewing software  Leeds Virtual Microscope 
(LVM)  
Omnyx VL4  
Number of consultant 
participants  
4  1  
 
Table 33. Digital pathology scanning and viewing specifications – validation data  
 
All pathologists followed the validation protocol for primary digital diagnosis 
described in chapter 4. The “live” breast histopathology work of all participating 
consultants was scanned prospectively, in accordance with the V2, live validation 
phase of the protocol. All cases were viewed digitally in the first instance, and 
consultants recorded their diagnosis in a spreadsheet. The corresponding glass slides 
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for the case were then viewed, and any difference in diagnostic opinion recorded 
before final sign out of the case.  
   
7.3.2.3 Results  
During their “live” validation phase, pathologists at the 2 sites viewed a total of 1077 
complete breast pathology cases. (View table 34 for a breakdown of the data by site).  
   
   Leeds 
Teaching 
Hospitals NHS 
Trust  
United 
Lincolnshire 
Hospitals NHS 
Trust  
Combined 
results for 
both sites  
Number of cases  896  181  1077  
Number of readers  4  1  5  
Complete 
concordance  
887  180  1067  
Discordances  9  1  10  
Concordance rate 
(%)  
99.0  99.4  99.1  
   
Table 34. Direct comparison digital pathology versus light microscopy validation data.  
 
The clinical concordance rate for combined data across both sites was 99.1%. Only 
10 clinically significant discordances were observed, the majority of which were 
differences in invasive tumour grading attributable to differences in mitotic count 
scoring and the detection of small diagnostic objects (eg. isolated tumour cells in a 
sentinel lymph node).  (See table 35 for a detailed list of discordances, and table 33 
for a reminder of B codes).  
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Digital 
diagnosis  
Digital 
diagnostic 
category  
Glass slide diagnosis  Glass 
slide 
diagnostic 
category  
Ground 
truth  
Grade 2 IDC B5b  Grade 3 IDC  B5b  Glass  
Grade 2 IDC B5b  Grade 3 IDC B5b  Glass  
Benign 
phyllodes 
tumour  
B3  Fibroadenoma with 
inflammation  
B2  Glass  
Benign breast 
tissue  
B2  Atypical intraductal 
proliferation  
B3  Glass  
Sclerosing 
adenosis  
B2  Sclerosing adenosis, 
small focus DCIS  
B5a  Glass  
Microcysts  B2  Microcysts and weddelite  B2  Glass  
Benign lymph 
node  
LB2  Isolated tumour cells  LB5  Glass  
Columnar cell 
change  
B2 Grade 2 ILC B5b  Glass  
Normal lymph 
node  
LB2  Reactive lymph node  LB2  Glass  
Small focus 
DCIS 
B5a  No DCIS B2  Digital  
Grade 2 IDC  B5b  Grade 3 IDC B5b  Glass  
   
Table 35. Discordances from direct comparison validation data 
 
 
7.3.3 Breast cancer screening intraobserver variation study  
7.3.3.1 Materials and methods  
The study was performed in the histopathology department of Leeds Teaching 
Hospitals NHS Trust.  Fifty anonymised breast biopsy screening specimens were 
selected from the archive of the Department of Histopathology, St James’ University 
Hospital. Diagnostically challenging B2, B3 and B5a specimens were selected, 
allowing the study to focus on the ability to categorise borderline lesions on the 
ductal atypia spectrum. All slides were scanned using the same Leica AT2 scanner, 
and viewed with Leeds Virtual Microscope viewing software. A single representative 
slide was selected for each case.  Three consultant breast histopathologists were 
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recruited. Each pathologist viewed each case on four separate occasions, twice using 
conventional glass slides, and twice using digital slides. Participants were asked to 
interpret each slide as they would in their normal clinical practice, and to complete a 
diagnostic proforma adapted from the NHS Breast Screening Programme for each 
case. A washout period of two weeks was observed between slide reads of the same 
case. (See slide viewing schedule in table 36).  
 
Pathologist  Read 1  Read 2  Read 3  Read 4  
A  Glass slide  Digital slide  Glass slide  Digital slide  
B  Digital slide  Glass slide  Digital slide  Glass slide  
C  Glass slide  Digital slide  Glass slide  Digital slide  
   
Table 36. Pathologist slide viewing schedule for breast cancer screening study. 
 
In accordance with this schedule, each pathologist reviewed the same fifty cases four 
times: twice on the light microscope, and twice on the digital microscope giving a 
total of two hundred viewings and diagnoses each, and six hundred slide viewings 
and diagnoses over all.  
   
7.3.3.2 Results  
Intraobserver variability was evaluated using percentage agreement and calculating 
Cohen’s kappa with confidence intervals for each pathologist. The kappa value for 
intraobserver agreement for repeat digital reads of the same case was 0.80, 
compared with a value of 0.78 for reads on the light microscope, and 0.80 for digital 
versus light microscopy reads. (See table 37). This equates to excellent intraobserver 
agreement with no evidence of inferiority of using digital, with the kappa value for 
digital versus digital reads non-inferior to the kappa for light microscopy versus light 
microscopy reads.  
174 
 
   
Modality  % agreement  Kappa value  Confidence 
interval  
Glass slide v glass 
slide  
85  0.78  0.57-0.81  
Digital slide v 
digital slide  
87  0.80  0.72-0.87  
Glass slide v 
digital slide  
87  0.80  0.70-0.90  
 
Table 37. Intraobserver variability for breast lesion classification using digital and glass 
slides.  
 
7.3.4 Discussion  
Pathology services stand to benefit from the transferability and resilience of digital 
slide versus glass slide reporting, and there is great interest in using DP to report 
cases for the UK national cancer screening programmes including NHSBSP. For this 
specific use case, where healthy, non-symptomatic women are being screened, 
particular care must be taken to ensure that diagnostic quality and confidence are 
maintained or improved by the adoption of DP as a new platform of reporting. The 
data presented in this study relating to needle core biopsies includes both screen-
detected and symptomatic lesions. In the screening setting the gold standard for 
histological diagnosis is the needle core biopsy. Some borderline lesions are over 
represented in the screen detected setting compared with the symptomatic setting, 
but the large number of cases in this study minimise this impact.  
   
Systematic review data, and large non inferiority studies have demonstrated a high 
level of concordance between glass and digital slide diagnoses by pathologists.  
The combined data for digital:glass concordance from the experimental concordance 
studies demonstrated a concordance rate of 98.7% for breast pathology cases, 
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validating the use of digital slides as replicas of the original glass slide. Data from 
direct comparison validation also indicated excellent rates of concordance, with an 
observed concordance of 99.1%. Further data from an intraobserver variation study 
of deliberately challenging NHSBSP specimens indicated an excellent level of 
agreement between glass and digital slide diagnoses for individual pathologists.  
The majority of clinical discordances encountered in the experimental data 
presented were attributable to differences in mitotic count, with an observed 
tendency to underestimate the mitotic count on the digital slide. Two causes were 
identified for this by participants:  first, a suggestion that less contrast between 
chromatin and the background on digital slides made mitoses harder to identify on 
initial low power assessment of the slide, and second, the inability to adjust the fine 
focus on high power examination of suspected mitotic figures on the digital 
microscope. A number of workarounds could mitigate difficulty in this area, including 
the use of adjunctive immunohistochemistry or the use of image analysis software 
to automate or semi-automate mitotic counts. It is interesting to note that Centre for 
Pathology, Vilnius, observed significantly more discordance than University Hospitals 
Coventry (4% versus 1%). One possible explanation for this might be the use of 
routine 20x equivalent scanning rather than 40x equivalent.  A number of previous 
validation studies of digital pathology for various topographies have observed that 
pathologists found diagnostic accuracy and confidence improved using 40x scans, 
particularly for tasks dependent on small object detection 58, 69 (eg. micro-organism 
detection, granulocyte classification).  
 
From our experience the most challenging diagnostic findings apart from the above 
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mentioned entities include stromal cellularity, which may make assessment of some 
phyllodes tumors difficult on digital images, assessment of the degree of cytonuclear 
pleomorphism and assessment of low grade atypia. In this study, the majority of the 
discordant cases observed were unlikely to impact of further management provided 
that MDT review was carried out, which is the routine scenario in the UK for 
management of screen-detected breast lesions.  
 
The pathologists at all four clinical sites have found a number of benefits in reporting 
their work digitally, including: 
- loss of glass slide transport and transfer delays  
- rapid and convenient availability of images for sharing and second opinion 
- rapid access to previous biopsies for comparison with resection/repeat 
biopsies 
- Perceived increased efficiency in the diagnosis of large volume biopsies and 
multislide, multilevel cases 
- Occupational health benefits. - one pathologist would have been unable to 
complete her breast screening workload on the light microscope one day 
due to a neck injury, but was able to complete her work on digital without a 
problem 
- Enhanced opportunities to demonstrate pathology in MDT meetings 
- Utility for teaching a larger cohort of trainees also facilitates inclusion of 
trainees from a distant site by connecting through video link, eliminating the 
need of travelling to site of teaching. The cases can also be visualised by 
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these trainees digitally in their own time hence avoiding any slide transfers 
between sites 
- The feasibility of applying AI based tools in the routine setting of breast 
pathology reporting 
   
   
The new digital pathology guidelines from the Royal College of Pathologists 1describe 
the need for individual pathologists to be validated with sufficient rigour to satisfy an 
internal or external observer that safety and clinical effectiveness are maintained. 
This evidence supports the notion that digital pathology is non-inferior to standard 
light microscopy, for suitably trained and validated pathologists, and would support 
them to diagnose breast cancer screening programme specimens on digital slides.  
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Chapter 8 Conclusion 
Digital pathology is a technology with the potential to revolutionise the way 
pathology services are delivered in the National Health Service, and worldwide, 
presenting opportunities to future proof an increasingly stretched diagnostic service 
whilst improving the quality and timeliness of cancer reporting. In undertaking this 
period of PhD study, the author sought to follow an evidence based approach to 
patient safety aspects of digital pathology use in the clinic, and in this way facilitate 
adoption in the NHS. This thesis presents a body of work in which a novel digital 
pathology training and validation protocol was designed, implemented and modified 
to adapt to diverse clinical use cases. Clinical adoption has been hampered by a lack 
of information and guidance regarding validation, training and patient safety. Much 
of the published literature regarding digital pathology in the clinic is targeted at 
“early adopter” clinicians, and assumes a certain level of technological knowledge, 
and an enthusiasm for WSI. For regional or national scale utilisation of digital 
pathology, a critical mass of practising pathologists working at diverse sites, and with 
diverse experience with and enthusiasm for digital reporting will have to be 
convinced they can work competently and confidently on the digital microscope.  The 
author was motivated to produce and share documentation relating to training, 
education and patient safety topics, based on evidence based review of existing 
literature, and real world experience from trialling the training and validation 
protocol. 
In chapter 1, background information was provided explaining the basic technology 
underpinning digital pathology, and describing the many potential benefits of, and 
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prevailing barriers to digitisation in the clinical pathology laboratory. Over the last 
three years, rapid progress has been made, and digital pathology is increasingly 
characterised as a mainstream clinical pathology topic rather than a niche application 
for the early adopter and the pathology informatician. 
In chapter 2, the results of a nationwide survey of UK pathology departments was 
presented, revealing that at the start of this body of work, 41% of respondent 
departments were actively scanning glass slides, although these were predominantly 
for educational, research or quality assurance purposes. Low level use for primary or 
secondary diagnosis was reported by around a third of respondent institutions. 
Predictions of usage levels a year in the future suggested that an increasing number 
of departments expected to use digital pathology more frequently for clinical 
diagnosis. The majority of departments listed clinical digital pathology adoption as a 
high or essential level priority, and whilst the key barrier to implementation was cited 
as cost, departments would also value clear guidelines and statements from key 
professional bodies on how to adopt digital pathology without compromising patient 
safety or professional standards.  
The findings from the survey prompted a detailed and innovative analysis of the 
digital pathology concordance literature to identify key training and safety points 
regarding WSI based primary diagnosis, which is presented in chapter 3. In the 
traditional validation literature, concordance and discordance rates are often 
reported without any discussion of the clinical implications in terms of patient 
outcomes or pathologist workload. Reassuringly, the types of errors or misdiagnoses 
made on digital slides were no more likely to cause significant patient harm than 
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those made on conventional glass slides. Thorough examination of discordant 
diagnoses recorded on the digital microscope allowed the identification of key 
“problem areas”, where pathologists were more likely to encounter difficulty 
interpreting digital slides. These included the identification and grading of dysplasia, 
the location of small diagnostic objects and features, and the location and the 
identification and quantification of mitotic figures. 
In chapter 4, this information was used to guide the development of learning targets 
for a validation and training protocol for digital pathology – the first of its kind, 
offering individualised training in primary diagnosis in real world settings. In chapter 
5, this protocol was implemented in two diagnostic subspecialties at Leeds Teaching 
Hospitals, breast and neuropathology. Following a comprehensive validation 
procedure, excellent rates of clinical concordance were achieved by all participants, 
and from a clinical standpoint, it is important to note that since their validation 
period, all 5 pathologists (3 breast pathologists, 2 neuropathologists) complete all 
their primary diagnoses on the digital microscope as standard, only deferring to glass 
in a small number of specified clinicopathological scenarios (less than 1% of all cases), 
and in the case of breast pathologists, to satisfy PHE that key slides from screening 
cases have been reviewed on glass. Modification of the protocol, following the 
general approach utilising evidence based training sets of “difficult on digital” cases, 
and mitigating risk with glass slide checks or other safety nets in problematic 
scenarios, allowed for stand-alone training modules in two further use cases: frozen 
section assessment and immunohistochemistry assessment. 
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Finally, in chapter 7, guidance regarding safety aspects of clinical digital pathology 
was presented. A detailed, practical description of laboratory and diagnostic 
considerations for obtaining ISO 15189 accreditation for clinical digital services was 
provided, and applied to achieve the UKAS accreditation for digital diagnosis at a 
large fully digital NHS laboratory.  Data regarding the safety of digital slide for breast 
cancer screening patients was collected and analysed, using experimental and “real 
world” validation data from 4 European cancer centres. An accumulation of evidence 
from diverse sources suggested cautious optimism for the use of digital slides in 
breast cancer screening programme specimens. The majority of clinical discordances 
encountered in all experimental studies were attributable to differences in mitotic 
count, which would not have affected clinical outcome for the patients in question. 
One of the key enabling factors for digital pathology implementation raised by 
participants in the survey discussed in chapter 2 was access to more information and 
guidance on safe implementation.  The contents of this thesis have been 
disseminated widely amongst both the pathology informatics/ digital pathology 
community and the general clinical pathologist publication. A suite of peer reviewed 
scientific papers resulting from this work27, 47, 85, 87, 89-92 have been complemented 
with major presentations and invited speaker plots at leading international digital 
pathology conferences (eg. Pathology Visions (2017,2019)  and Pathology Informatics 
(2017, 2020) in addition to national general pathology conferences in 10 countries. 
The content of the thesis is also presented in a more personal way at the Leeds Digital 
Pathology workshops which were designed by the author, and delivered with the 
support of other Leeds digital pathology team members. (See figure 23). 
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Figure 23. The author delivering a session on digital pathology implementation at one of 
the Leeds Digital Pathology Workshops in 2018. 
 
To date 8 workshops and have been held, and more than 150 delegates have been 
invited to the department to see digital pathology in action, and learn about the 
evidence base, training and validation. Some of the content from the workshops is 
replicated in the Leeds Guide to Digital Pathology, an accessible overview summary 
of key topics in digital pathology implementation aimed at pathologists, laboratory 
managers, IT professionals and policy makers.  
In addition, the author has delivered bespoke validation workshops in Switzerland 
and Denmark to aid regional digital deployments, and contributed to digital 
pathology guidance documentation on behalf of the Royal College of Pathologists 
and the European Society of Toxicologic Pathology.  
The work described in the thesis has several limitations, including the relatively small 
number of pathologists included in the validation protocol trials (chapters 5 and 6), 
and the setting of these studies being limited to a single teaching hospital, Leeds 
Teaching Hospitals NHS Trust. The studies detailed in chapter 7 include data from 4 
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different institutions in 2 countries, the UK and Lithuania, but 3 of these are major 
cancer centre/ teaching hospitals. Since its publication, the primary diagnostic 
validation protocol has been utilised in a number of other institutions across the 
world, including hospitals in Oxford, Lincoln and London in the UK, and Linköping in 
Sweden. It will be interesting to compare attitudes to the validation process itself, as 
well as collect more data on areas of diagnostic difficulty. The protocol is easily 
modified for the general pathologist, as described in chapter 7, and will shortly be 
rolled out to a further 6 district general hospitals in West Yorkshire as part of the 
Northern Pathology Imaging Co-Operative clinical network, a £17 million project 
funded by the Industrial Strategy Challenge Fund and industry partners. 
 As experience with digital pathology broadens, it will be possible to gather more data 
on challenging areas of digital diagnosis. Sharing of this data will not only allow 
pathologists to improve existing training and education resources for digital 
reporting, it could also be used to influence the design of new digital pathology 
hardware and software which could improve diagnostic accuracy and confidence. 
Beyond this, the data might be used to prioritise appropriate features and tasks for 
the development of AI applications which can support the pathologist with difficult 
areas.  
The necessity for further research and development work in several specific areas 
has been identified following on from this body of work. Foremost amongst this is 
the need to address the challenge and opportunities presented by artificial 
intelligence (AI). The success of deep learning techniques render the possibility of 
hybrid human/computer assisted diagnosis of pathology images in the near future 
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more likely than ever.  With this in mind, the pathology community will have to think 
carefully about how AI applications should be validated for clinical use, especially in 
the case of “human in the loop” products, which depend upon a combination of 
computer and human intelligence working in tandem to produce a diagnosis or 
assessment. One way of validating the performance of an AI application is the use of 
feature studies, where the ability of the algorithm to detect certain diagnostic 
features in a field of view is compared with the ability of a pathologist to perform the 
same task. For this type of study, it is important that the features chosen are clinically 
relevant. The evidence based list of diagnostic features detailed in chapter 7 of this 
thesis (Table 29). 
In the last few weeks before submission of this thesis (March 2020), the Coronavirus 
pandemic emerged as a major challenge to health services across the world. Sick 
leave, self-isolation and carer duties have resulted in unprecedented staffing issues, 
whilst departments battle to clear diagnostic backlogs. Digital pathology, as an 
enabler of remote working in diagnostic pathology, could help support those needing 
to self isolate, and allow them to continue vital diagnosis from home. Whilst some 
individuals have experience of this, little work has been done to determine optimum 
conditions for home reporting, including technical and training considerations.  
This publication produced in response to the pandemic provides information 
regarding risk assessment of home reporting of digital slides, summarises available 
information on specifications for home reporting computing equipment and shares 
access to a novel point of use quality assurance tool for assessing the suitability of 
home reporting screens for digital slide diagnosis.94 What is needed is evidence based 
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evaluation of home reporting systems, and particularly display screens, to ensure 
that the high standards of diagnosis that are aimed for in the hospital are replicated 
in the home office.  
In 2017, when the work contained in this thesis commenced, a lack of guidance and 
reassurance, particularly regarding patient safety, training and validation was a 
significant barrier to widespread clinical adoption of digital pathology. It is the 
authors hope that in conducting a comprehensive and novel analysis of the evidence 
base, creating innovative validation protocols, training materials and guidance 
documents and disseminating work through scientific publications, presentations 
and workshops, pathologists now have access to pragmatic material which can advise 
and assist them in transitioning from conventional light microscopy to digital 
microscopy.  
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List of abbreviations 
 
Abbreviation Expansion 
AI Artificial intelligence 
CAP College of American Pathologists 
CE European Conformity 
CLIA Clinical Laboratory Improvement Amendments 
CM-Path Cellular Molecular Pathology 
CMV Cytomegalovirus 
DCIS Ductal carcinoma in situ 
DP Digital Pathology 
ER Oestrogen receptor 
FDA Food and Drug Administration 
H&E Haematoxylin and eosin 
Her2 Human epidermal growth factor receptor 2 
IHC Immunohistochemistry 
ISO International Organisation for Standardization 
JPEG Joint photographic experts group 
LIMS Laboratory Information System 
LVM Leeds Virtual Microscope 
MDT Multi-disciplinary team 
MDTM Multi-disciplinary team meeting 
NCRI National Cancer Research Institute 
NHS National Health Service 
PHE Public Health England 
PR Progesterone receptor 
RCPath Royal College of Pathologists 
SOP Standard Operating Procedure 
SV40 Simian virus 40 
SWEDAC Swedish Accreditation Body 
TAT Turn around time 
UKAS United Kingdom Accreditation Service 
WHO World Health Organization 
WSI Whole slide image 
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